{
  "name" : "twin.sci-hub.se_6561_5050034f3c72aac3de0162e846e2071f_lalwani2016.pdf",
  "metadata" : {
    "source" : "META",
    "title" : "Toxicology of graphene-based nanomaterials",
    "authors" : [ "Gaurav Lalwani", "Michael D'Agati", "Amit Mahmud Khan", "Balaji Sitharaman" ],
    "emails" : [ "gauravlalwani06@gmail.com" ],
    "sections" : [ {
      "heading" : null,
      "text" : "Contents lists available at ScienceDirect\nAdvanced Drug Delivery Reviews\nj ourna l homepage: www.e lsev ie r .com/ locate /addr\nToxicology of graphene-based nanomaterials☆\nGaurav Lalwani a,b,⁎, Michael D'Agati b, Amit Mahmud Khan b, Balaji Sitharaman a,b,⁎⁎ a Theragnostic Technologies Inc., Long Island High Technology Incubator Suite 123, Stony Brook, NY 11790, USA b Department of Biomedical Engineering, Stony Brook University, Stony Brook, NY 11794-5281, USA\n☆ This review is part of the Advanced Drug Delivery Revi ⁎ Correspondence to: G. Lalwani, Theragnostic Technol ⁎⁎ Correspondence to: B. Sitharaman, Department of Bio Tel.: +1 631 632 1810.\nE-mail addresses: gauravlalwani06@gmail.com (G. Lal\nhttp://dx.doi.org/10.1016/j.addr.2016.04.028 0169-409X/© 2016 Elsevier B.V. All rights reserved.\na b s t r a c t a r t i c l e i n f o\nArticle history: Received 22 January 2016 Received in revised form 28 March 2016 Accepted 26 April 2016 Available online 3 May 2016\nGraphene basednanomaterials possess remarkable physiochemical properties suitable for diverse applications in electronics, telecommunications, energy and healthcare. The human and environmental exposure to graphenebased nanomaterials is increasing due to advancements in the synthesis, characterization and large-scale production of graphene and the subsequent development of graphene based biomedical and consumer products. A large number of in vitro and in vivo toxicological studies have evaluated the interactions of graphene-based nanomaterials with various living systems such as microbes, mammalian cells, and animal models. A significant number of studies have examined the short- and long-term in vivo toxicity and biodistribution of graphene synthesized by variety of methods and starting materials. A key focus of these examinations is to properly associate the biological responseswith chemical andmorphological properties of graphene. Several studies also report the environmental and genotoxicity response of pristine and functionalized graphene. This review summarizes these in vitro and in vivo studies and critically examines the methodologies used to perform these evaluations. Our overarching goal is to provide a comprehensive overview of the complex interplay of biological responses of graphene as a function of their physiochemical properties.\n© 2016 Elsevier B.V. All rights reserved.\nKeywords: Graphene Toxicity In vitro In vivo Antimicrobial Environmental Biodistribution\nContents\n1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110 2. In vitro toxicity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111\n2.1. Dose, time, and morphology dependent cytotoxicity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111 2.2. Functionalization dependent cytotoxicity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117 2.3. Cell dependent cytotoxicity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119 2.4. Size dependent cytotoxicity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119 2.5. Immunotoxicity of graphene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119 2.6. Hemolytic toxicity of graphene . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 120 2.7. Surfactant/coating dependent cytotoxicity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 122 3. In vivo toxicology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 122 3.1. Intravenous administration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 122 3.2. Intraperitoneal administration. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 128 3.3. Oral administration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129 3.4. Pulmonary administration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133 3.5. Intravitreal administration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 134 4. Antimicrobial toxicity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 135 5. Environmental toxicity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 137 6. Mechanisms of toxicity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 140 7. Conclusion and future perspective . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 142 Acknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 142 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 142\news theme issue on “Graphene-based materials in nanomedicine”. ogies Inc., Long Island High Technology Incubator Suite 123, Stony Brook, NY 11790, United States. Tel.: +1 631 512 3980. medical Engineering, Bioengineering Building Room 115, Stony Brook University, Stony Brook, NY 11794-5281, United States.\nwani), balaji.sitharaman@stonybrook.edu (B. Sitharaman).\n1. Introduction\nCarbon nanomaterials such as fullerenes, carbon nanotubes and graphene are the most widely researched class of materials and hold immense potential to impact several scientific disciplines [1–3]. Their transformative potential has been recognized with multiple honors including the Kavli and Nobel Prize [4,5]. Owing to the distinct arrangement of sp2 bonded carbon atoms, each carbon nanomaterial can exhibit significantly different physical, morphological and chemical properties.\nGraphene, a two-dimensional (2D) sheet of carbon atoms packed in a honeycomb lattice iswidely regarded as a basic building block of graphitic allotropes (Fig. 1) [6]. The theoretical existence of graphene was discussed over 55 years ago by Slonczewski and Weiss [7]. Landau, Peierls andMermin reported that existence of atomically thin 2D crystals (suchas graphene)was practically impossible due to thermodynamic instabilities, a theory that was supported by several independent experimental observations [8–11]. However, in 2004, Novoselov and Geim isolated single sheets of graphene by micromechanical cleavage of graphite or the “scotch-tapemethod” [12] and characterized their quantum electrodynamics [13,14]. Since then research on graphene has exploded. The number of research papers published on graphene has been increasing exponentially (Fig. 2) attracting scientists from all areas of science and technology towards the graphene “gold-rush”. In 2013, the European Union announced the graphene flagship project — a $1.3 billion 10 year investment in graphene research and development to translate graphene-based technologies fromacademic labs to themarketplace [15]. The Korean Graphene Project, also announced in 2013, is a\nFig. 1. Graphene is the building material for 0D full Schematic adapted from Reference [6] with permis\n$44 million 5 year investment for graphene research [16]. In 2011, United Kingdom committed £50 million investment for graphene research [17]. Recently, in October 2015, Chinese company Huawei Technologies has announced a $1 billion 5 year investment towards the development of information and communication technologies focused on graphene [18].\nGraphene has interesting optical, thermal, mechanical and electrical properties. The sp2 hybridization of 2D graphene plane results in delocalized out of plane π bonds that provide an exceptionally high carrier mobility (~200,000 cm2 V−1 s−1 for suspended graphene [19,20] and ~500,000 cm2 V−1 s−1 for graphene-based field effect transistors) [21,22]. Graphene exhibits room temperature quantum hall effect for electrons and holes [13,23]. Graphene sheets also exhibit high surface area (2630 m2 g−1) [21], thermal conductivity (~5000 Wm K−1) [24], mechanical property (Young's modulus of ~1 TPa) [25] and optical transparency (single layer graphene absorbs ~2.3% of visible light) [26].\nGraphene can be synthesized using various physical (such as mechanical cleavage (“scotch tape method”) [27] or arc discharge [28]) and chemical methods (chemical vapor deposition [29], Hummer's method (chemical oxidation of graphite followed by mechanical exfoliation) [30] or longitudinal unzipping of carbon nanotubes [31]). Depending on the method of synthesis, graphene can exist in various morphologies such as sheets, platelets, ribbons, onions and quantum dots (Fig. 3). Pristine graphene is apolar and very hydrophobic. It needs to be oxidized to improve its dispersibility in aqueous media.\nOxidized graphene is typically synthesized via chemical oxidation. Depending on the synthesis or morphology of the graphene, oxidized graphene are referred by various terminologies. For example, oxidized\nerenes, 1D carbon nanotubes and 3D graphite. sion, copyright © Macmillan Publishers Limited, 2007.\ngraphene prepared by Hummer's method is typically referred as graphene oxide (GO) or graphene nanoplatelet. Oxidized graphene prepared by longitudinal unzipping are referred as graphene oxide nanoribbons. The pristine sp2 characteristic of graphene can to a large extend (but not completely) be restored by treating oxidized graphene nanoparticles with reducing agents such as hydrazine and hydrogen iodide [32]. Although the presence of hydrogen bonds between the polar oxidative functional groups (such as oxide, acid, alcohol, and epoxide) of oxidized graphene imparts colloidal stability, the dispersibility of oxidized graphene in aqueous and biological media is inadequate for several biomedical applications. Functionalization strategies have been employed to further improve graphene's aqueous dispersibility. Graphene can be covalently or non-covalently functionalized with several chemical moieties (for instance amine) or biological molecules (such as nucleic acids and proteins). Oxidized graphene nanoparticlebased formulations has been extensively explored for several biomedical applications such as bioimaging [33–35], drug and gene delivery [36–38], photothermal therapy [39,40], tissue engineering [41–43], and stem cell technology [44,45]. Pristine or nearly pristine (oxidized graphene treatedwith reducing agents) graphene have also been investigated for several biomedical applications [27,35,46,47].\nThe evaluation of in vitro cytotoxicity and in vivo biocompatibility is critical to develop nanoparticle-based formulations for biomedical applications. The potential widespread use of graphene-based nanomaterials for commercial materials science applications will increase their interactions with biological and environmental constituents. Furthermore, a thorough analysis of the biocompatibility of graphene is an essential prerequisite before their use for in vivo biomedical applications. Consequently, several studies have been performed to assess the in vitro and in vivo cyto- and bio-compatibility of graphene-based nanomaterials [48–56]. These studies indicate that the toxicity of graphene is dependent on the complex interplay of several physiochemical properties such as shape, size, oxidative state, functional groups, dispersion state, synthesis methods, route and dose of administration, and exposure times [48–57]. Post synthesis processing steps could lead to disruption of graphene structure and production of smaller carbonaceous debris or methods to synthesize graphene could lead to the incorporation of severalmetallic impurities in the final product. These confounding factors may elicit variable toxicity responses [58–60].\nIn this article, we provide a comprehensive review of recent in vitro and in vivo toxicity studies using graphene-based nanomaterials and examine the methodologies used to perform these evaluations. We also review studies investigating the effects of graphene on antimicrobial biota (e.g. bacteria and fungi) and environmental constituents (e.g. crops, waste water). Finally we summarize the current understanding\nof the toxicity mechanisms of graphene-based nanomaterials. The goal of this article is to provide the readers with an overview on graphene toxicity and its dependence on the various physiochemical properties of graphene. Such an understanding could lead to development of strategies to mitigate potential adverse effects towards successful development of graphene-based consumer and healthcare products.\n2. In vitro toxicity\nThe assessment of in vitro cytotoxicity is the initial step towards significantly expensive and elaborate in vivo studies. Table 1 summarizes the in vitro cytotoxicity of graphene and graphene oxide (GO) assessed using several representative cell lines at various treatment concentrations.\n2.1. Dose, time, and morphology dependent cytotoxicity\nZhang et al. investigated the interactions of graphene (diameter 100– 110 nm, thickness 3–5 nm) with rat pheochromocytoma PC12 cells using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and lactate dehydrogenase (LDH) assays and compared the results with single-walled carbon nanotubes (SWCNTs) [61]. More than 70% cell death was observed for 100 μg/ml treatment concentration of SWCNTs whereas no cell death was observed for 0.01–10 μg/ml concentrations of graphene (Fig. 4A). Nearly 15–20% cell deathwas observed for graphene treatment at 100 μg/ml. The observed cytotoxicity was attributed to the agglomeration of graphene, generation of reactive oxygen species (Fig. 4B) and an increased caspase-3 activation (Fig. 4C) resulting in apoptosis. These results showed a dose dependent cytotoxicity trend that was dependent on the morphology (shape and composition) of the nanomaterial, with graphene exhibiting an overall lower toxicity compared to single-walled carbon nanotubes (SWCNTs). Vallabani et al. investigated the toxicity of graphene oxide using normal human lung cells (BEAS-2B) after 24 and 48 h of exposure at concentrations between 10 and 100 μg/ml. A significant dose- and time-dependent decrease in cell viability and an increase in the number of early and late apoptotic cells was observed using MTT assay [62].\nYuan et al. evaluated the cytotoxicity of graphene oxide on human hepatoma HepG2 cells using MTT assay, DFDA fluorescence analysis and 2D LC–MS proteome analysis [63]. After 48 h of exposure to GO at 1 μg/ml concentration, HepG2 cells showed 6% mitochondrial damage, 8% increase in ROS generation and no significant changes in apoptotic cell population, cell cycle, and expression of metabolic and cytoskeletal proteins. Cells treated with oxidized-SWCNTs (ox-SWCNTs) showed ~20% mitochondrial damage, N100% increase in ROS generation, ~26% increase in apoptotic cell population, and ~30 differentially expressed\nproteins involved in metabolic pathway, redox regulation, cytoskeleton formation, and cell growth. These results suggested that GOmay be less cytotoxic compared to ox-SWCNTs. In another study, Lv et al. showed that GO does not elicit cytotoxic or apoptotic effects in human neuroblastoma SH-SY5Y cells at low concentrations (b80 μg/ml) [64]. Interestingly, GO enhanced the retinoic acid induced differentiation of SHSY5Y cells, improving neurite length and expression of MAP2 (neuronal marker), suggesting that GO may be suitable for applications in neurodegenerative diseases.\nTalukdar et al. investigated the effects of graphene nanostructures of various morphologies (such as oxidized-nanoribbons (GONRs), oxidized-nanoplatelets (GONPs), andnanoonions (GNOs)) on the toxicity and stem cell differentiation potential of humanmesenchymal stem cells (hMSCs) [44]. hMSCs (derived from bone marrow and adipose\ntissue) were treated with various concentrations (5–300 μg/ml) of GONRs, GONPs and GNOs for 24 or 72 h and cytotoxicity was evaluated usingAlamar blue and CalceinAM assays. Results showed a dose-dependent (no time-dependent) cytotoxicity of various 2D graphene nanostructures with concentrations N50 μg/ml eliciting no cytotoxicity. TEM imaging showed cellular and nuclear uptake of GNOs and GONPs (Fig. 5A–D). Furthermore, results showed that all graphene nanostructures did not induce any changes in the adipogenic and osteogenic differentiation of hMSCs (Fig. 5E–J) suggesting the use of graphene as labels for stem cell imaging and therapy.\nChng et al. have reported a comparative study on the cytotoxicity of GONRs and GONPs [65]. GONRswere synthesized from the longitudinal unzipping of CNTs and GONPswere synthesized from stacked graphene nanofibers. In vitro cytotoxicity evaluated using MTT andWST-8 assays\nTable 1 In vitro cytotoxicity of graphene.\nMaterial Characterization Properties Treatment concentration Cell line Assays Conclusions References\nGraphene, SWCNT TEM, SEM, AFM, X-ray diffraction G: thickness = 3–5 nm 0.01– 100 μg/ml\nPC12 cells MTT, LDH, ROS, caspase 3/7\nDose and shape dependent cytotoxicity was observed for graphene and SWCNT. Zhang et al. [61]\nGO, ox-SWCNT AFM, FTIR, EDS GO: length = 100 nm; height = 1 nm\n1 μg/ml HepG2 cells MTT, ROS, FITC, DFDA fluorescence analysis, 2D LC–MS proteome analysis GO shows less mitochondrial damage, ROS generation, apoptotic cell population compared to cells treated with ox-SWCNTs. Yuan et al. [63]\nGO AFM, DLS, FTIR, Uv–Vis GO: thickness = 1 nm; size = 100–600 nm\n10–100 μg/ml SH-SY5Y cells MTT, caspase-3 Viability of cells are dose and time dependent. No apoptosis induced by GO. MAP2 expression and neurite length improved. Lv et al. [64]\nGNO, GONP, GONR (PEG-DSPE dispersed) TEM, Raman, TGA, zeta potential, hydrodynamic diameter GNO: diameter = 50–300 nm; ID/IG = 0.92; ζ-potential = −32.3 ± 1.35; hydrodynamic radius = 460.76 ± 53.58 5–300 μg/ml Human adMSCs and bmMSCs Alamar blue, calcein AM, adipogenic differentiation (oil red O) and osteogenic differentiation (alizarin red, ALP, calcium deposition) Dose dependent cytotoxicity (not time dependent; Graphene does not affect differentiation potential of human stem cells. Talukdar et al. [44]\nGONR: width = 60–90 nm, length = 500–1500 nm; ID/IG = 1.28; ζ-potential = −26.3 ± 0.75; hydrodynamic radius = 457.5 ± 35.70 GONP: diameter = 20–40 nm, thickness = 3–5 nm; ID/IG = 1.09; ζ-potential = −12.47 ± 0.12; hydrodynamic radius =\n296.4 ± 20.32 GONR and GONP Raman, XPS GONR: ID/IG = 1.09; lattice\nsize = 22.2 nm; C/O ratio = 1.9; percentage of C_O groups = 28.22 3–400 μg/ml A549 cells MTT, WST-8 Size and functional group dependent toxicity; GONR exhibit greater toxicity than GONP due to presence of greater number of carbonyl groups and greater length Chng et al. [65]\nGONP: ID/IG = 0.88; lattice size = 19.1 nm; C/O ratio = 1.9; percentage of C_O groups = 11.06\nGONR, rGONR, GOS and rGOS TEM, SEM, AFM, XPS, Raman spectroscopy GONR and rGONR: length = 10 μm, width = 50–200 nm; thickness = 1 nm; O/C ratio = 54% for GONR and 19% for rGONR; increase in ID/IG ratio upon reduction 0.01– 100 μg/ml\nHuman MSCs ROS assay, RNA efflux, cell viability (FDA) assay, Comet assay, Giemsa staining Dose and shape dependent cytotoxicity with GONRs more cytotoxic than GOS. GONRs and rGONRs induce DNA fragmentation and chromosomal aberrations at 1 μg/ml. Akhavan et al. [66]\nGOS and rGOS: thickness = 1.2 nm; lateral size = 2 μm; reduction in oxygen content and increase in ID/IG ratio upon reduction\nGP TEM, z-potential GP: diameter = 450 nm– 1.5 μm; z-potential = −9.61 5–100 μg/ml U87, U118 Trypan blue, XXT-based proliferation, LDH, apoptosis kit\nActivated apoptosis and necrosis in U87 cells whereas only apoptosis was activated in U118 cells. Jaworski et al. [67]\nPristine-G, COOH-GO\nTEM, AFM, Raman, XPS\nThickness = 0.5 μm 0–300 μg/ml Vero cells Alamar blue, LDH, apoptosis, ROS\nSurface functionalization of graphene is critical for pacifying strong hydrophobic interaction associated with toxicity effects. Sasidharan et al. [68]\nGQD-NH2, GQD-COOH, GQD-CO-N(CH3)2 UV–Vis, TEM, FTIR\nGQD-NH2: diameter = 7.5 nm; UV–Vis peak = 230 nm; Ex/Em= 420/500 nm; FTIR peaks at 1627 cm−1 (C_O), 1417 cm−1 (N–H), 1328 cm−1 (C–N), 0–200 μg/ml A549 and C6 glioma cells MTT, Trypan blue, fluorescence imaging No cytotoxic effects upto 200 μg/ml treatment for all GQDs. Intracellular accumulation of GQDs was observed, nuclear translocation was absent. Yuan et al. [70] GQD-COOH: diameter = 15 nm; UV–Vis peak = 362 nm; Ex/Em = 400/440 nm; FTIR peaks at 1388 and 1571 cm−1 (COO–), GQD-CO-N(CH3)2: diameter = 3–10 nm; UV–Vis peak = 300 nm; Ex/Em= 400/500 nm; FTIR peaks at 1400 and 1304 cm−1 (C–N)\n(continued on next page)\nTable 1 (continued)\nMaterial Characterization Properties Treatment concentration Cell line Assays Conclusions References\nGO and rGO AFM, EDX, aerodynamic diameter (dae) Lateral dimension = 100 nm– 5 μm; height = 1.1–15 nm; dae = 20–200 nm; oxygen content = 40% in GO and 10% in rGO 0.0125– 12.5 μg/cm2 A549 and RAW 264.7 cells MTT, DNA assay, FMCA assay, apoptosis, ROS, cell TEM\nDose dependent cytotoxicity. Cellular internalization of GO inside phagoendosomes was observed Horváth et al. [71]\nPEG-amine functionalized GO\nTEM, AFM, FTIR, DLS Thickness = 1.8 nm; hydrodynamic size = 10–120 nm;\n75 μg/ml Saos-2 osteoblasts, MC3t3-E1 preosteoblast, RAW-264.7 macrophages ROS, Hoechst 33,258, Gen-Probe Diaclone kit After internalization, nanosheets are localized on F-actin filaments inducing cell-cycle alterations, apoptosis, and oxidative stress. Matesanz et al. [69]\nGO, rGO AFM, TEM, XPS, Raman spectroscopy Flake size = 0.4–0.8 μm; thickness = 1 nm\n1–10 μg/ml HUVEC MTT, LDH, ROS, FACS, RT-PCR, Comet assay Oxidation state, dose and size dependent cytotoxicity. GO exhibits higher toxicity than rGO due to ROS generation. Small flake size graphene exhibit greater cytotoxicity compared to larger sheets due to intracellular accumulation of graphene. Das et al. [72]\nGQD-PEG AFM, TEM, FTIR, TGA, XPS, elemental analysis Diameter = 3–5 nm; height = 0.5–1 nm; 1–2 graphene layers; oxygen content 36% 10–640 μg/ml HeLa, A549 WST-1, annexin V and PI, LDH, ROS, No cytotoxicity; (HeLa cells treated with 160 μg/ml and A549 cells with 320 μg/ml doses show no cytotoxicity) Chong et al. [73] TRGO-Cl, TRGO-Br, TRGO-I\nRaman spectroscopy, elemental analysis, XPS TRGO-Cl: crystallite size/nm= 14.4, amt. of halogen = 2.1, C/O = 16.77; TRGO-Br: crystallite size/nm= 15.4, amt. of halogen = 1.6, C/O = 20.37; TRGO-I: crystallite size/nm= 22.3, amt. of halogen = 0.2, C/O = 11.75. 0–200 μg/ml A549 MTT, WST-8 Dose-dependent cytotoxicity between 3.125 and 200 μg/ml. Cytotoxicity depends on the amount of halogen content and follows the trend: TRGO-Cl N TRGOO-Br N TRGO-I. Teo et al. [74]\nFluorinated Graphene (F-G) SEM, Elemental analysis, XPS, FTIR, XRD Three different formulations with varying F content — 1.5%, 42.6%, 50.7%, C_C (284.5 eV), C–F (289 eV), C–F2 (284.5 eV), C–CF (286.1 eV), C–CF2 (287.3 eV), CF–CF2 (290.5 eV), C–F3 (293.5 eV); FTIR peaks at 1150 cm−1 (C–F) 0–400 μg/ml A549 MTT, WST-8 Dose-dependent cytotoxicity of fluorinated graphene with greater cytotoxicity for graphene containing higher mono-fluoro substituted carbon atoms. Teo et al. [75] Highly hydrogenated graphene (HHG) and GO XPS, elemental analysis HHG: C/O ratio (8.79), H (37.42%), O (10.41%); GO: C/O ratio (2.78), H (25.72%), O (37.65%)\n0–400 μg/ml A549 MTT, WST-8 Greater cytotoxicity was observed due to increased adsorption of micronutrients on hydrophobic surface of HHG sheets limiting their availability. Chng et al. [76]\nrGO, rGO + Arg, rGO + Pro\nTEM, FTIR, zeta ζ potential Size: 100 nm–1.5 μm. ζ = 19.5 (rGO), 32.5 (rGO + Arg), 39.8 (rGO + Pro) FTIR: rGO: 1769 cm−1 (C_O), 1602 cm−1 (C_C) and 1289 cm−1 (C–O); rGO + Arg and rGO + Pro: 3500– 3140 cm−1 (O–H, N–H), 1570 cm−1 (C–O, C–N), 890–810 cm−1 (N–H), 1725 cm−1 (C_O) 50 μg/ml U87 Trypan blue, XTT, gene expression Reduction in GBM tumor volume was observed. rGO + Arg shows anti-angiogenic and pro-apoptotic characteristics and has potential for GBM therapy. Sawosz et al. [77]\nGONR (PEG-DSPE dispersed) TEM, Raman Width = 125–220 nm, length = 500–2500 nm; ID/IG = 1.3\n10–400 μg/ml HeLa, MCF-7, SKBR, NIH3T3 Alamar blue, neutral red, Trypan blue, LDH, ROS Cell type dose, and time dependent cytotoxicity. Significant cell death observed for HeLa cells.\nMullick Chowdhury et al. [36]\nrGONP, GONP AFM, XPS, Raman\nGONP: length = 3.8 ± 0.4 μm; thickness = 0.7 nm 0.01– 100 μg/ml\nhMSCs FDA, ROS, RNA efflux, comet Size dependent cytotoxic response with smaller particles eliciting lower cytotoxicity compared to larger particles. Oxidative stress and direct contact interaction of extremely sharp edges of graphene were determined as most likely mechanisms for cytotoxicity of sheets and nanoplatelets. Akhavan, et al. [78] rGONP: Length = 418 ± 56 nm; thickness = 1.1–2.3 nm\nTable 1 (continued)\nMaterial Characterization Properties Treatment concentration Cell line Assays Conclusions References\nGO TEM, AFM, FTIR, Raman spectroscopy, XPS, particle-size distribution and ζ-potential Large (l-GO): size = 780 ± 410 nm, thickness = 0.9 nm, hydrodynamic diameter = 556 nm, FTIR peaks at 1720 cm−1 and band at 3400 cm−1, oxygen content = 33.1%, ID/IG = 1.27, ζ-potential =−72.9 10–200 μg/ml A549 cells CCK-8, Trypan blue, LDH, FITC-annexin V apoptosis, ROS Cell viability and ROS generation is dependent on the size of GO sheets. Smaller GO sheet exhibit greater cell viability and less ROS generation. Chang et al. [79]\nSmall (s-GO): size = 160 ± 90 nm, thickness = 0.9 nm, hydrodynamic diameter = 148 nm, FTIR peaks at 1720 cm−1 and band at 3400 cm−1, oxygen content = 37%, ID/IG = 1.26, ζ-potential = −51.9 Mixture (m-GO): size = 430 ± 300 nm, thickness = 0.9 nm, hydrodynamic diameter = 588 nm, FTIR peaks at 1720 cm−1 and band at 3400 cm−1, oxygen content = 35.8%, ID/IG = 1.25, ζ-potential = −59.2\nGO AFM, stability and dispersion capacity, carboxyl group assay, TEM GO: length = 350 nm and 2 μm; height = 3.9 and 4.05 nm; thickness = 1 nm; 0–20 μg/ml PMØ, J774A.1, LLC, MCF-7, HepG2, HUVEC LIVE/DEAD, CCK8, Coomassie Blue, CLSM, cytokine assay Cellular internalization independent of graphene size due to differential uptake mechanisms. Removal of Mn from Graphene sheets resulted in reduction of toxicity. Micron sized graphene induced stronger inflammatory response and release of cytokines. Yue et al. [80] GO, PVP-GO AFM, UV–Vis, FTIR\nGO: thickness = 1.7 nm; UV absorption peaks at 230 nm and 300 nm; FTIR peaks at 3395 cm−1, 1726 cm−1, 1620 cm−1, 1410 cm−1, 1226 cm−1, 1052 cm−1 25–100 μg/ml Dendritic cells, macrophages, T lymphocytes MTT assay, phenotype assessment, apoptosis assay PVP functionalized GO sheets are immunocompatible and may be used as adjuvants to improve vaccine therapy Zhi et al. [81] PVP-GO: thickness = 2.5 nm; UV absorption peak at 265 nm; FTIR peaks at 3395 cm−1, 1726 cm−1, 1620 cm−1\nPristine Graphene in 1% F108 pluronic SEM, XRD, Raman\nGO: ID/IG = 1.23; thickness = 2–3 nm; size = 500–1000 nm 0–100 μg/ml RAW 264.7 macrophages ROS, MMP, apoptosis, TEM, Western-blotting, PCR Pristine Graphene can induce cytotoxicity through the depletion of mitochondrial membrane potential resulting in the increase of ROS leading to the activation of MAPK and TGF-β that in turn activate caspase-3 and PARP proteins resulting in apoptosis. Li et al. [82]\nGO AFM, HRXPS, ATR-FTIR, DLS GO: thickness = 1–1.2 nm; hydrodynamic diameter = 2.4 μm and 350 nm\n5 or 100 μg/ml\nSNY-449, Mahlavu, A549, HEK293, RAW264.7\nTEM, immunofluorescence, Western-blotting, RT-PCR, Flow cytometry, siRNA GO simultaneously triggers autophagy and activates toll-like receptors TLR4/TLR9 resulting in inflammatory responses. Chen et al. [83]\nGO, C60, C60-TRIS TEM, SEM, AFM, microscopy, spectroscopy, X-ray diffraction GO: z-potential = −32.4 mV; C60-fullerenes: z-potential = −13.6; sizes = 45.2 ± 25.3 nm; C60-TRIS fullerenes: z-potential = −26.1; size = 45.6 ± 18.8 nm 1.0, 6.25, 25.0 μg/ml\nB3Z T cells LAL, FITC/Lucifer Yellow\nBoth C60 and graphene capable of modulating antigen-specific T cell responses due to ability to directly affect functional activity of dendritic cells. GO suppresses antigen processing machinery of DCs. Tkach et al. [84]\nGO, GS X-ray diffraction, AFM, XPS, DLS, Z-potential GO: diameter = 765 nm; z-potential = −40.6; GS: diameter = 3018 nm; z-potential = −37.2 mV\n3–200 μg/ml Suspended human RBCs and adherent skin fibroblasts MTT, WST-8, Trypan blue, ROS Individually dispersed GO leads to greater RBC membrane damage compared to aggregated graphene sheets. Chitosan coated GO show no hemolytic activity Liao et al. [85]\n(continued on next page)\nTable 1 (continued)\nMaterial Characterization Properties Treatment concentration Cell line Assays Conclusions References\nGO, rGO HR-TEM, 2DFFT, FTIR Size = 0.2–5 μm 0–20 μg/ml Human platelets\nFITC, immunoblotting, LDH, ROS, Electron Microscopy GO can evoke strong aggregatory response in platelets comparable to that elicited by thrombin. Singh et al. [86]\nG-NH2 FTIR, HR-TEM, FFT, Raman, z-potential, FSC, SSC Size = 2 μm 0–10 μg/ml Human platelets\nROS, MTT G-NH2 is not associated with any pro-thrombotic characteristics and does not induce platelet-stimulating response. Membrane integrity of RBCs is maintained. Singh et al. [94]\nGO, rGO HR-TEM, Raman, UV/vis, XRD Size = 100–350 nm 3–100 μg/ml L929 mice fibroblast cells\nWST-1 Dose and surfactant dependent cytotoxicity of GO and rGO. Good cytocompatibility observed for concentrations between 3.125 and 12.5 μg/ml of GO and rGO dispersed in PEG. Wojtoniszak et al. [90]\nGNP-Dex AFM Diameter = 60–100 nm; thickness = 2–4 nm\n1–10 mg/ml RBL-2H3 mast cells, human platelets\nHistamine release, platelet activation, complement activation, cytokine release, blood cell hemolysis Dextran coated graphene oxide nanoplatelets exhibit no hematological toxicity Mullick Chowdhury et al. [88]\nFBS-GO TEM, AFM Thickness = 1 nm 20 and 100 μg/ml A549 cells MTT, Bradford protein assay FBS coating of GO attenuates cytotoxicity Hu et al. [91] BSA-GO FITC-BSA, steady state fluorescence spectra, AFM, Z-potential, SEM, CLSM, flow cytometry, TEM Flake size: 50 nm or 1 μm; z-potential = −10 mV; thickness = 9.1 ± 7.1 nm 50 μg/ml C2C12 cells TEM, SEM, confocal microscopy, WST-1 BSA coated GO sheets exhibit size-dependent internalization. Small GO sheets are internalized by clathrin-mediated endocytosis and large GO sheets are internalized by phagocytosis. Mu et al. [92] FBS and human plasma serum functionalized GONRs\nAFM, XPS, Raman spectroscopy, FTIR, mass spectrometry Width = 100 nm; height = 1 nm; FTIR peaks at 3400 cm−1 (O–H), 1760 cm−1\n(C_O), 1300 cm−1 (C–OH), 1080 cm−1 (C–O); O/C ratio = 0.54; ID/IG = 1.38\n10–100 μg/ml A549 cells Trypan blue and apoptosis assay\nDose dependent cytotoxicity of protein-functionalized GONRs was observed. Concentrations below 50 μg/ml did not exhibit cytotoxic effects. Mbeh et al. [93]\nusing human epithelial (A549 cells) showed that GONRs exhibit a significantly higher cytotoxic response than GONPs over all concentrations (3–400 μg/ml). The increased cytotoxicity of GONRs was attributed to the presence of a greater amount of carbonyl groups (28.22% on GONRs vs. 11.06% on GONPs) and the high aspect ratio (width × length of GONRs ~310 × 5000 nm and GONPs ~100 × 100 nm) of GONRs.\nAkhavan et al. reported the cyto- and geno-toxicity of reducedGONRs and reduced graphene oxide sheets (rGOS) using human MSCs derived from umbilical cord blood [66]. Cell viability measured by fluorescein diacetate (FDA) test showed that rGONRs are toxic, significant cytotoxicity was observed after 1 h of exposure with rGONRs at 10 μg/ml, while\nthe same cytotoxicity was observed upon incubation with 100 μg/ ml of rGOS after 96 h. The cytotoxicity of rGOS was attributed to the generation of oxidative stress whereas the cytotoxicity of rGONRs was attributed to DNA fragmentation and chromosomal aberrations (observed even at low concentrations of ~1 μg/ml after 1 h) due to penetration of rGONRs inside the cells. These results suggested that the cytotoxicity and genotoxicity of graphene is dependent on the dose and shape of the nanomaterial (sheets vs. nanoribbons).\nJaworski et al. reported the interactions of graphene platelets with human glioblastoma U87 and U118 cells [67]. After 24 h of incubation with 100 μg/ml graphene, 42% and 52% cell mortality was observed for U87 and U118 cells, respectively. However, graphene activated\nnd (C) caspase-3 activity (apoptosis marker) of PC12 cells treated with 0.1–100 μg/ml of\napoptosis only in U118 cells not in U87 cells where apoptosis and necrosis both were activated.\n2.2. Functionalization dependent cytotoxicity\nSasidharan et al. investigated the cytotoxicity of pristine graphene and carboxylated GO (GO-COOH) using monkey renal cells at concentrations between 10 and 300 μg/ml to assess the differences between cellular interactions of hydrophobic and hydrophilic graphene derivatives [68]. Pristine graphene accumulated on the cell membrane leading to the destabilization of F-actin alignmentwhereasGO-COOHwas internalized by cells and accumulated in the perinuclear region without any membrane destabilization even at 300 μg/ml doses. These results suggested that hydrophilic (more oxidized) graphene nanoparticles may be more cytocompatible and efficient intracellular delivery systems. In another study, Matesanz et al. observed internalization and localization of poly(ethylene glycol amine)-functionalized GO sheets on F-actin filaments resulting in cell-cycle alterations, oxidative stress and apoptosis in MC3T3-E1 murine pre-osteoblasts, Saos-2 osteoblasts and RAW264.7 macrophage cells [69].\nYuan et al. investigated the cytotoxicity and distribution of three kinds of GQD (NH2, COOH and CO-N(CH3)2 functionalized) in human neural glioma C6 and A549 lung carcinoma cells using MTT and Trypan blue assay [70]. Results showed absence of apoptosis or necrosis at all treatment concentrations (10–200 μg/ml) after 24 h for all three GQD groups. Furthermore, Raman spectroscopic analysis showed intracellular accumulation of all three GQDs; nuclear translocation was absent.\nHorváth et al. evaluated the toxicity of GO and rGO in A549 human lung epithelial cells and RAW 264.7 mouse peritoneal macrophages usingMTT assay, fluorometric DNAassay andfluorometricmicroculture cytotoxicity assay (FMCA) [71]. Cells treated with 0.0125–12.5 μg/cm2\nof GO or rGO for 5 days showed a dose dependent cytotoxicity. Significant differences in cell death between control and GO or rGO treated cells were observed from day 2 in A549 cells and day 3 in RAW 264.7 macrophages at concentrations of 1.25–12.5 μg/cm2. Cells treated with lower concentrations of GO (0.0125–0.125 μg/cm2) did not lead to an increases in ROS production. Cellular internalization of GO was observed in phagoendosomes without signs of any intracellular damage.\nAggregation of pristine graphene in biological buffers could result in greater cytotoxicity in comparison to oxidized graphene derivatives that can be readily dispersed without aggregation during the duration of cytotoxicity studies. Das et al. reported higher cytotoxicity of GO sheets compared to reduced graphene oxide sheets of similar dimensions, an effect attributed to the presence of high density of oxidative functional groups on the surface of GO which lead to the generation of reactive oxygen species [72]. HUVEC cells treated with 1, 5 or 10 μg/ml concentration of GO and rGO showed a dose and functionalization state dependent cytotoxicity. Furthermore, a size dependent cytotoxicity was also observed for both GO and rGO. Upon a 10 fold reduction in the size of oxidized and reduced graphene sheets, smaller graphene nanosheets showed a higher toxicity compared to non-sonicated larger GO or rGO sheets which was attributed to an increased intracellular interaction and uptake of small sized graphene. However, Chong et al. have reported the low cytotoxicity of PEG dispersed graphene quantum dots (N30 nm diameter stacks of 1–10 graphene layers) upto 160 μg/ml for HeLa cells and 320 μg/ml for A549 cells (Fig. 6) [73].\nTeo et al. investigated the cytotoxicity of halogenated graphene sheets [74]. GO sheets prepared by oxidation of graphitewere thermally reduced with chlorine, bromine, and iodine vapor to form chlorine-, bromine-, and iodine-doped graphene, respectively (TRGO-Cl, TRGOBr, and TRGO-I). A549 cells were treated with 0–200 μg/ml\nconcentration of halogenated graphene for 24 h and cell viability was analyzed using MTT andWST-8 assays. Results showed that all halogenated graphene nanoparticles exhibit a dose-dependent cytotoxicity between 3.125 and 200 μg/mlwith TRGO-Cl exhibiting highest cytotoxicity (~25.7% cell viability at maximum treatment concentration of 200 μg/ml). The levels of observed cytotoxicity followed the trend: TRGO-Cl N TRGO-Br N TRGO-I andwas dependent on the amount of halogen functionalization. In another study, Teo et al. reported the cytotoxicity of fluorinated graphene (FG) [75]. Three types of graphene derivatives with varying amount of fluorine content were prepared (1.5%, 42.6%, and 50.7%). A549 cells were treated with 0–400 μg/ml of fluorinated graphene and cytotoxicity was analyzed using MTT and WST-8 assays. Results show a dose-dependent cytotoxicity response with greater cytotoxicity observed for graphene with higher monofluoro substituted carbon atoms. In a similar study, Chng et al. synthesized highly hydrogenated graphene (HHG) and evaluated their in vitro cytotoxicity profile against A548 cells [76]. After 24 h of exposure, MTT andWST-8 assay results show a dose-dependent cytotoxicity of HHG compared to GO controls at all treatment concentrations (0– 400 μg/ml). The increased cytotoxicity of HHG was hypothetically\nattributed to the preferential adsorption of essential micronutrients on the hydrophobic surfaces of HHG compared to hydrophilic surfaces of GO sheets, thereby limiting nutrient availability.\nSawosz et al. have investigated the cytotoxicity of arginine (Arg) and proline (Pro) functionalized rGO using U87 glioblastoma multiforme (GBM) cells and tumors in vitro [77]. Cells were treated with 50 μg/ml of rGO, rGO + Arg and rGO + Pro for 24 h and cell viability was evaluated using Trypan blue and XTT assay. Results show ~40% cell death for rGO group and ~15% cell death for rGO + Arg and rGO + Pro groups. GBM tumors cultured on chorioallantoic membrane of chicken embryo were injected with rGO, rGO+ Arg and rGO+ Pro for 3 days. A greater reduction in tumor volume was observed for rGO group, compared to rGO+Arg and rGO+ Pro groups, which reduced the tumor volume albeit lower than rGO. Histological analysis of tumors showed the presence of white gaps and rupture sites indicating necrosis and endothelial proliferation. rGO + Arg were observed close to microglial cells and small blood vessels whereas rGO + Pro were aligned outside the cells in the tissue rather than inside the cells. Tumor cells require arginine for aggressive growth, therefore rGO + Arg were present in the outer layers of tumor — site for active angiogenesis. Gene expression\nanalysis suggests that rGO + Arg, leads to the down regulation of MDM2 expression and increased expression of NQO1. Furthermore, no change in the expression of COX6 and CASP3 mRNA expression were observed. These results suggest that rGO + Arg is anti-angiogenic and pro-apoptotic and has potential for GBM therapy.\n2.3. Cell dependent cytotoxicity\nCytotoxicity of certain types of graphene nanoparticles could be dependent on cell type. Mullick-Chowdhury et al. reported the cytotoxicity screening of graphene oxide nanoribbons (GONRs) dispersed in DSPEPEG (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N[amino(polyethylene glycol)]) using six different assays and four representative cell lines: NIH-3T3 mouse fibroblast cells (NIH-3T3), Henrietta Lacks cells (HeLa) derived from cervical cancer tissue, Michigan cancer foundation-7 breast cancer cells (MCF7), and Sloan Kettering breast cancer cells (SKBR3) [36]. All cell lines exhibit a dose dependent (10–400 μg/ ml) and time dependent (12–48 h) decrease in cell viability. HeLa cells showed the least cell viability (5–25%), compared to other cell types (78–100%), depending on the treatment concentration and exposure time. An increased cellular uptake of GONRswas observed andattributed to an increased cytotoxic response in HeLa cells. TEM imaging (Fig. 7) show the formation of cytoplasmic vesicles to facilitate intracellular uptake. Swollen and ruptured plasma membrane was observed suggesting necrotic cell death.\n2.4. Size dependent cytotoxicity\nAkhavan et al. investigated the cytotoxicity of reduced graphene oxide nanoplatelets (rGONPs) of various sizes (11 ± 4 nm, 91 ± 37 nm and 418 ± 56 nm) and as prepared GO (3.8 ± 0.4 μm) using human mesenchymal stem cells (hMSCs) [78]. The cytotoxicity and cell viability was assessed using fluorescein diacetate (FDA) assay, ROS assay, RNA efflux and Comet assay. Results showed a significant sizedependent cytotoxicity; a treatment concentration of 100 μg/ml rGONPs (11 ± 4 nm) showed N95% cell death which reduced with increasing lateral size dimensions (Fig. 8). As-prepared GO with largest lateral size dimensions (3.8 ± 0.4 μm) showed lowest (~20%) cell death. Results showed that rGONPs can also induce DNA fragmentation even at a low concentration of 0.1 μg/ml.\nChang et al. investigated the cytotoxicity of GO of various sizes (160 ± 90 nm, 430 ± 300 nm and 780 ± 410 nm) using A549 (human lung adenocarcinoma) cells [79]. Cell viability was assessed using CCK-8 assay after 24–72 h of incubation at GO concentrations between 10–200 μg/ml. Small GO sheets (160 ± 90 nm) showed lower cell viability of ~67% compared to large GO sheets (430 ± 300 nm and 780 ± 410 nm) that showed N80% cell viability. However, GO sheets of dimensions 780 ± 410 nm show N50% higher ROS generation compared to GO of dimensions 160±90 nmand 430±300 nm. The results suggested that the cell viability and ROS generation potential of GO is dependent on the size of graphene sheets.\nDasgupta et al. reported the size dependent cytotoxicity of graphene oxide nanoribbons (GONRs) after post processing sonication steps that result in a size reduction of nanoparticles [60]. GONRs were dispersed in cell culture media by bath sonication (5 or 20 min) or probe sonication (1, 5 or 10 min) and MCF-7 and A549 cells were exposed to GONR containing media at 20 μg/ml concentrations. LDH assay, presto blue assay and ROS generation showed that GONR solutions prepared via probe sonication results in a decrease of metabolic stress of cells in vitro. No adverse effects were noted when cells were exposed to non-sonicated and bath sonicated solutions of GONRs. TEM analysis showed presence of smaller GONR fragments and carbonaceous debris after probe sonication,whichmay be the cause of observed cytotoxicity.\nYue et al. reported that cellular internalization and regulation of cellular responses are directly dependent on the lateral dimension of GO [80]. In this study, six representative cell lines (peritoneal macrophage\nPMØ, murine macrophage J774A.1, murine Lewis lung carcinoma LLC, human breast cancer MCF-7, human hepatocarcinoma cells HepG2, and human umbilical vein endothelial cells HUVEC) were exposed to GO sheets of different sizes (350 nm and 2 μm) at a concentration of 20 μg/ml for cell viability analysis (LIVE/DEAD assay). After 48 h of incubation, a significant cytotoxicity (~40–60% cell death) was detected for all six cell types. However, cell viability was restored upon the removal of manganese (Mn), an impurity present during the oxidative synthesis of GO. Cells upon treatment withMn-free GO at 20 μg/ml showed ~80– 100% cell viability. The results highlighted the importance of purification steps involved during the synthesis of GO to eliminate false positive contributions frommetal ions. PMØ and J774A.1macrophage cells were treated with 2–6 μg/ml of nano- and micro-sized GO. Cellular uptake studies showed that internalization of GO was independent of size and both nano- andmicro-sized GO (350 nmand 2 μm)had similar intracellular accumulation. The analyses of uptakemechanisms showed that GO of size 350 nmwas wrapped by filopodia of macrophages and internalized whereas GO of 2 μm was internalized via direct penetration. Post cellular internalization, the micron sized GO developed wrinkle formations and appeared to be sequestered into lysosomes. Furthermore, the micron sized GO induced a stronger inflammatory response and release of cytokines. These results suggested that cytokine release and inflammatory response are dependent on the size of GO sheets.\n2.5. Immunotoxicity of graphene\nZhi et al. reported the immunotoxicity of GO with and without functionalization by poly(vinyl pyrrolidone) (PVP) against human immune cells such as T lymphocytes, dendritic cells and macrophages [81]. Results showed that PVP-coated GO (PVP-GO) exhibit lower immunogenicity compared to pristine GO at concentrations between 25 and 100 μg/ml. The differentiation and maturation of dendritic cells was unaffected upon incubation with PVP-GO; the levels of secreted TNF-α and IL-1β showed no significant differences between GO and PVP-GO groups, yet the secretion of IL-6 was maintained in PVP-GO group. Incubationwith PVP-GO also delayed the apoptosis of T lymphocytes and stimulated and enhanced the physiological activity of macrophages.\nLi et al. investigated the interactions of pristine graphene with RAW 264.7 macrophage cells at concentrations between 5 and 100 μg/ml (dispersed in 1% pluronic F108 surfactant) [82]. Pristine graphene showed dose-dependent cytotoxicity in RAW 264.7 cells; ~78% cell death was observed at 100 μg/ml treatment concentrations. Further investigation of the mechanisms of cytotoxicity showed that interaction of pristine graphenewithmacrophage cellmembrane leads todepletion ofmitochondrialmembrane potential thereby increasing ROS leading to the activation of apoptotic cascade. MAPK and TGF-β signaling pathwayswere activatedwhich in turn activated two pro-apoptotic proteins (Bim and Bax). Consequently, caspase-3 and PARP proteins were activated triggering apoptosis. The identification ofmechanisms of cytotoxicity is extremely important and provides information towards development of strategies to control graphene-induced apoptosis.\nChen et al. showed that GO triggers autophagy (catabolic selfdestruction of dysfunctional cellular components) in liver cancer cells (SNU-449 and mahlavu), lung cancer cells (A549), human embryonic kidney cell (HEK293), and RAW 264.7 macrophages by stimulating toll-like receptor signaling cascade (release of cytokines such as IL-2, IFN-γ, IL-10 and TNF-α) at treatment concentrations of 5 or 100 μg/ml [83]. Toll like receptors — TLR4 and TLR9 were activated resulting in GO-mediated inflammatory responses. The results of this study show that GO exposure to cells simultaneously triggers autophagy and TLR4/9 mediated inflammatory responses.\nTkach et al. showed that treatment of dendritic cells (DCs) with GO at 6.25 μg/ml results in an impaired stimulatory potential of DCs (activation of T-cells); treatment with similar concentrations of fullerenes (C60 and C60-tris) promotes the ability of DCs to activate T-cells [84]. Further\nanalysis showed that GO did not alter antigen uptake by DCs nor inhibit antigen peptide presenting abilities of DCs. However, exposure of DCs to GO resulted in suppression of an immunoproteosome subunit (LMP-7), which is a critical component of MHC-I antigen processing machinery (APM) illustrating the mechanism of inactivation of DCs by GO. These results suggested that GO may modulate antigen-specific T-cell response and emphasized the importance of elaborate assessment of immunomodulatory effects of graphene nanoparticles.\n2.6. Hemolytic toxicity of graphene\nHemolytic potential of graphene is dependent on the size and aggregation state of individual nanosheets. Liao et al. investigated the cytotoxicity of graphene and GO using human erythrocytes (RBCs) [85].\nHemolysis was quantified by measuring the amount of hemoglobin released due to RBC membrane damage upon incubation with graphene and GO at 3–200 μg/ml for 3 h. At 200 μg/ml, individually dispersed GO sheets showed ~60% hemolysis, significantly higher than graphene dispersions which showed ~20% hemolysis. The aggregation of graphene in DI water resulted in fewer cell-contractable ROS groups on the surface of graphene. However, cells interact with several ROS species present on the surface of individually dispersed GO, leading to greater hemolysis. Chitosan coated GO aggregate in DI water due to pH dependent conformational change of chitosan resulting in no hemolytic toxicity of GO.\nSingh et al. have reported the in vitro hemolytic toxicity of GO and rGO using human platelets [86]. Freshly isolated suspension of platelets exposed to GO (2 μg/ml) showed aggregation and platelet activation at\nlevels greater than induction by thrombin (1 U/ml, a strong platelet agonist). Exposure of platelets to GO resulted in the activation of Src kinases and release of calcium, leading to thrombus formation. In comparison, rGO at 2 μg/ml induced minor platelet aggregation, only 10% of aggregation induced by GO. In another study, Singh et al. showed that amine functionalized GO does not induce lysis of erythrocytes and has no stimulatory effects on platelets highlighting their nonthrombotoxic properties [87]. The results suggested that surface modifications of graphene nanoparticles play an important role towards defining their hemolytic activity.\nMullick Chowdhury et al. showed that graphene oxide nanoplatelets (GONPs) functionalized with biocompatible polymer dextran (GNPDex) exhibit no hematological toxicity [88]. RBL-2H3 mast cells and human platelets showed no histamine release, platelet activation or blood cell hemolysis upon treatment with GNP-Dex at concentrations ranging from 1 to 10 mg/ml. At concentrations N7 mg/ml, RBL-2H3 cells showed 12–20% increase in complement protein expression. However, cytokine TNF-alpha and IL-10 levels remainedwithin physiological levels. In another study,Mullick Chowdhury et al. investigated the interactions of DSPE-PEG functionalized graphene oxide nanoribbons\n(GONRs) with blood vascular system components [89]. No release of histamine, platelet PF4 activation and complement activation was observed from mast cells upto treatment concentrations of 80 μg/ml. TEM imaging shows significant uptake of GONRs into endothelial cells and exhibit a concentration dependent reduction of cell viability. Results indicated that DSPE-PEG functionalized GONRs could be hemocompatible upto a concentration of 80 μg/ml.\n2.7. Surfactant/coating dependent cytotoxicity\nWojtoniszak et al. investigated the cytotoxicity of GO and rGO dispersed using three surfactants (polyethylene glycol (PEG), polyethylene glycol–polypropylene glycol–polyethylene glycol (Pluronic P123), and sodium deoxycholate (DOC)) at concentrations between 3.12 and 100 μg/ml using mice fibroblasts L929 cells [90]. Cytotoxicity analysis using WST-1 assay showed that the cell viability is dependent on the surfactant used to stabilize the suspension, chemical state of material (oxidized or reduced), and the treatment concentration. GO functionalized with PEG exhibits the lowest toxicity (cell viability ~36.3% at 100 μg/ml) whereas GO functionalized with DOC and Pluronic P123 shows 15.5% and 6.3% cell viability, respectively. L929 cells exposed to the PEG dispersed rGO between 3.125 and 25 μg/ml show ~95–60% cell viability. Similar results are observed for rGO functionalized with DOC, however rGO functionalized with Pluronic P123 showed least cell viability. Both, GO and rGO showed good cytocompatibility between 3.125 and 12.5 μg/ml. GO dispersed in PEG showed the best cytocompatibility. These results suggested that GO and rGO exhibit a dose- and surfactant-dependent cytotoxicity.\nHu et al. investigated the cytotoxic effects of fetal bovine serum (FBS) coated GO using A549 cells [91]. At 100 μg/ml exposure, FBS coated GO showed ~90% cell viability whereas GO without FBS coating showed only ~50% cell viability. TEM analysis showed irreversible cell membrane damage after 2 h of exposure to GO. FBS coated GO did not induce any membrane damage. These results suggested that cytotoxicity of GO is a result of direct physical interactions with cell membrane that can be mitigated by coating GO with FBS.\nMu et al. investigated the cellular uptake of bovine serum albumin (BSA) coatedGO (flake size ~500nmor ~1 μm)bymousemesenchymal progenitor C2C12 cells [92]. Results showed that small GO (~500 nm) are internalized by clathrin-mediated endocytosis whereas large GO (~1 μm) are internalized by phagocytosis. Large GO sheets translocate into the reticuloendothelial system and small GO sheets are accumulated in various organelles.\nMbeh et al. have reported the cytotoxicity of albumin functionalized GONRs against A549 cells evaluated using Trypan blue and apoptosis (hoechst and propidium iodide staining) [93]. A dose-dependent cytotoxicity was observed wherein albumin functionalized GONRs at concentrations b50 μg/ml did not exhibit significant cytotoxicity, whereas incubation of A549 cells with higher concentrations (100 μg/ml) resulted in loss of cell proliferation and induction of apoptosis.\n3. In vivo toxicology\nA crucial step in the toxicological assessment of graphene-based formulations is their dose- and/or time-dependent safety pharmacological assessment in small and large animal models under various modes of administration (e.g. intravenous, intraperitoneal, oral). Table 2 summarizes the in vivo toxicological studies of graphene-based formulations.\n3.1. Intravenous administration\nIntravenous (IV) administration is a widely employed method wherein a needle is inserted into the vein and formulation is administered through that needle. It is the preferredmode of systemically introducing pharmaceutical formulations for imaging, drug delivery or therapy. Singh et al. investigated the in vivo platelet aggregation of GO\nand rGO nanosheets. GO and rGO sheets were administered intravenously via tail vein injection to Swiss male mice (8–12 weeks old) at 250 μg/kg dose for 15min [86]. A collagen-epinephrinemixturewas administered as positive control whereas saline was used as the negative control. After 15 min post injection, the mice were euthanized and lungs were harvested for histological analysis. Hematoxylin and eosin (H&E) staining showed ~48% thromboembolism whereas the collagen–epinephrine control solution resulted in ~64% occlusion of blood vessels. rGO was not as effective as GO towards platelet activation; rGO administration resulted in ~8% blood vessel blockage, significantly less than GO. These results showed that GO induces severe pulmonary thromboembolism thatmay be attributed to the greater surface charge density of graphene surface upon oxidation. In a follow-up study, Singh et al. investigated the in vivo thrombogenic properties of amine-modified GO (NH2-GO) [94]. Compared to GO which induces platelet aggregation, NH2-GO does not elicit any stimulatory effects on platelets or pulmonary thromboembolism. H&E staining revealed that GO resulted in ~46% blockage of pulmonary blood vessels while NH2GO showed no signs of obstruction.\nSasidharan et al. reported the long term in vivo toxicology of pristine and functionalized few layered graphene (FLG), FLG-COOH and FLGPEG (Fig. 9A) administered intravenously to Swiss albino mice at 20 mg/kg for 1, 8, 30, and 90 days [95]. Sterile physiological saline was administered to control animals. All animals survived over the course of 90 days, however, the body weight of FLG, FLG-COOH and FLG-PEG treatedmicewas lower on days 60–90 compared to controlmice. To dynamically track the in vivo biodistribution, 99mTc labeled FLG-COOH and FLG-PEG were injected and whole body images were captured at 0.1, 1, 3, 12, and 24h (Fig. 9B). 99mTc-FLG-COOH showed accumulation and retention in lungs over 24 h. However, after 12 h, 99mTc-FLG-PEG was redistributed to RES system such as spleen and liver. FLG-COOH accumulated in the lungs resulting in thicker alveolar walls. Injection of FLG and FLG-COOH resulted in extensive spleen damage including the loss of dividing line between red pulp and marginal zone, abundance of megakaryocytes in the red pulp 90 days post injection, and lack of lymphocytes in the white pulp. On the contrary, FLG-PEG did not result in any injury to themarginal zone and only several black spots in the red pulp were observed. Liver tissue analysis revealed that FLG and FLGCOOH induced liver tissue degeneration while FLG-PEG did not and was observed as black spots. However, kidney necrosis was observed upon administration of both FLG and FLG-COOH as early as the first day of administration. FLG-PEG was noted as black spots on the tissue but did not exhibit any signs of necrosis. FLG, FLG-COOH, and FLG-PEG did not damage brain, heart, or testis suggesting that graphene cannot pass through the blood–brain barrier.\nZhang et al. have reported the toxicity of dextran functionalized graphene oxide (GO-Dex) intravenously administered via tail vein injection to female Balb/c mice at 20 mg/kg dose for 1, 3, and 7 days [96]. H&E staining of liver sections showed a significant increase in black spots – areas of GO aggregation – after 7 days indicating clearance of GO-Dex from mouse liver. For biodistribution and pharmacokinetic studies, 125I labeled GO-Dex (125I-GO-Dex) was injected via tail vein at 4 mg/kg concentration and blood was collected after 4, 24, 72, and 168 h. After 4 h of administration, 125I-GO-Dex was found in liver, spleen, stomach, lungs, kidney, and intestine. At later time points, 125IGO-Dex was predominantly found in the liver and spleen. Histological sections of liver and kidney confirmed the presence of 125I-GO-Dex as black dots that were abundant at day 1 and decreased at later time points suggesting the excretion of 125I-GO-Dex via renal and fecal pathways. Since GO-Dex has a wide size distribution, small GO-Dex sheets could pass through glomerulus for renal excretion and large GO-Dex sheets accumulated in RES organs could be excreted out in feces via biliary pathway.\nZhang et al. have reported the distribution and biocompatibility of GO after intravenous administration to male Sprague Dawley rats at 1 and 10 mg/kg dose [97]. Histopathological analysis of lung, liver, spleen\nTable 2 In vivo toxicity of graphene.\nMaterial Characterization Properties Animal model Dose, route and duration Conclusion References\nIntravenous administration GO, rGO HR-TEM,\nzeta-potential, UV–Vis NIR spectroscopy, flow cytometry and fluorescence spectroscopy GO: size = 0.2–5 μm, bilayer GO sheets with intersheet distance of 0.40 ± 0.02 nm. FFT diffraction pattern confirms single and bi-layer GO. FTIR peak at 1735 cm−1 confirming C_O groups. rGO: size = 0.2–5 μm, UV Vis: red shift to 260 nm. FTIR confirms removal of oxygenated functional groups. Swiss male mice (8–12 weeks old) Intravenous administration. 250 μg/kg dose injected via tail vein. Lungs collected for histological analysis (H&E staining) after 15 min. GO: thrombotoxicity, pulmonary embolism and human platelet aggregation observed. Nearly 48% lung vessels totally or partially obstructed by platelet thrombosis. rGO: limited platelet aggression and reduced thromboembolism compared to GO. rGO induce ~8% total or partial obstruction of lung blood vessels. Singh et al. [86]\nAmine Graphene Oxide (NH2-GO) HR-TEM, FTIR, Raman spectroscopy, zeta-potential, UV–Vis NIR spectroscopy, flow cytometry Sheet size: 2 μm, FTIR peaks: 950 cm−1, 1250 cm−1, 1573 cm−1; Raman spectroscopy: G band = 1580 cm−1, D band = 1350 cm−1. High absorbance in visible and NIR region. No detectable fluorescence properties. Swiss male mice (8–12 weeks old) Intravenous administration. 250 μg/kg dose injected via tail vein. Lungs collected for histological analysis (H&E staining) after 15 min. NH2-GO: no thrombotoxicity. Blood vessels appear normal with no indication of occlusive pathology Singh et al. [94] FLG, FLG-COOH, FLG-PEG, 99mTc-FLG-COOH, 99mTc-FLG-PEG HR-TEM, AFM, Raman spectroscopy, FTIR, BET\nGraphene sheets with 2–4 layers; size: 128 ± 37.6 nm; thickness: 0.7 ± 0.31 nm; Raman peaks at 1325 cm−1, 1575 cm−1, and 2640 cm−1 corresponding to D, G, and 2D bands, respectively; BET surface area = 210–650 m2/g. FTIR peaks at 3400 cm−1, 1715 cm−1 Swiss albino mice (4–5 weeks old) Intravenous administration. A single dose of 20 mg/kg injected via tail vein. Brain, kidney, lungs, liver, spleen, intestine, heart and testis were collected after 1, 8, 30, and 90 days. Mice survived after 90 days of graphene administration. Body weight of mice on days 60, 70, 80, and 90 were significantly lower than untreated mice. Sasidharan et al. [95]\nGO-Dex, 125I-GO-Dex\nAFM, FTIR, TGA, UV–Vis Size: 50–100 nm; thickness: 2.8 nm; UV–VIS absorbance peak at 230–240 nm\nFemale Balb/c mice\nIntravenous administration. 20 mg/kg GO-Dex injected into tail vein. Major organs collected for histology after 1, 3 and 7 days post injection. 125I-GO-Dex injected at a dose of 4 mg/kg. Blood collected for pharmacokinetics and biodistribution study at 4, 24, 72, and 168 h post injection. No short-term toxicity, excretion via renal and fecal pathways. Zhang et al. [96]\nGO, 188Re-GO AFM, Raman spectroscopy, zeta potential\nSize: 100–800 nm; thickness: 1 nm; single layered sheets; zeta potential = −29.87 (GO), −20.47 (188Re-GO) Kun Ming mice (Sprague–Dawley rats, 6–8 weeks old) Intravenous administration. GO: 1 and 10 mg/kg dose. Histopathological analysis of lung, liver, spleen and kidneys performed after 14 days post injection. 188Re-GO: 200 μl (50 μCi) dose. Biodistribution measured after 1, 3, 6, 12, 24, and 48 h post injection. Dose dependent toxicity. No significant pathological changes were observed after day 1 whereas inflammation, cell infiltration, pulmonary edema and granuloma formation were observed after 14 days. GO exhibits high blood half life (5.3 ± 1.2 h) and low RES uptake. Maximum uptake was observed in lungs. Zhang et al. [97]\nGO AFM, TEM, FTIR Monolayer sheet; Thickness: 1 nm; FTIR peaks at 3395 cm−1\n(O–H), 1726 cm−1 (C_O), 1426 cm−1 (O–H), 1226 cm−1 (C–O), 1052 cm−1 (C–O) Female Kunming mice (Sprague–Dawley rats, 4–5 weeks old) Intravenous administration. Doses: 0 mg, 0.1 mg, 0.25 mg and 0.4 mg per mouse injected via tail vein. Histology and biodistribution analysis performed after 1, 7, and 30 days post injection. No toxicity observed upto 0.25 mg dose. Chronic toxicity observed for 0.4 mg dose with 4/9 mice death. Long-term accumulation observed in liver, kidneys and spleen along with granuloma formation in lungs. No accumulation in brain — GO cannot pass blood brain barrier. Wang et al. [98]\nGO, 125I-GO AFM, TEM, Raman spectroscopy, infrared spectroscopy, particle size distribution, zeta potential, DLS Size: large GO = 1–5 μm, small GO = 110–500 nm; thickness: 0.9 nm (single layer); Dh for large GO = 914 nm, Dh for small GO = 243 nm. Male ICR mice Intravenous administration. Single dose of 1–10 mg/kg administered via tail vein injection for biodistribution and pharmacokinetics studies. Tissue samples collected after 2–180 min post injection. For ultrastructural observation, 10 mg/kg dose was administered and lungs and liver collected 10 min post injection. GO elimination from blood was observed. Large GO sheets accumulated in lungs and small GO accumulated in liver. Small GO has a longer blood half-life than large GO. Liu et al. [99]\n(continued on next page)\nTable 2 (continued)\nMaterial Characterization Properties Animal model Dose, route and duration Conclusion References\nNanoGraphene Sheets functionalized with polyethylene glycol (NGS-PEG) AFM, FTIR, UV–Vis, NIR fluorescence\nSize: 10–50 nm; single or bi-layered sheets; FTIR peaks at 2800 cm−1 (C–H) and 1100–1500 cm−1 (C–O) Tumor bearing Balb/c mice Intravenous administration. Single dose of 20 mg/kg. Organs harvested after 1, 6, and 24 h post injection. High tumor build up, no sign of abnormalities on the kidney, spleen, heart, liver and lung. Gradual elimination. Low uptake by RES. Photothermal therapy resulted in disappearance of tumor after 1-day treatment and an increase in the longevity of mouse by at least 24 days. Yang et al. [100]\nNanoGraphene Sheets functionalized with polyethylene glycol (NGS-PEG), 125I-NGS-PEG AFM, FTIR, XPS Size: 10–30 nm; single or bi-layered GO sheets; FTIR peaks at 2800 cm−1 (C–H) and 1100–1500 cm−1 (C–O) Balb/c mice Intravenous administration. Pharmacokinetics study: Mice injected with 4-mg/kg doses of 125I-NGS-PEG and blood drawn between 0 and 25 h. Biodistribution study: 4 mg/kg dose injected then sacrificed at 1 h, 6 h, 1 d, 3 d, 7 d, 15 d, 30 d, 60 d. Blood biochemistry/hematology study: injected intravenously 20 mg/kg sacrificed at 3, 7, 20, 40, and 90 days. NGS-PEG mainly accumulates in the reticuloendothelial system and can be gradually cleared by renal and fecal excretion. Yang et al. [101] GNP-Dex TEM, AFM Disk shaped; diameter: 100 nm; thickness: 3 nm\nWistar rats Intravenous administration. Dose: 1, 50, and 100 mg/kg 3 times a week for 3 weeks. Heart, liver, kidney and brain harvested for histology. 1 mg/kg and 50 mg/kg doses show no sign of toxicity. All vital parameters such as body weight, blood pressure, breathing and heart rate were normal. Two out of 8 animals died for 100 mg/kg dose after 2 weeks. Kanakia et al. [102]\nGNP-Dex AFM Diameter range: 60–100 nm. Thickness: 2–4 nm. Soluble in water up to 100 mg/ml Male hamsters Hamsters' left cheek pouch was exteriorized, pinned across a Lucite pedestal, and cleared of connective tissue. GNP-Dex was micropipetted at dosages of 0, 0.1, 0.5, 2.6, 10, 50 mg/ml at 30 s exposure and 5-min washout between dosages. GNP-Dex showed no signs of arteriole dilation upto concentrations of 50 mg/ml. Chowdhury et al. [88] GNP-Dex TEM, AFM Disk shaped; diameter: 100 nm; thickness: 3 nm\nWistar male rats Intravenous administration. Single doses of 1, 25, 50, 125, 250 and 500 mg/kg were injected via tail vein. Organs were harvested 1 and 30 days post injection of GNP-Dex for biodistribution and histopathological analysis. Maximum tolerable dosage is between 50 mg/kg and 125 mg/kg. No changes in brain, neither cardiovascular, nor hematological factors at dosages less than 125 mg/kg. Kanakia et al. [103]\nGO, GO-NH2, GO-DOTA, 111In-DOTA-GO TEM, AFM, FTIR, XPS, TGA, Raman spectroscopy Size: 50–2000 nm; single or bilayered GO sheets, FTIR peaks at 3400 cm−1 (OH), 1729 cm−1\n(C_O), 1624 cm−1 (H–O–H), 1374 cm−1 (O–H), 1225 cm−1 (C–O–C); ID/IG = 1.34 (GO-DOTA), 1.21 (GO), 0.31 (graphite)\nC57BL/6 mice (6–8 weeks)\nIntravenous administration. A dose of 200 μl of 111In-GO-DOTA (5–6 MBq) was injected via tail vein (t = 1, 4, 24 h) for SPECT/CT study. For biodistribution study, animals were injected with 1–2 MBq equivalent dose for 1, 4, and 24 h. Maximum accumulation was observed in liver and spleen, however, GO translocation from liver to spleen was also observed. No biliary excretion or metabolism by hepatocytes was observed. GO was eliminated via urine. These results suggest that chemical functionalization of GO sheets can alter their biodistribution. Jasim et al. [104]\nIntraperitoneal administration 125I labeled GO, nGO-PEG, RGO-PEG and nRGO-PEG\nAFM Size: diameters of GO, nGO-PEG, RGO-PEG and nRGO-PEG are 450, 25, 50 and 27 nm, respectively. Average thickness of GO, GO-PEG, RGO-PEG, and nRGO-PEG are 0.94, 1.22, 4.43 and 5.66 nm, respectively. Female Balb/c mice\nIntraperitoneal administration: 80 mice were intraperitoneally injected with GO, nGO-PEG, RGO-PEG, and nRGO-PEG at 50 mg/kg (20 μCi) and euthanized 1, 7, 30, and 90 days post administration. Oral administration: 15 mice were orally injected with nGO-PEG at 100 mg/kg dose and euthanized at 1, 7, and 30 days post injection. Blood was collected for serum biochemistry and blood panel analysis. All major organs were collected for histology and biodistribution. High accumulation in liver and spleen after intraperitoneal administration. No accumulation was observed after oral administration. PEG GO derivatives were phagocytized in the RES system in a size and surface coating dependent manner. Despite long-term retention, no toxicity was observed in blood analysis, serum biochemistry and histology analysis. Toxicity and biodistribution of graphene is dependent on size, surface coatings and route of administration. Yang et al. [105]\nTable 2 (continued)\nMaterial Characterization Properties Animal model Dose, route and duration Conclusion References\ncGO and pGO (highly pure GO) TEM, AFM, FTIR, Raman spectroscopy, UV–Vis Size: cGO: N 0.1 μm2, pGO: 0.01–0.02 μm2; Thickness ~ 1 nm. UV absorbance peak at 230 nm. Raman spectroscopy: D Band= 1350 cm−1, G Band = 1590 cm−1 C57BL/6 mice (6–8 weeks old) Intraperitoneal administration: dose 50 μg in 0.5 ml saline. Animals euthanized 24 h and 7 days post administration and assessment of inflammatory reactions, protein levels in peritoneal lavage and histology of diaphragm was performed. Highly purified single layered GO sheets show no signs of inflammation or granuloma formation upto 50-μg/animal dose administered intraperitoneally. Ali-Boucetta et al. [106] GO-pluronic hydrogel TEM, SEM, rheology Size: 100–500 nm. Gelation at pH = 7, absorbs IR light\nFemale Balb/c mice (6–7 weeks old) Intraperitoneal administration. Gel composition: 0.4% GO-0.25–1% pluronic. GO-pluronic gel implanted in subcutaneous cavity of mice. After 3 and 8 weeks post implantation, dermal tissue was analyzed by histology. No toxicity was observed. Mild inflammation observed after 3 weeks of implantation. After 8 weeks, the number of macrophages reduced. No tissue necrosis, acute inflammation or tissue hemorrhaging was observed suggesting a good biocompatibility of GO-pluronic gels. Sahu et al. [107]\nGO, graphite, nanodiamonds (ND) TEM, Zeta potential\nSize: 8–25 nm (GO), 3–4 nm (graphite and ND); zeta potential: −83.8 ± 0.25 mV (GO), 12.5 ± 0.43 (graphite), −15.8 ± 0.55 mV (ND) Female Wistar rats (6 weeks old)\nIntraperitoneal administration: 40 mice were injected with a dose of 4 mg/kg administered for 4 or 12 weeks at 3-day intervals. Liver and blood collected post euthanasia for analysis of blood serum biochemical indices, blood morphology and liver physiology. No toxicity was observed. Blood biochemical indices and liver enzymes were within physiological range. Large aggregates of nanomaterials were observed at the injection site, smaller aggregates were observed in liver serosa and mesentery. Strojny et al. [108]\nOral administration GO TEM, AFM, XRD,\nFTIR, XPS, UV–Vis and Raman spectroscopy\nSize: 0.2 μm; thickness = 1.8 nm; XRD peaks at 12° and 43°; UV–Vis peaks at 232 nm and 280 nm; FTIR peaks at 1715 cm−1 (C_O), 1120 cm−1 (C–O–C), 3400 and 1620 cm−1 (O–H); XPS — C:O molar ratio 2:11, C1s peaks at 285 eV (C_C), 286.1 eV (C–O), 287.5 eV (C_O), 288.5 eV (C_O); Raman peaks at 1355 cm−1 (D band), 1588 cm−1 (G band) and 2680 cm−1 (2D band). Female ICR mice (6–8 weeks old) Oral administration. Dose: 0.5 and 0.05 mg/ml. GO mixed with drinking water. Days 1–38 for maternal mice and 1–21 for filial mice. After 21 and 38 days, blood was collected for biochemistry analysis and organs were harvested for H&E staining. Decrease in body weight, body length and tail length for high concentration group. No significant differences in blood biochemistry. Pathological examination shows severe atrophy of all major organs. H&E staining of intestine showed increased villi and duodenum width. Results show that GO is toxic to developmental offsprings in mice. Fu et al. [109]\n125I-rGO TEM, particle size distribution Size: small GO (~100 nm), large GO (~450 nm) Male C57b/ 6 mice (6–8 weeks old) Oral administration. Dose 60 mg/kg, administered via oral gavage every 24 h for 5 days. Initial decrease neuromuscular coordination and locomotor activity, which were restored to normal levels at later time points (15 and 60 days post administration). No significant differences in blood biochemistry, liver function, kidney function, blood enzyme levels, learning, memory, anxiety, and spatial and exploratory behaviors. rGO administered via oral administration is non-toxic. Zhang et al. [110] GO TEM, AFM, FTIR, Raman spectroscopy and particle size tracking Size: 72 ± 11 nm; thickness: 1 nm, FTIR peaks: 3425 cm−1 (O–H), 1749 cm−1 (C_O), 1630 cm−1 (C_O), 1130 cm−1\n(C–O). Raman peaks at 1377 cm−1 (D band) and 1609 cm−1 (G band); zeta potential = −20.2 mV.\nCaenorhabditis elegans\nOral administration. GO mixed with food (K medium) at 0.1–100 mg/l. Acute exposure (24 h) and prolonged exposure (larvae to adult). Lethality, growth, reproduction and locomotion behavior was analyzed. Prolonged exposure to 0.5–100 mg/l of GO caused damage in primary (intestine) and secondary (neurons and reproductive) organs. GO translocated into intestinal wall due to loss of villi and were distributed surrounding mitochondria. Additional observations were increased mean defecation cycle length and hyper-permeable state of intestinal barrier. Results suggest that GO exposure to environmental organisms is toxic. Wu et al. [111]\n(continued on next page)\nTable 2 (continued)\nMaterial Characterization Properties Animal model Dose, route and duration Conclusion References\nPulmonary administration GNPs SEM, EPR, BET,\ndensity measurement, aerodynamic diameter, ICP-MS\nSize: diameter= 5.64± 4.56 nm, layers = 1–10; surface area = ~100 m2/g; density = ~2; EPR =\n867.3 ± 77.5 a.u.\nFemale C57BL/6 mice (9 weeks old) Pharyngeal administration. Dose — 50 μg/mouse. Mice sacrificed after 24 h and 1-week post exposure. BAL fluid was extracted. Intrapleural injection: dose — 5 μg/mouse. Mice sacrificed after 24 h and 7 days. Pleural space was lavaged and the surrounding tissue was excised for histology. GNPs upto 25 μm are respirable and deposit beyond ciliary airways post inhalation. GNPs induced inflammation in lung and pleural space with an increase in the levels of MIP-1α, MCP-1, MIP-2, IL-8 and IL-1β. SEM images revealed signs of frustrated phagocytosis. Inflammatory response decreased one-week post exposure. Schinwald et al. [112]\nGraphene (aggregated in water), graphene (2% pluronic), GO AFM, XPS, Raman spectroscopy, optical absorbance Optical absorbance: 600 nm; size: 40,000 nm2 (graphene), 200,000 nm2 (GO); thickness: 1.2–5 nm (graphene), 0.5–2 nm (GO) Male C56BL/6 mice (8–12 weeks old)\nPulmonary administration. Dose — 50 μg/mouse administered via intratracheal instillation. GO is injected directly into the lungs. Lung assessment post 24 h using histology and electron microscopy Inflammation, apoptosis, increase of mitochondrial respiration and pulmonary inflammation were observed. Duch et al. [113]\n125I-GO TEM, SEM, AFM, FTIR, Raman spectroscopy Size: 10–800 nm; thickness: 1 nm; FTIR peaks at 1731 cm−1\n(O–H), 1628 cm−1 (C_C), 1078 cm−1 (C–O); Raman peaks: 1333 cm−1 (D band), 1594 cm−1 (G band).\nMale Kunming mice (biodistribution) and male C57BL/6 mice (pulmonary toxicity) Pulmonary administration. Dose: 1, 5, 10 mg/kg for dose dependent acute and chronic pulmonary toxicity assessed after 24 h. 10 mg/kg for time dependent toxicity assessed after 0, 24, 48, 72 h and 1 week. 10 mg/kg for long-term chronic toxicity assessed after 1 and 3 months. Biodistribution evaluated by SPECT imaging, pulmonary toxicity by histology and cell injury, lung edema and neutrophil infiltration assays. Acute lung injury, thickening of alveolar septa, increased neutrophil counts and oxidative damage were observed. GO can pass through air–blood barrier albeit in smaller amounts and care must be taken to ensure minimal exposure by inhalation during large-scale production of GO. Li et al. [114]\nIntravitreal administration GO AFM, FTIR,\nRaman spectroscopy\nSize: 50–500 nm; thickness: 1 nm; FTIR peaks at 3430 cm−1, 1720 cm−1, and 1000 cm−1; Raman spectroscopy: D band at 1370 cm−1, G band at 1590 cm−1. ID/IG = 0.75 Japanese white rabbits (2–3 kg) Intravitreal administration. Dose: 0.1, 0.2, or 0.3 mg. Eye function was measured using electroretinography (ERG) after 2, 7, 28 and 49 days post injection. After 49 days, animals were euthanized and eyes were collected for histological examination. Balanced saline solution was used as the controls. No significant differences in ERG amplitudes compared to controls. H&E staining showed small amounts of GO residue, however, no retinal abnormality was observed. Yan et al. [115]\nand kidneys performed 14 days post injection shows no pathological changes for all organs examined for 1 mg/kg dose. For 10 mg/kg treatment, all organs except lung showed normal pathophysiology. However, due to high accumulation and slow clearance, GO accumulated in lungs resulted in pulmonary edema, granulomatous lesions, inflammatory cell infiltration, and fibrosis. These results suggest that GO is biocompatible, however, accumulation in lungs at higher concentration may lead to safety concerns. Biodistribution of GO was assessed by tracking intravenously administered 188Re labeled GO (188Re-GO) after 1, 3, 6, 12, 24, and 48 h. It was observed that GO cleared from blood, accumulated in lungs, liver and spleen and was up taken by mononuclear phagocytes in the reticuloendothelial system.\nWang et al. reported the biocompatibility of GO administered via tail vein injections to 4–5 week old female kunmingmice (Sprague Dawley rats) at 0, 0.1 mg (low), 0.25 mg (medium), and 0.4 mg (high) doses [98]. No toxicity was observed for low and medium doses. However, for high dose, 4 out of 9 mice died after 1 week due to airway blockage caused by accumulation of GO. Histology analysis after 1, 7, and 30 days shows long-term accumulation of graphene in liver, kidney and spleen. Granuloma formation alongwith the presence of neutrophils and foamy alveolar macrophages was observed in lungs suggesting a foreign body\nimmune response. No accumulation was observed in brain suggesting that GO cannot pass the blood brain barrier. These results suggest that GO is non-toxic at low concentrations and results in irreversible airway damage and chronic pulmonary toxicity at high concentrations.\nLiu et al. reported the dose- and size-dependent toxicity and biodistribution of GO sheets [99]. Male ICR mice were intravenously injected with small and large GO sheets (s-GO and l-GO) labeled with 125I to enable radioactive tracking of tissue biodistribution, organ accumulation and blood clearance of GO after 2–180min post injection at 1– 10 mg/kg doses. It was observed that s-GO mainly accumulated in the liver with some aggregates present in lungs and spleen, however, after 180 min, clearance of s-GO was observed with a residual accumulation of ~11% in liver and b1% in lungs. On the contrary, in comparison to s-GO, l-GO showed higher accumulation in lungs with a residual accumulation of ~19% after 180 min. TEM analysis of lung sections show intracellular accumulation of s-GO in phagocytic cells while l-GO particles (bigger than 1 μm) was lodged in cell gaps of lungs. The sizeregulated biodistribution of s-GO and l-GO was attributed to the different aggregation states of thenanoparticles. The less dispersedGO resulted in the formation of larger GO-protein complexes,whichwere filtered by the pulmonary blood vessels. At higher doses, s-GO aggregated to\nlarge particulates resulting in the entrapment in lungs. The blood halflife of s-GO was 2.2 min (T1/2 alpha) and 170 min (T1/2 beta). For l-GO, T1/2 alpha was 1.8 min and T1/2 beta was 102min. These results suggest that s-GO possesses longer blood retention time than l-GO.\nYang et al. reported in vivo biodistribution and photothermal activity of PEG functionalized nano graphene sheets (NGS-PEG) [100]. Cy7 dye labeled NGS-PEG was intravenously injected into tumor bearing Balb/ C mice at a dose of 20 mg/kg and organs were harvested after 1, 6, and 24 h. Significant accumulation of NGS-PEG was observed in tumors purportly due to leaky vasculature alongwith low accumulation in RES organs. After 24 h post injection, the kidneys showed strongfluorescence (Fig. 10) attributed to the renal excretion of small sized NGS particles. NGS-PEG showed no toxicity — neither death nor significant weight loss was observed in all animals. After NGS-PEG administration, the tumors on the right shoulder of 4T1 Balb/c mice were exposed to 808 nm laser until the surface temperature reached ~50 °C. The tumors disappeared 1-day post laser treatment leaving a black scar that disappeared after one week. No tumor regrowth was observed after 40 days. These results suggest that PEG functionalized graphene can be suitable for in vivo photothermal therapy applications. In another study, Yang et al. have reported the long term in vivo biodistribution and pharmacokinetics of 125I-labeled NGS-PEG intravenously administered in Balb/c mice at 4 mg/kg dose [101]. For pharmacokinetics\nstudy, blood was drawn after 0–25 h and measured by a gamma counter. To examine the biodistribution of 125I-NGS-PEG, 4 mg/kg was administered intravenously and organs were harvested at various time points: 1 h–60 days post injection. NGS-PEG initially accumulated in several organs, however accumulation at later time pointswas observed in liver and spleen. H&E staining of liver and spleen sections showed a reducing number of NGS-PEG aggregates over time suggesting removal of NGS-PEG from RES system. Renal pathway cleared out smaller sized NGS-PEG (10 nm diameter) while larger NGS-PEG aggregates were excreted through biliary pathway into the feces. Blood biochemistry and hematology analysis showed normal levels of urea, blood cells, hemoglobin and other factors suggesting that there were no toxic effects of NGS-PEG to liver and kidneys. These results suggest that NGS-PEG does not exhibit long-term in vivo toxicity in mice.\nKanakia et al. reported the sub acute toxicity of dextran functionalized graphene nanoplatelets (GNP-Dex) administered via intravenous injections to Wistar rats at 1, 50, and 100 mg/kg doses 3 times a week for three weeks [102]. No signs of toxicity were observed for 1 mg/kg and 50 mg/kg doses. All vital parameters such as body weight, blood pressure, breathing and heart rate were normal. However, for 100 mg/kg dose, 2 out of 8 animals died after 2 weeks. A complete blood count analysis showed physiological levels of blood urea nitrogen and creatinine indicating normal kidney function. ALT and ALP levels\nwere elevated, however, blood glucose was normal. Histology analysis after 3 weeks showed the presence of GNP-Dex in hepatic Kupffer cells and pulmonary alveolar macrophages, which increased with increasing dose of GNP-Dex (Fig. 11). No adverse effects or inflammation were observed in brain, heart, spleen and kidney.\nMullick Chowdhury et al. reported the in vivo vasoactivity of GNPDex using male hamsters cheek pouch model [88]. GNP-Dex was administered at doses ranging from 1 to 50 mg/ml to the excised left cheek pouch tissue of hamsters using a micropipette. The arcadeterminal arteriolar network junctionwas themicrovascular observation site. The baseline diameters of arcade and terminal arterioles were 23 μm and 8 μm, respectively. The administration of 0.1 mg/ml and 0.5 mg/ml GNP-Dex had no significant effect on the arteriole diameters. No significant differences in the dilation of arterioles were observed at higher doses of 10 mg/ml and 50 mg/ml. However, the administration of FDA-approved natural biopolymer dextran at 35 mg/ml resulted in ~23% dilation of arcade arterioles and ~63% dilation of terminal arterioles. The lack of dilation post GNP-Dex administration and an increased dilation due to dextran suggests that the observed minor vasoactive effects of GNP-Dex could be due to the dextran coating of GNPs.\nIn another study, Kanakia et al. have evaluated the acute toxicity and biodistribution of GNP-Dex administered via intravenous injections in male Wistar rats at doses between 1 and 500 mg/kg after 1 and 30 days [103]. The results show that the maximum tolerable dose\n(MTD) of GNP-Dex is between 50 and 125 mg/kg. Blood half-life of GNP-Dex is ~30 min. Maximum accumulation of GNP-Dex after day 1 was found in liver and kidney, which reduced (at least 2–4 folds) after 30 days of administration suggesting a clearance of GNP-Dex via RES system (Fig. 12A & B). ICP analysis showed that GNP-Dex administered at 50 mg/kg had a higher blood concentration than 500 mg/kg doses 30 min post-administration (Fig. 12C). Majority of GNP-Dex nanoparticles were excreted via feces (~60–90%) within 24 h (Fig. 12D), small amounts were excreted via urine (Fig. 12E). Histopathological changes (Fig. 12F–J) were observed in heart, lung, liver, kidney and spleen at high treatment concentrations (250 μg/ml). No adverse effectswere observed in brain. Hematological factors and cardiovascular parameters remained at physiological levels upto 125 mg/ml treatment doses. These results suggest that GNP-Dex is non-toxic with a MTD of 125 mg/kg.\nJasim et al. reported the in vivo biodistribution of chemically functionalized graphene (GO-DOTA) labeledwith 111In after intravenous injections in C57BL/6 mice at 200 μl dosage [104]. Post 1, 2, and 24 h of administration, 111In-DOTA-GOwas accumulated in bladder and excreted via urine. No fecal elimination was observed. Maximum accumulation was observed in liver and spleen. Furthermore, at later time points, translocation of GO from liver to spleen was also observed. No organ damage was observed at all time points. The results suggested that chemically functionalized GO sheets are non-toxic and possess distinctly different physiological behavior (biodistribution and excretion characteristics) than pristine or non-covalently functionalized graphene sheets.\n3.2. Intraperitoneal administration\nIntraperitoneal (IP) administration is the injection of the formulation into the peritoneum (or body cavity). Yang et al. have reported the in vivo toxicity of PEG functionalized GO administered intraperitoneally and orally in female Balb/c mice [105]. PEG functionalized and 125I labeled nano-graphene oxide (nGO-PEG), reduced graphene oxide (rGO-PEG), and nano reduced graphene oxide (nrGO-PEG) of diameters 25, 50, and 27 nm, respectively, were administered intraperitoneally at 50 mg/kg dose and orally at 100 mg/kg. Animals were euthanized post 1, 7, 30 and 90 days post intraperitoneal administration and 1, 7, and 30 days post oral injections. All major organs were collected for histology and biodistribution analysis and bloodwas collected from the orbital for complete blood panel and serumbiochemistry analysis. The radioactivity of GO formulations after oral administration was undetectable after 1week suggestingnegligible uptake of PEGylatedGOadministered orally. However, after intraperitoneal administration, PEGylated GO showed high accumulation in RES organs (black colored liver and spleen) after 1 and 7 days. Larger sized RGO-PEG showed higher uptake (N2 fold, determined by radioactivity measurements) than smaller nGO-PEG and nrGO-PEG formulation. No animal death, body weight loss, inflammation, or significant changes in bloody panel or serum biochemistry were observed after 90 days post intraperitoneal administration indicating no signs of toxicity. The results suggested that PEGylated GO do not elicit any adverse effects under the above conditions in rodents, and the biodistribution and clearance profiles depend on the size, surface coating and route of administration.\nAli-Boucetta et al. have investigated the in vivo pathogenicity of highly pure, colloidally stable dispersions of GO [106]. Conventional GO (cGO, size N0.10 μm2) prepared using Hummer's method was subjected to several purification steps to obtain highly pure GO (pGO, size 0.01 μm2 to 0.02 μm2). Both, cGO and pGO had similar chemical functional groups (carbonyls, hydroxyls and epoxides). pGO sheetswere administered intraperitoneally at a dose of 50 μg/animal for 1 and 7 days. CNTswere used as positive controls. The inflammatory responsewas investigated by observing the change in protein levels and the change in the number of polymorphonuclear leucocytes 1 and 7 days post administration. After 1 day, pGO did not show a change in polymorphonuclear\nleucocyte (PMN) and protein levels whereas CNT controls induced at least 2-fold increase in total PMN count. After 7 days, therewas accumulation of macrophages and giant cells with a deposition of collagen on the mesothelial membrane for CNT controls; pGO groups did not show any such effects. These results indicated that highly pure single layered GO sheets may not induce inflammation or granuloma formation upto 50 μg/animal dose administered intraperitoneally.\nSahu et al. investigated the in vivo biocompatibility of GO dispersed pluronic gels administered intraperitoneally via implantation in subcutaneous pockets in 6–7 weeks old Balb/c mice [107]. Mild inflammation was observed 3 weeks post implantation. After 8 weeks, the number of macrophages reduced and no chronic inflammation, tissue necrosis or hemorrhagingwas observed. Furthermore, no gel degradation or degradation products were observed in the surrounding tissues.\nStrojny et al. reported the intraperitoneal toxicity of GO, graphite and nanodiamonds administered to 6 weeks old female Wistar rats [108]. Nanoparticle suspensions were injected at a dose of 4 mg/kg for 4 or 12 weeks at three-day intervals. After 4 or 12 weeks, rats were euthanized and liver and blood were collected. Results show the presence of nanoparticle aggregates in the peritoneal cavity close to the injection\nsite. Smaller aggregates were observed in themesentery and liver serosa suggesting transportation and accumulation of nanoparticles in liver. No adverse health effects were observed for all nanoparticles (GO, graphite or nanodiamonds) at all time points (4 or 12 weeks). Blood analysis and liver enzyme levels were normal suggesting liver biocompatibility.\n3.3. Oral administration\nIn oral administration, a formulation/substance is administered via mouth in cases where a systemic effect is desired. Fu et al. have investigated the development of mice offsprings after oral administration of graphene oxide at 0.5, and 0.05 mg/ml to maternal mice [109]. GO suspension in drinking water was administered to female ICR mice (8–9weeks old) from 1 to 38 postnatal days (PND). Filial micewere administered GO water during the suckling period from 1 to 21 PND and normal water during the weaning period from 22 to 38 PND. After 21 and 38 days, pupswere weighed and euthanized. Compared to the control groups that received normal water, significant decrease in body weight, body length and tail length of filial mice were observed for\n0.5 mg/ml treatment group. Blood biochemistry analysis showed no significant differences in the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN) and creatinine (CREA) for both the GO groups. Pathological examination of heart, lung, spleen, kidney and liver of filial mice administeredwith 0.5mg/ml GO suspension showed severe atrophy (Fig. 13A). H&E staining of duodenum, ileum, jejunum (parts of small intestine) showed increase in villi length and duodenum width post GO administration (Fig. 13B). These results show that GO can have significant negative effects on the development of filial mice during the lactation period.\nZhang et al. investigated the short-term and long-term effects of reduced GO (rGO) on general locomotor activity, neuromuscular coordination, balance, anxiety, learning and memory of male C57b/6 mice (6–8 weeks old) using rotarod, open field and Morris water maze tests [110]. HEPES buffer dispersed rGO were administered via oral gavage every 24 h for 5 days at 60 mg/kg dose. rGO treated mice maintained\nnormal body weight, organ weight, and instinctive behaviors (eating, etc.) compared to control mice administered with chow and HEPES buffer. However, initial 3–4 days post treatment, mice showed decreased neuromuscular coordination and locomotor activity failing the rotarod and open field tests. At later time points (15 and 60 days post administration), all these parameters returned to their normal state. No significant differences in blood biochemistry, liver function and kidney function and aging parameters were observed. Themorphologies of neurons in the hippocampus andneuroglia cells aswell as choline acetyl transferase and hippocampal acetylcholine esterase (enzymes involved in memory and learning) levels also remained normal post rGO administration. These results show that exposure to high concentration of rGO sheets via oral administration results in a short term decrease in neuromuscular coordination and locomotor activitywhich return to normalcy a few days post exposure; it does not affect learning, memory, anxiety, spatial and exploratory behaviors.\nWu et al. investigated the toxicity of graphene oxide at doses between 0.1 and 100mg/l administered orally on nematode Caenorhabditis elegans after acute (24 h) and prolonged exposure (larva to adult) [111]. GO was mixed with nematode food (K medium) and lethality, growth, reproduction and locomotion were analyzed. Results show that prolonged exposure at concentrations 0.5mg/l and greater lead to significant primary (intestine) and secondary (neurons and reproductive)\norgan damage. Additionally, GO induced loss of villi and translocates into the intestinal walls. Other adverse events noted were increased defecation cycle and hyper permeable intestinal barrier. These results showed\nGO, rGO and GO or rGO antibacterial paper SEM, AFM, TEM Thickness: 1.1 nm (GO), 1 nm (rGO); 1.5 μm (GO paper), 4.6 μm (rGO paper) 0, 20, 85 μg/ml\nPristine graphene, GO, rGO TEM, SEM, zeta potential, FTIR Pristine graphene: size = 1.86 ± 0.6 μm, zeta potential = −17.7 ± 4.3 mV, C_C. GO: size = 1.27 ± 0.1 μm, zeta potential = −49.8 ± 1 mV, O–H, C_C, C_O, C–O, C–H. rGO: size = 2.53 ± 0.2 μm, zeta potential = −25.1 ± 2.6 mV, C_C, C–O, C_O. 25 and 250 μg/ml GO AFM, SEM, XPS Size: 0.753, 0.127, 0.065, 0.035, 0.013, 0.010 μm2, thickness: 1 nm; XPS peaks at 283.17 eV (C_C), 285.21 eV (C–O), 286.9 eV (C_O). 0–80 μg/ml GO, rGO AFM, SEM, FTIR, XPS\nSize: 300 nm (GO), 2.71 μm (rGO); thickness: 1 nm (GO) and few microns (rGO, aggregated); FTIR peaks at 3430 cm−1 (O–H), 1720 cm−1 (C_O), 1215 cm−1 (C–OH), 1050 cm−1 (C–O), for rGO no peaks at 1720 cm−1, 1050 cm−1 and 1215 cm−1 5–80 μg/ml\nthat GO upon exposure to environment would come into contact with nematodes, worms and other environmental organisms andmay induce long-term adverse effects in the environmental flora.\nE. coli ATP assay GO and rGO demonstrate superior antibacterial effect with only mild cytotoxicity towards mammalian cells (A549). rGO showed slightly greater toxicity towards A549 cells than GO Hu et al. [122] Listeria monocytogenes and Salmonella enterica Bacterial growth inhibition\nGO inhibits (~100% cell death) both bacterial strains at high and low treatment concentration. Pristine graphene and rGO exhibit variable antibacterial response. Presence of oxidative functional groups is important for bacterial cell attachment to graphene Kurantowicz et al. [126]\nE. coli Antibacterial activity Size dependent antibacterial activity of GO sheets. Larger sheets exhibit greater antibacterial activity Liu et al. [128] E. coli Bacterial membrane, oxidative stress\nGO has a higher antibacterial activity than other materials including reduced graphene oxide, graphite oxide and reduced graphite oxide that can be attributed to membrane and oxidative stresses. Liu et al. [127]\n3.4. Pulmonary administration\nSchinwald et al. have reported the in vivo toxicity of pristine GNPs after intrapleural and pharyngeal administration in 9 weeks old female C57BL/6 mice at 5 μg and 50 μg per mouse doses, respectively [112]. After 24 h and 1week of administration, a differential cell count of lavage fluid showed that mice exposed to GP had elevated levels (2× of physiological levels) of eosinophils and neutrophils. The chemokine and cytokine protein levels (MIP-1α, MCP-1, MIP-2, IL-8 and IL-1β) were also elevated. Microscopy imaging showed that pleural macrophages were not able to fully phagocytize GNPs due to their size and shape; multiple macrophages surrounding a singleGNP forming a rosette-like cell/particle aggregation suggested frustrated phagocytosis. Histological evaluation showed extended retention of GNPs in pleural space and the formation of ganulomatous lesions in bronchiolar lumen. The initial inflammatory response to GNPs reduced after 1-week post administration; reduction in the number of inflammatory cells in the parietal pleura was observed. Clearance of GNPs from the pleural space to cranial mediastinal lymph nodes was observed. 1-week post administration, numerous small sized GNP fragments were observed in lymph nodes. This study shows that the toxicity of GNPs is dependent on the nanomaterial shape and size. The 2D size of GNPs leads to frustrated phagocytosis in lungs.\nDuch et al. have reported the pulmonary toxicity of three types of graphene (aggregated pristine graphene in water, pristine graphene in 2% pluronic and graphene oxide) administered via intratracheal instillation to male C56BL/6 mice at 50 μg/mouse dose [113]. After 24 h of administration, mice were euthanized and lungs were analyzed by histology and electron microscopy. Results show that the pulmonary\ntoxicity of graphene varies as a function of dispersion and oxidation state. Highly dispersed pristine graphene in pluronic co-polymer solution induces an acute non-fibrotic lung inflammation, which is significantly lower compared to the local fibrotic response induced by aggregated graphene. Pristine graphene in dispersed or aggregated form does not induce apoptosis or ROS generation in lungmacrophages. However, GO formulations lead to persistent lung injury that lasts N21 days (Fig. 14). These results suggest that compared to GO, the use of pristine graphene may reduce potential health risks associated with pulmonary exposure.\nLi et al. have analyzed the in vivo biodistribution and pulmonary toxicity of GO after intratracheal instillation in kunmingmice at a dose of 0, 1, 5 or 10 mg/kg to evaluate dose-dependent acute and chronic pulmonary toxicity for 24 h [114]. The authors have also evaluated timedependent pulmonary toxicity by administering 10 mg/kg GO for 0, 24, 48, 72 h and 1 week and chronic pulmonary toxicity at 10 mg/kg dose evaluated 1 and 3 months post instillation. Biodistribution was evaluated using SPECT imaging and pulmonary toxicity was assessed using histology and assays for cell injury, lung edema and neutrophil infiltration. Results show that GO was localized in the lungs even after 3 months of administration. Furthermore, GO induced a dosedependent acute lung injury and resulted in chronic pulmonary fibrosis. A dose-dependent increase in neutrophils was observed in bronchoalveolar lavage fluid. Lung histopathological analysis showed alveolar septa thickening, extensive hemorrhage, changes in alveolar architecture and moderate interstitial edema. Furthermore, increases in the levels of superoxide dismutase and glutathione peroxidase were observed suggesting oxidative stress post 48 h of GO administration. SPECT imaging showed that GO was mainly localized in the lungs with\n) Plot of rGO concentration (μg/ml) vs. mycelial growth inhibitory activity (%) of A. niger,\nminor presence in other organs such as liver and intestines suggesting that GO can pass through the air-blood barrier. These results show that GO at the doses anddurationsused in the study could induce severe pulmonary toxicity.\n3.5. Intravitreal administration\nIn intravitreal administration, a substance/formulation is administered directly into the eye using a needle. Yan et al. have evaluated the\nFig. 17. Scanning electron microscopy images of E. coli after 2 h of incubation with (A, B) sa membrane integrity is clearly observed. Adapted from Reference [127] with permission, copyright © American Chemical Society, 2011\nocular toxicity of GO after intravitreal administration in Japanese white rabbits at 0.1, 0.2, or 0.3 mg doses [115]. Eyes were reviewed for the effects of GO using a slit-lamp biomicroscopy and fundoscopy. Results show that GO did not have any effect on the corneas, interior media, posterior media, and the retina compared to the control group. The intraocular pressure showed no difference between the control and the experimental eye. Electroretinography (ERG) was performed to assess changes in the electrical impulse conduction in the eye. Compared to the controls, GO administration did not result in any significant\nline solution, (C, D) GO dispersions 40 μg/ml, (E, F) rGO dispersions at 40 μg/ml. Loss of\n.\nTable 4 Environmental toxicity of graphene.\nMaterial Characterization Properties Conclusion References\nGraphene AFM, SEM, TEM Height: 1 nm. TEM reveals typical wrinkled structure. Range of length × breadth: 0.5 × 0.6–1.5 × 6.5 μm Cotyledons and root system growth were slowed down with increasing concentration on tomatoes, cabbage, and red spinach; had no effect on lettuce. Primary roots were shorter and disappeared root hairs compared to the control. Graphene caused decreased root and shoot weight. Decreased number of leaves. Begum et al. [129] Few layer graphene TEM, AFM Thickness: 2–5 nm; diameter: 100–200 nm No significant effect on growth of tomato plants. Khodakovskaya et al. [130] GONRs AFM, FTIR, Raman spectroscopy\nBath sonication: 700–900 nm (20 min) Probe sonication: 300–400 nm (1 min), b300 nm (5 min), b200 nm (10 min) ID/IG ratio: 1.30 (bath sonication)–2.30 (probe sonication)\nPost processing high energy sonication leads to reduction in size of GONRs. Probe sonicated solutions of GONRs show greater medaka embryo mortality compared to non-sonicated or bath sonicated solutions. Mullick Chowdhury et al. [60]\nGO AFM, XPS, SEM Interlayer spacing: 1 nm Inhibition of metabolic activity at all concentrations. GO is biodegraded by at least 50% after 5 h. Inhibition of nitrifying bacteria. Ahmed et al. [131] Graphene TEM, AFM, Raman spectroscopy No holes or defects, basic hexagonal lattice. Height: 0.34 nm Post hydrogen peroxide treatment: randomly distributed holes in graphene. Diameter of holes increase with higher concentration of H2O2. Xing et al. [132] GONRs and rGONRs\nTEM, Raman spectroscopy, UV–Vis\nFlat, smooth, and uniform multi-layered sheets.\nLignin peroxidase activity: GONR: structure completely degraded by 96 h. rGONR: holes from outer to inner layers in the sheets. Both materials eventually degrade, but there is a delay in degradation for rGONR compared to GONR Lalwani et al. [133]\nchanges in ERG amplitudes after 2, 7, 28 or 49 days of administration. H&E staining of eyes harvested 49 days post administration showed small amounts of GO residue, however, no retinal abnormality was observed.\n4. Antimicrobial toxicity\nTable 3 summarizes the studies assessing antimicrobial toxicity of graphene. Sawangphruk et al. have investigated the antifungal activity of reduced graphene oxide (rGO) against Aspergillus niger, Aspergillus oryzae, and Fusarium oxysporum between 0 and 500 μg/ml treatment concentrations [116]. Antifungal effects of rGO were assessed by quantifying mycelial growth inhibition. It was found that the rGO was effective against all three fungi with IC50 value between 50 and 100 μg/ml\nindicating a good antifungal activity of rGO (Fig. 15). A. niger and F. oxysporum are pathogenic strains of fungi whereas A. oryzae is nonpathogenic, therefore; antifungal activity of rGO against A. oryzae could be a concern towards the development of graphene based broad spectrum antifungal agents. Akhavan et al. reported the antibacterial activity of graphene oxide nanowalls (GONWs) and reduced graphene oxide nanowalls (rGONWs) against Escherichia coli and Staphylococcus aureus [117]. Results showed that bacterial cells were damaged by the direct contact of the cell membrane with extremely sharp edges of GO. Gram positive S. aureus without cell membrane showed greater cell death compared to gram positive E. coli which was more resistant due to the presence of outer membrane. Additionally, rGONWs were more toxic to bacterial cells than GONWs due to effective charge transfer between bacteria and edges of nanowalls during bacterial cell contact.\ns and root systems of cabbage, tomato and red spinach after exposure to 500–2000 mg/l and biomass production is observed.\nCai et al. investigated the antibacterial activity of polyethyleneiminemodified reduced graphene oxide (PEI-rGO) and sliver nanoparticles functionalized PEI-rGO (PEI-rGO-AgNPs) against E. coli and S. aureus between 0 and 958 mg/l treatment concentration [118]. The results show that PEI-rGO-AgNPs are extremely effective in killing bacteria, N90% reduction in cell viabilitywas observed for both E. coli and S. aureus colonies at 958mg/l concentration. The long termantibacterial activity of PEI-rGOAgNPs was attributed to the damage of bacterial cell due to interactions with sharp blade like edges of GO which may facilitate effective interactions of Ag+ ions with the intracellular contents, eventually killing bacteria. Chen et al. have reported the dose-dependent antibacterial activity of GO and rGO against a rod shaped, gram negative phytopathogenic bacterium Xanthomonas oryzae pv. oryzae (Xoo) [119]. GO exhibited a greater antibacterial effect with ~94.5 and 86.4% cell mortality in DI water and 0.9% NaCl dispersions at 250 μg/ml treatment concentration. rGO at 250 μg/ml concentration resulted in 36.1 and 22.3% cellmortality Furthermore, an increased incubation time from 1 h to 4 h resulted in significant increases in the antibacterial activity of GO (from19.4% to 66.1%) and rGO (13.8% to 30.5%). Further analysis by TEM and thiol quantification assay showed that GO resulted in physical damage and increased oxidative stress to bacterial cells. These results suggest that GO has a significantly greater dose- and time-dependent antibacterial activity compared to rGO.\nSantos et al. investigated the antibacterial activity of poly(Nvinylcarbazole) graphene (PVK-G) solutions and thin films against E. coli and Bacillus subtilis at concentrations between 0.01 and 1 mg/ml [120]. Results show a dose-dependent antibacterial effect of PVK-G solutions with ~80% reduction in the percentage of metabolically active cells at 1 mg/ml treatment concentration. AFM imaging showed less bacterial coverage on PVK-G films compared to PVK and ITO (control) surfaces after 24 h of incubation with E. coli. Furthermore, PVK-G solutions at 1 mg/ml concentration showed ~80% cell viability of NIH3T3 fibroblast cells. These results showed good antibacterial activity of PVK-G composites and thin films and suggest a potential use of PVK-G nanocomposites for a wide variety of antibacterial applications where bactericidal properties along with good biocompatibility are desired. In another study, Carpio, Santos et al. have investigated the antibacterial properties of PVK-graphene oxide (PVK-GO) nanocomposites between 10 and 1000 μg/ml treatment concentrations against E. coli, Cupriavidus metallidurans, B. subtilis, and Rhodococcus opacus [121]. The results showed a similar effect wherein addition of GO to PVK enhances the antimicrobial properties of the nanocomposite. PVK-GO nanocomposites in solution appear to effectively encapsulate the bacterial cells leading to reduction in microbial metabolic potential and eventual cell death. AFM imaging showed significant reduction in E. coli biomass after 48 h of culture on PVK-GOfilms in comparison to PVK and ITO (controls) surfaces. Additionally, similar to PVK-G nanocomposites, PVK-GO nanocomposites were also cytocompatible (~90% cell viability of NIH3T3 cells was observed after 48 h of exposure to PVK-GO solutions at 1000 μg/ml concentration).\nHu et al. investigated the antibacterial activity of GO and rGO nanosheets against E. coli cells at concentrations of 0, 20, and 85 μg/ml [122]. After 2 h of incubation with GO at 20 and 85 μg/ml, the metabolic activity of E. coli cells (measured by luciferase-based ATP assay) decreased to ~70% and ~13%, respectively (Fig. 16A). rGO exhibited antibacterial activity, 2 h of incubation of E. coli cells with rGO solutions at 85 μg/ml resulted in only ~24% cell viability (Fig. 16B). TEM studies showed loss of cell integrity via physical damages to the cell membrane upon exposure to GO and rGO (Fig. 16C–E). Furthermore, cells cultured on GO and rGO paper also showed damages to cell membrane of bacteria. However, Mangadlao et al. [123], Hui et al. [124], and Li et al. [125] have reported that antibacterial effect of GO films is not due to cell membrane rupture by graphene edges. The antibacterial effect is observed due to charge transfer betweenbasal plane of graphene and bacterial cell body leading to inactivation of bacteria.\nKurantowicz et al. investigated the interactions of pristine graphene, graphene oxide (GO) and reduced graphene oxide (rGO) against food\nborne bacterial pathogens — Listeria monocytogenes and Salmonella enterica [126]. Bacteria were incubated with high (250 μg/ml) and low (25 μg/ml) treatment concentrations of pristine graphene, GO and rGO for 18 h. At 250 μg/ml concentration, all nanomaterials consistently inhibited 100% growth of S. enterica and L. monocytogenes. However, at lower concentration (25 μg/ml), only GO showed 100% inhibition of both bacteria. Pristine graphene inhibited the growth of S. enterica by 96.5% and L. monocytogenes by 54.5%whereas rGO inhibited the growth of L. monocytogenes by 91% and S. enterica by 46%. TEM results showed a uniform distribution of bacterial cells over the surface of GOwhereas on the surface of pristine graphene and rGO, bacterial cells adhered to the edges and wrinkles of the graphene sheets. The authors hypothesized that the presence of oxidative functional groups throughout the surface of GO and on the edges of pristine graphene and rGO act as bait for attracting bacteria. After attaching to the flakes, cell may be damaged via direct contact or destabilization of the phospholipid cell membrane. These results suggested functionalization-dependent antibacterial effect of graphene and GO.\nLiu et al. investigated the time- and dose-dependent antibacterial activity of four types of graphene-basedmaterials (graphite (Gt), graphite oxide (GtO), graphene oxide (GO), and reduced graphene oxide (rGO)) against E. coli [127]. At 40 μg/ml treatment concentration after 2 h of incubation, Gt, GtO, GO and rGO showed ~26.1 ± 4.8%, 15.0 ± 3.7%, 69.3 ± 6.1% and 45.9± 4.8%, respectively. After 4 h, GO and rGO dispersions lead to ~89.7 ± 3.1% and 74.9 ± 4.8% inhibition of E. coli. GO and\nrGO exhibited a concentration dependent antibacterial activity, cell mortality increases from 10.5 ± 6.6% to 91.6 ± 3.2% by increasing the GO concentration from 5 μg/ml to 80 μg/ml. Similarly, increases in rGO concentration from 5 μg/ml to 80 μg/ml leads to increased E. colimortality from 8.4 ± 7.3% to 76.8 ± 3.1%. The antibacterial activity of GO and rGO was primarily due to inactivation of cellular functions due to loss of cell integrity. SEM imaging showed that direct contact of E. coli cells with GO and rGO disrupts cell membrane (Fig. 17). Additionally, graphene-based materials also oxidize glutathione, which is a redox mediator in bacterial cells, leading to oxidative stress. In another study, Liu et al. investigated the lateral-dimension dependent antibacterial activity of GO [128]. The sizes of GO sheets used in this study were 0.753, 0.127, 0.065, 0.035, 0.013, and 0.010 μm2, respectively. Results showed that large GO sheets exhibit significantly greater antibacterial activity compared to small GO sheets. The results of both these investigations taken together suggested that GO and rGO are effective antibacterial agents and physiochemical properties such as functional group density, size, and morphology play an important role in influencing the antibacterial potential of graphene-based materials.\n5. Environmental toxicity\nThe use of graphene for various industrial and healthcare applications would lead to increased environmental exposure and its disposal into waste streams. Therefore, it is important to assess the short- and\nhene oxide nanoribbons (GONRs — A–D) and (rGONRs — E–H) after 0, 4, 48, and 96 h of graphene sheets. Extensive biodegradation of GONRs whereas the formation of holey zymatic cycle of lignin peroxidase and (K) Schematic representation of degradation of\nlong-term environmental toxicity of graphene and graphene-based materials and develop effective strategies to minimize any potential deleterious impact to flora and fauna. Table 4 summarizes the studies assessing environmental toxicity of graphene. Begum et al. have investigated the phytotoxicity of graphene and its effects on root and shoot growth and shape, cell death and biomass by incubating seedlings of cabbage, tomatoes, red spinach and lettuce with 500–2000 mg/l for 20 days [129]. The results of physiological and morphological analysis showed that graphene significantly inhibited plant growth and biomass production (Fig. 18) and led to a reduction in the number and size of leaves in a dose-dependent manner. At 2000 mg/l concentration, ~18– 78% root growth inhibition was observed depending on the plant species. Furthermore, leaves show wilting, necrotic lesions and reduction in leaf area. Graphene at high treatment concentrations (N500 mg/l) led to the production of reactive oxygen species leading to necrosis, loss of plasma membrane, and eventual cell death. No toxic effects were observed on lettuce at similar treatment concentrations. These results indicated that the phytotoxicity of graphene depends on the concentration, exposure time and plant species.\nKhodakovskaya et al. investigated the toxicity of several carbon nanomaterials (activated carbon, graphene, single- and multi-walled carbon nanotubes) on the germination of tomato seedlings [130]. All nanomaterials were mixed with Murashige and Skoog (MS) growth medium at 50 μg/mL used to grow surface sterilized tomato seedlings. Examination of leaves and roots show that graphene (out of all materials tested) induced lowest activation of stress-related LeAqp2 gene (tomato water-channel protein); highest activation was observed for CNT groups. Photothermal and photoacoustic imaging studies showed that graphene did not affect the plant growth rate due to the inability to penetrate plant tissues.\nMullick Chowdhury et al. evaluated the post-processing effects of graphene oxide nanoribbons (GONRs) dispersed in biological buffers\nusing various sonication steps (bath sonication for 5 or 20 min or probe sonication for 5 or 10 min) on Medaka embryos [60]. Results show precocious hatching of the embryos when exposed to GONR solutions prepared by bath sonication. However, significantmortality (~50% increase in cell death) of the embryos was observed for GONR solutions prepared by probe sonication. AFM imaging showed the presence of smaller GONR particles and carbonaceous debris after probe sonication. Probe sonicated GONR solutions lead to structural damage of the chorionic membrane of embryos. These results suggested that postprocessing steps of graphene such as high-energy sonication may lead to variable environmental toxicity.\nAhmed et al. investigated the effects of graphene oxide on themicrobial community present in wastewater [131]. Efficient biological wastewater treatment requires functioning of diverse microbial species. Active sludge samples were incubated with 10–300 mg/l concentration of GO for 5 h at room temperature to observe short-term toxicity. Results show a dose-dependent toxicity with significant reduction in bacterial metabolic activity, viability, and their capacity to effectively remove nutrients such as organics, phosphorous andnitrogen fromactivated sludge in the presence of GO. A dose-dependent reduction in the conversion of ammonia to nitrate was observed suggesting a reduction in the concentration of nitrifying bacteria. It was noted that the presence of GO in wastewater led to deterioration of the quality of final wastewater effluent (increased turbidity was observed). Results showed that interaction of GO with wastewater sludge induced production of reactive oxygen species which may disrupt the functioning of antimicrobial community leading to compromised wastewater treatment performance.\nHydrogen peroxide (H2O2) is a naturally occurring ubiquitous compound found in rain and surface water, and in biological systems at concentrations ranging between 1 μM and 10,000 μM. Xing et al. have investigated the effects of hydrogen peroxide on the biodegradation of graphene [132]. TEM and AFM imaging studies show the presence of\nof oxidative stress induced toxicity by graphene oxide.\nJohn Wiley & Sons Inc., 2012.\nrandomly distributed holes on graphene sheets in the presence of physiologically and environmentally relevant concentrations of H2O2 (Fig. 19). After 10 h of incubation with H2O2, the diameter of holes was between 1 and 15 nm. An increase in the concentration of H2O2 from1 μMto 10,000 μMinduced the formation of holeswith significantly greater diameters (10–30 nm) suggesting a concentration dependent biodegradation of graphene. AFM studies show the depth of holes between 9.4 and 13.5 nm; greater than the height of a single graphene sheet (~0.34 nm). Based on these results, it was concluded that H2O2 attacked the inner layers of graphene along with the outer surface layers. Raman spectroscopy results showed a progressive time- and concentration-dependent decrease in the intensity for both D and G bands for all H2O2 treatment groups. The biodegradation of graphene by H2O2 may further be accelerated by the presence of trace elements such as nickel or iron (used as catalysts during the synthesis of graphene) by catalyzing the conversion of hydrogen peroxide to hydroxyl radicals via the Haber–Weiss reaction. The\nresults of this study showed that multilayered graphene can undergo effective biodegradation at environmental and physiological concentrations of H2O2.\nLalwani et al. have investigated the oxidative biodegradation of graphene oxide nanoribbons (GONRs) and reduced graphene oxide nanoribbons (rGONRs) by lignin peroxidase (LiP), an enzyme released by white rot fungi (Phanerochaete chrysosporium) distributed worldwide in forests soils with dead and decaying organic matter [133]. LiP degrades lignin — a component of plant cell wall. TEM (Fig. 20) and Raman spectroscopy analysis of GONRs and rGONRs treated with LiP for 4–96 h showed the formation of holes confirming the structural degradation of graphene sheets. It was observed that GONRs showed a higher rate of biodegradation compared to rGONRs; numerous holes (1–5 nm diameter) were detected on GONR sheets within 4 h of treatment which increased to ~300–350 nm after 48 h. The diameter of holes on rGONRs was between 5 and 30 nm after 48 h of enzymatic treatment. After 96 h, GONRs appeared to have\nell apoptosis via ROS mediated MAPK and TGF-beta pathways (mitochondria dependent\ncompletely degraded whereas numerous holes extending throughout the width of rGONRs were observed. These results suggested that oxidized and reduced graphene nanoribbons released in the environment may undergo oxidative biodegradation by lignin peroxidase.\n6. Mechanisms of toxicity\nThe interactions of graphene with cells, proteins, and other biomolecules are influenced by its physiochemical properties such as\nand (B) amine-modified graphene (positive surface charge) on platelet function. Surface n platelet membrane. right © American Chemical Society, 2011 and 2012.\nshape, size, functional group density and charge transfer abilities. The main mechanism of graphene toxicity is associated with the generation of intracellular reactive oxygen species that cause damage to proteins and DNA leading to cell death via apoptotic or necrotic pathways [82,134,135]. Graphene can be internalized into cells via passive internalization (endocytosis) [136,137] or active internalization (clathrin mediated energy dependent endocytosis [138] or actindependent macropinocytosis [36]). Studies have elucidated two mechanism of graphenemediated ROS damage: (1) Upon cellular internalization, GO interferes with the electron transport system, induces overproduction of H2O2 and hydroxyl radicals. This leads to the oxidization of cardiolipin and the release and translocation of hemoprotein frommitochondrial innermembrane to the cytoplasm. This triggers release of cytochrome c complex (cyt c) which induces calcium release from endoplasmic reticulum and activates caspase 9 which in turn activates caspases 3 and 7 leading to cell death (Fig. 21) [135]. (2) GO induces the activation of MAPK (JNK, ERK, p38) and TGF-β signaling pathways that lead to activation of Bcl-2 proteinswhich in turn activate mitochondria-induced apoptosis (Fig. 22) [82]. In addition to ROS induced cell death, GOmay also lead to the activation of toll-like receptors and induce autophagy via inflammatory pathways (Fig. 23) [83]. Post internalization; graphenemay induce DNA cleavage due to interactions such as pi–pi stacking, hydrophobicity, and electrostatic interactions\n[139–141]. Singh et al. have shown that surface charge distribution on graphene sheets plays an important role in the activation of src kinases and release of calcium eventually leading to platelet aggregation (Fig. 24) [86,94].\nSeveral studies have reported that extremely sharp edges of graphene lead to membrane destabilization and loss of cell integrity by direct contact [66,117]. Wang et al. have shown that adsorption of GO on RBCs leads to the loss of cell membrane resulting in hemolysis [136]. Long sheets of graphene have also been observed to wrap around bacterial cells thereby inhibiting their growth [121]. Single layered GONRs exhibit greater cyto- and geno-toxicity due to the interactions between cells and sharp edges of nanoribbons resulting in extensive chromosomal aberration and DNA fragmentation [66]. Li et al. have shown that graphene micro sheets enter cells through spontaneous membrane penetration at corner sites and edge asperities [142]. Molecular dynamics simulation studies have shown that graphene has a strong affinity for phospholipids and can be localized into the hydrophobic interior of biological membranes [143]. Tu et al. reported that due to strong interactions between graphene and lipids, graphene penetrates into and extracts significantly large amounts of phospholipids from cell membrane leading to cytotoxicity (Fig. 25) [144]. Graphene quantumdots affected cellular function by inserting into cell membrane [145]; pristine GO has been reported to form aggregates on cell\nn in the outermembrane (pure palmitoyloleoylphosphatidylethanolamine, POPE) and inner an lines with hydrophilic charged atoms as colored spheres (hydrogen—white, oxygen— yellow sheet with a large sphere marked at one corner representing restrained atom in\n13.\nmembrane thereby affecting cellular morphology [68]. rGO sheets inhibited the growth of fungal mycelium due to their direct insertion into the membrane of fungal cells [116].\n7. Conclusion and future perspective\nThe studies till date indicate that toxicity of graphene could be dependent on the shape, size, purity, post-production processing steps, oxidative state, functional groups, dispersion state, synthesis methods, route and dose of administration, and exposure times. Themorphology, shape and size of graphene nanoparticles could influence their cellular uptake characteristics whereas presence of functional groups can alter their interactions with proteins, biomolecules and micronutrients. The initial starting materials and the methods used in the production of oxidized graphene can result in the presence ofmetallic impurities and oxidative debris in the final product, which could result in variable toxicity effects. The post synthesis processing steps employed to disperse the nanoparticles in aqueous media could also influence toxicity. Reactive oxidation speciesmediated cell damage has been postulated as a primary cytotoxicity mechanism of graphene. Graphene sheets with sharp edges could induce direct physical damage and interact with phospholipids leading tomembrane destabilization. Surface coating of graphene with several biocompatible moieties (e.g. natural polymers) can mitigate these cytotoxicity effects.\nThe studies taken together provide information on dosaging, biodistribution and pharmacology of various graphene-based formulations. It must be noted that even though there are many types of graphene nanoparticles, GO have been the most widely used for biomedical applications and studies that employ GO dominate the review. While majority of published literature on toxicity of other members of the graphene family have been reviewed herein, more toxicological studies on formulations of other types of graphene nanoparticles are warranted. Additionally, for all types of graphene nanoparticles, it is important to investigate and critically evaluate the potential short- and long-term health risks and toxicity hazards after acute, sub-acute and chronic exposures using in vitro and in vivo (small and large animal) models. Towards clinical translation of any graphene-based biomedical application that requires its systemic administration, formulations with high purity, dispersibility in aqueous media, and controlled physiochemical properties are highly desirable. For each of these formulations, regulatory compliance would require mapping of their chemistry, manufacturing and control (CMC) process and completing new drug (IND)-enabling preclinical studies. With advancements in the synthesis methods and establishment of several commercial ventures for largescale industrial production of graphene, thewidespreaduse of graphene for several consumer products is becoming a reality. This ubiquitous use would lead to an increased environmental exposure of graphene. Therefore, more studies assessing the long-term environmental impact of graphene are required. Recent efforts have also involved incorporation of graphene nanoparticles in polymer matrices or their assembly in coating, films and porous scaffolds for bio-sensing, localized drug delivery or tissue engineering applications [146,147]. For these applications, additional in vitro and in vivo toxicological studies specific to biomedical devices and implants would be needed. Finally, advances in graphenelike inorganic nanoparticles for biomedical applications allow opportunities to compare the biological response of graphene and its inorganic analogs [41,43,148–151]. All these studies will further advance the knowledge required to develop safe graphene-based technologies and products suitable for healthcare applications and to minimize risks to human health.\nAcknowledgments\nThe authors acknowledge the financial support of National Institutes of Health (grant no. 1DP2OD007394-01) and Wallace H. Coulter Foundation's Translational Research Award.\nReferences\n[1] M.S. Dresselhaus, G. Dresselhaus, P.C. Eklund, Science of Fullerenes and Carbon Nanotubes: Their Properties and Applications, Academic press, 1996. [2] A.K. Geim, Graphene: status and prospects, Science 324 (5934) (2009) 1530–1534. [3] G. Lalwani, B. Sitharaman, Multifunctional fullerene-and metallofullerene-based\nnanobiomaterials, Nano. LIFE 3 (3) (2013) 1342003 (-1-22). [4] The rise and rise of graphene, Nat. Nanotechnol. 5 (11) (2010) 755. [5] The Kavli Prize, Kavli Prize Laureates in Nanoscience, http://www.kavliprize.org/prizes-\nand-laureates/prizes/2008-kavli-prize-laureates-nanoscience2008 ( ). [6] A.K. Geim, K.S. Novoselov, The rise of graphene, Nat. Mater. 6 (3) (2007) 183–191. [7] J. Slonczewski, P. Weiss, Band structure of graphite, Phys. Rev. 109 (2) (1958) 272. [8] R. Peierls, Quelques propriétés typiques des corps solides, Annales de l'institut Henri\nPoincaré, 1935. [9] L. Landau, Zur Theorie der phasenumwandlungen II, Phys. Z. Sowjetunion 11 (1937)\n26–35. [10] L.D. Landau, E. Lifshitz, Statistical physics, part I, Course Theor. Phys. 5 (1980) 468. [11] N.D. Mermin, Crystalline order in two dimensions, Phys. Rev. 176 (1) (1968) 250. [12] K.S. Novoselov, A.K. Geim, S. Morozov, D. Jiang, Y. Zhang, S.A. Dubonos, I. Grigorieva, A.\nFirsov, Electric field effect in atomically thin carbon films, Science 306 (5696) (2004) 666–669. [13] K. Novoselov, A.K. Geim, S. Morozov, D. Jiang, M. Katsnelson, I. Grigorieva, S. Dubonos, A. Firsov, Two-dimensional gas of massless Dirac fermions in graphene, Nature 438 (7065) (2005) 197–200. [14] K. Novoselov, D. Jiang, F. Schedin, T. Booth, V. Khotkevich, S. Morozov, A. Geim, Twodimensional atomic crystals, Proc. Natl. Acad. Sci. U. S. A. 102 (30) (2005) 10451–10453. [15] D. Johnson, Europe invests €1 billion to become “graphene valley”, IEEE Spectr. (2013). [16] M. Spasenovic, South Korea to spend US$40million on graphene development, Graphene\nTracker, 2013. [17] M. Brown, Government announces £50m funding hub for UK graphene research,WIRED,\n2011. [18] HUAWEI, Huawei Announces Partnership With the University of Manchester to Develop\nGraphene-based Technologies, 2015. [19] K.I. Bolotin, K. Sikes, Z. Jiang, M. Klima, G. Fudenberg, J. Hone, P. Kim, H. Stormer,\nUltrahigh electron mobility in suspended graphene, Solid State Commun. 146 (9) (2008) 351–355. [20] X. Du, I. Skachko, A. Barker, E.Y. Andrei, Approaching ballistic transport in suspended graphene, Nat. Nanotechnol. 3 (8) (2008) 491–495. [21] M.D. Stoller, S. Park, Y. Zhu, J. An, R.S. Ruoff, Graphene-based ultracapacitors, Nano Lett. 8 (10) (2008) 3498–3502. [22] L. Ponomarenko, A. Geim, A. Zhukov, R. Jalil, S. Morozov, K. Novoselov, I. Grigorieva, E. Hill, V. Cheianov, V. Fal'Ko, Tunable metal–insulator transition in double-layer graphene heterostructures, Nat. Phys. 7 (12) (2011) 958–961. [23] Y. Zhang, Y.-W. Tan, H.L. Stormer, P. Kim, Experimental observation of the quantum Hall effect and Berry's phase in graphene, Nature 438 (7065) (2005) 201–204. [24] A.A. Balandin, S. Ghosh, W. Bao, I. Calizo, D. Teweldebrhan, F. Miao, C.N. Lau, Superior thermal conductivity of single-layer graphene, Nano Lett. 8 (3) (2008) 902–907. [25] C. Lee, X. Wei, J.W. Kysar, J. Hone, Measurement of the elastic properties and intrinsic strength of monolayer graphene, Science 321 (5887) (2008) 385–388. [26] R. Nair, P. Blake, A. Grigorenko, K. Novoselov, T. Booth, T. Stauber, N. Peres, A. Geim, Fine structure constant defines visual transparency of graphene, Science 320 (5881) (2008) 1308. [27] P. Avouris, C. Dimitrakopoulos, Graphene: synthesis and applications, Mater. Today 15 (3) (2012) 86–97. [28] K. Subrahmanyam, L. Panchakarla, A. Govindaraj, C. Rao, Simple method of preparing graphene flakes by an arc-discharge method, J. Phys. Chem. C 113 (11) (2009) 4257–4259. [29] K.S. Kim, Y. Zhao, H. Jang, S.Y. Lee, J.M. Kim, K.S. Kim, J.-H. Ahn, P. Kim, J.-Y. Choi, B.H. Hong, Large-scale pattern growth of graphene films for stretchable transparent electrodes, Nature 457 (7230) (2009) 706–710. [30] S. Stankovich, D.A. Dikin, R.D. Piner, K.A. Kohlhaas, A. Kleinhammes, Y. Jia, Y. Wu, S.T. Nguyen, R.S. Ruoff, Synthesis of graphene-based nanosheets via chemical reduction of exfoliated graphite oxide, Carbon 45 (7) (2007) 1558–1565. [31] D.V. Kosynkin, A.L. Higginbotham, A. Sinitskii, J.R. Lomeda, A. Dimiev, B.K. Price, J.M. Tour, Longitudinal unzipping of carbon nanotubes to form graphene nanoribbons, Nature 458 (7240) (2009) 872–876. [32] S. Pei, H.-M. Cheng, The reduction of graphene oxide, Carbon 50 (9) (2012) 3210–3228. [33] S. Kanakia, J.D. Toussaint, S.M. Chowdhury, G. Lalwani, T. Tembulkar, T. Button, K.R.\nShroyer, W. Moore, B. Sitharaman, Physicochemical characterization of a novel graphene-based magnetic resonance imaging contrast agent, Int. J. Nanomedicine 8 (2013) 2821. [34] G. Lalwani, X. Cai, L. Nie, L.V. Wang, B. Sitharaman, Graphene-based contrast agents for photoacoustic and thermoacoustic tomography, Photoacoustics 1 (3) (2013) 62–67. [35] G. Lalwani, J.L. Sundararaj, K. Schaefer, T. Button, B. Sitharaman, Synthesis, characterization, in vitro phantom imaging, and cytotoxicity of a novel graphene-based multimodal magnetic resonance imaging-X-ray computed tomography contrast agent, J. Mater. Chem. B 2 (22) (2014) 3519–3530. [36] S. Mullick Chowdhury, G. Lalwani, K. Zhang, J.Y. Yang, K. Neville, B. Sitharaman, Cell specific cytotoxicity and uptake of graphene nanoribbons, Biomaterials 34 (1) (2013) 283–293. [37] S.M. Chowdhury, C. Surhland, Z. Sanchez, P. Chaudhary, M.S. Kumar, S. Lee, L.A. Peña, M. Waring, B. Sitharaman, M. Naidu, Graphene nanoribbons as a drug delivery agent for lucanthone mediated therapy of glioblastoma multiforme, Nanomed.: Nanotechnol., Biol. Med. 11 (1) (2015) 109–118. [38] L. Feng, S. Zhang, Z. Liu, Graphene based gene transfection, Nanoscale 3 (3) (2011) 1252–1257. [39] B. Tian, C. Wang, S. Zhang, L. Feng, Z. Liu, Photothermally enhanced photodynamic therapy delivered by nano-graphene oxide, ACS Nano 5 (9) (2011) 7000–7009. [40] P. Huang, C. Xu, J. Lin, C. Wang, X. Wang, C. Zhang, X. Zhou, S. Guo, D. Cui, Folic acidconjugated graphene oxide loaded with photosensitizers for targeting photodynamic therapy, Theranostics 1 (2011) 240.\n[41] G. Lalwani, A.M. Henslee, B. Farshid, L. Lin, F.K. Kasper, Y.-X. Qin, A.G. Mikos, B. Sitharaman, Two-dimensional nanostructure-reinforced biodegradable polymeric nanocomposites for bone tissue engineering, Biomacromolecules 14 (3) (2013) 900–909. [42] S.C. Patel, G. Lalwani, K. Grover, Y.-X. Qin, B. Sitharaman, Fabrication and cytocompatibility of in situ crosslinked carbon nanomaterial films, Scie. Rep. 5 (2015). [43] B. Farshid, G. Lalwani, B. Sitharaman, In vitro cytocompatibility of one-dimensional and two-dimensional nanostructure-reinforced biodegradable polymeric nanocomposites, J. Biomed. Mater. Res. Part A 103 (7) (2015) 2309–2321. [44] Y. Talukdar, J.T. Rashkow, G. Lalwani, S. Kanakia, B. Sitharaman, The effects of graphene nanostructures on mesenchymal stem cells, Biomaterials 35 (18) (2014) 4863–4877. [45] T.R. Nayak, H. Andersen, V.S. Makam, C. Khaw, S. Bae, X. Xu, P.-L.R. Ee, J.-H. Ahn, B.H. Hong, G. Pastorin, Graphene for controlled and accelerated osteogenic differentiation of human mesenchymal stem cells, ACS Nano 5 (6) (2011) 4670–4678. [46] Y. Yang, A.M. Asiri, Z. Tang, D. Du, Y. Lin, Graphene based materials for biomedical applications, Mater. Today 16 (10) (2013) 365–373. [47] K. Yang, L. Feng, X. Shi, Z. Liu, Nano-graphene in biomedicine: theranostic applications, Chem. Soc. Rev. 42 (2) (2013) 530–547. [48] X. Hu, Q. Zhou, Health and ecosystem risks of graphene, Chem. Rev. 113 (5) (2013) 3815–3835. [49] A.B. Seabra, A.J. Paula, R. de Lima, O.L. Alves, N. Durán, Nanotoxicity of graphene and graphene oxide, Chem. Res. Toxicol. 27 (2) (2014) 159–168. [50] J. Zhao, Z.Wang, J.C. White, B. Xing, Graphene in the aquatic environment: adsorption, dispersion, toxicity and transformation, Environ. Sci. Technol. 48 (17) (2014) 9995–10009. [51] F.M. Tonelli, V.A. Goulart, K.N. Gomes, M.S. Ladeira, A.K. Santos, E. Lorençon, L.O. Ladeira, R.R. Resende, Graphene-based nanomaterials: biological and medical applications and toxicity, Nanomedicine 10 (15) (2015) 2423–2450. [52] D. Bitounis, H. Ali-Boucetta, B.H. Hong, D.H. Min, K. Kostarelos, Prospects and challenges of graphene in biomedical applications, Adv. Mater. 25 (16) (2013) 2258–2268. [53] A. Bianco, Graphene: safe or toxic? The two faces of the medal, Angew. Chem. Int. Ed. 52 (19) (2013) 4986–4997. [54] K. Yang, Y. Li, X. Tan, R. Peng, Z. Liu, Behavior and toxicity of graphene and its functionalized derivatives in biological systems, Small 9 (9–10) (2013) 1492–1503. [55] V.C. Sanchez, A. Jachak, R.H. Hurt, A.B. Kane, Biological interactions of graphenefamily nanomaterials: an interdisciplinary review, Chem. Res. Toxicol. 25 (1) (2011) 15–34. [56] A.M. Jastrzębska, P. Kurtycz, A.R. Olszyna, Recent advances in graphene family materials toxicity investigations, J. Nanopart. Res. 14 (12) (2012) 1–21. [57] B. Zhang, Y. Wang, G. Zhai, Biomedical applications of the graphene-based materials, Mater. Sci. Eng. C (2015). [58] C.H.A. Wong, Z. Sofer, M. Kubešová, J. Kučera, S. Matějková, M. Pumera, Synthetic routes contaminate graphene materials with a whole spectrum of unanticipated metallic elements, Proc. Natl. Acad. Sci. 111 (38) (2014) 13774–13779. [59] A. Ambrosi, C.K. Chua, B. Khezri, Z. Sofer, R.D. Webster, M. Pumera, Chemically reduced graphene contains inherent metallic impurities present in parent natural and synthetic graphite, Proc. Natl. Acad. Sci. 109 (32) (2012) 12899–12904. [60] S. Mullick Chowdhury, S. Dasgupta, A.E. McElroy, B. Sitharaman, Structural disruption increases toxicity of graphene nanoribbons, J. Appl. Toxicol. 34 (11) (2014) 1235–1246. [61] Y. Zhang, S.F. Ali, E. Dervishi, Y. Xu, Z. Li, D. Casciano, A.S. Biris, Cytotoxicity effects of graphene and single-wall carbon nanotubes in neural phaeochromocytoma-derived PC12 cells, ACS Nano 4 (6) (2010) 3181–3186. [62] N.V. Vallabani, S. Mittal, R.K. Shukla, A.K. Pandey, S.R. Dhakate, R. Pasricha, A. Dhawan, Toxicity of graphene in normal human lung cells (BEAS-2B), J. Biomed. Nanotechnol. 7 (1) (2011) 106–107. [63] J. Yuan, H. Gao, J. Sui, H. Duan, W.N. Chen, C.B. Ching, Cytotoxicity evaluation of oxidized single-walled carbon nanotubes and graphene oxide on human hepatoma HepG2 cells: an iTRAQ-coupled 2D LC–MS/MS proteome analysis, Toxicol. Sci. 126 (1) (2012) 149–161. [64] M. Lv, Y. Zhang, L. Liang, M. Wei, W. Hu, X. Li, Q. Huang, Effect of graphene oxide on undifferentiated and retinoic acid-differentiated SH-SY5Y cells line, Nanoscale 4 (13) (2012) 3861–3866. [65] E.L.K. Chng, C.K. Chua, M. Pumera, Graphene oxide nanoribbons exhibit significantly greater toxicity than graphene oxide nanoplatelets, Nanoscale 6 (18) (2014) 10792–10797. [66] O. Akhavan, E. Ghaderi, H. Emamy, F. Akhavan, Genotoxicity of graphene nanoribbons in human mesenchymal stem cells, Carbon 54 (2013) 419–431. [67] S. Jaworski, E. Sawosz, M. Grodzik, A. Winnicka, M. Prasek, M. Wierzbicki, A. Chwalibog, In vitro evaluation of the effects of graphene platelets on glioblastoma multiforme cells, Int. J. Nanomedicine 8 (2013) 413–420. [68] A. Sasidharan, L.S. Panchakarla, P. Chandran, D. Menon, S. Nair, C.N. Rao, M. Koyakutty, Differential nano-bio interactions and toxicity effects of pristine versus functionalized graphene, Nanoscale 3 (6) (2011) 2461–2464. [69] M.C. Matesanz, M. Vila, M.J. Feito, J. Linares, G. Goncalves, M. Vallet-Regi, P.A. Marques, M.T. Portoles, The effects of graphene oxide nanosheets localized on F-actin filaments on cell-cycle alterations, Biomaterials 34 (5) (2013) 1562–1569. [70] X. Yuan, Z. Liu, Z. Guo, Y. Ji, M. Jin, X. Wang, Cellular distribution and cytotoxicity of graphene quantum dots with different functional groups, Nanoscale Res. Lett. 9 (1) (2014) 1–9. [71] L. Horváth, A. Magrez, M. Burghard, K. Kern, L. Forró, B. Schwaller, Evaluation of the toxicity of graphene derivatives on cells of the lung luminal surface, Carbon 64 (2013) 45–60. [72] S. Das, S. Singh, V. Singh, D. Joung, J.M. Dowding, D. Reid, J. Anderson, L. Zhai, S.I. Khondaker, W.T. Self, Oxygenated functional group density on graphene oxide: its effect on cell toxicity, Part. Part. Syst. Charact. 30 (2) (2013) 148–157. [73] Y. Chong, Y. Ma, H. Shen, X. Tu, X. Zhou, J. Xu, J. Dai, S. Fan, Z. Zhang, The in vitro and in vivo toxicity of graphene quantum dots, Biomaterials 35 (19) (2014) 5041–5048. [74] W.Z. Teo, E.L.K. Chng, Z. Sofer, M. Pumera, Cytotoxicity of halogenated graphenes, Nanoscale 6 (2) (2014) 1173–1180. [75] W.Z. Teo, Z. Sofer, F. Šembera, Z. Janoušek, M. Pumera, Cytotoxicity of fluorographene, RSC Adv. 5 (129) (2015) 107158–107165. [76] E.L.K. Chng, Z. Sofer, M. Pumera, Cytotoxicity profile of highly hydrogenated graphene, Chem. Eur. J. 20 (21) (2014) 6366–6373.\n[77] E. Sawosz, S. Jaworski, M. Kutwin, K.P. Vadalasetty, M. Grodzik, M. Wierzbicki, N. Kurantowicz, B. Strojny, A. Hotowy, L. Lipińska, Graphene functionalized with arginine decreases the development of glioblastoma multiforme tumor in a gene-dependent manner, Int. J. Mol. Sci. 16 (10) (2015) 25214–25233. [78] O. Akhavan, E. Ghaderi, A. Akhavan, Size-dependent genotoxicity of graphene nanoplatelets in human stem cells, Biomaterials 33 (32) (2012) 8017–8025. [79] Y. Chang, S.T. Yang, J.H. Liu, E. Dong, Y. Wang, A. Cao, Y. Liu, H. Wang, In vitro toxicity evaluation of graphene oxide on A549 cells, Toxicol. Lett. 200 (3) (2011) 201–210. [80] H. Yue, W.Wei, Z. Yue, B. Wang, N. Luo, Y. Gao, D. Ma, G. Ma, Z. Su, The role of the lateral dimension of graphene oxide in the regulation of cellular responses, Biomaterials 33 (16) (2012) 4013–4021. [81] X. Zhi, H. Fang, C. Bao, G. Shen, J. Zhang, K. Wang, S. Guo, T. Wan, D. Cui, The immunotoxicity of graphene oxides and the effect of PVP-coating, Biomaterials 34 (21) (2013) 5254–5261. [82] Y. Li, Y. Liu, Y. Fu, T. Wei, L. Le Guyader, G. Gao, R.S. Liu, Y.Z. Chang, C. Chen, The triggering of apoptosis in macrophages by pristine graphene through the MAPK and TGF-beta signaling pathways, Biomaterials 33 (2) (2012) 402–411. [83] G.Y. Chen, H.J. Yang, C.H. Lu, Y.C. Chao, S.M. Hwang, C.L. Chen, K.W. Lo, L.Y. Sung,W.Y. Luo, H.Y. Tuan, Y.C. Hu, Simultaneous induction of autophagy and toll-like receptor signaling pathways by graphene oxide, Biomaterials 33 (27) (2012) 6559–6569. [84] A.V. Tkach, N. Yanamala, S. Stanley, M.R. Shurin, G.V. Shurin, E.R. Kisin, A.R. Murray, S. Pareso, T. Khaliullin, G.P. Kotchey, V. Castranova, S. Mathur, B. Fadeel, A. Star, V.E. Kagan, A.A. Shvedova, Graphene oxide, but not fullerenes, targets immunoproteasomes and suppresses antigen presentation by dendritic cells, Small 9 (9–10) (2013) 1686–1690. [85] K.H. Liao, Y.S. Lin, C.W. Macosko, C.L. Haynes, Cytotoxicity of graphene oxide and graphene in human erythrocytes and skin fibroblasts, ACS Appl. Mater. Interfaces 3 (7) (2011) 2607–2615. [86] S.K. Singh, M.K. Singh,M.K. Nayak, S. Kumari, S. Shrivastava, J.J. Gracio, D. Dash, Thrombus inducing property of atomically thin graphene oxide sheets, ACS Nano 5 (6) (2011) 4987–4996. [87] S.K. Singh, M.K. Singh, P.P. Kulkarni, V.K. Sonkar, J.J. Gracio, D. Dash, Amine-modified graphene: thrombo-protective safer alternative to graphene oxide for biomedical applications, ACS Nano 6 (3) (2012) 2731–2740. [88] S.M. Chowdhury, S. Kanakia, J.D. Toussaint, M.D. Frame, A.M. Dewar, K.R. Shroyer, W. Moore, B. Sitharaman, In vitro hematological and in vivo vasoactivity assessment of dextran functionalized graphene, Sci. Rep. 3 (2013). [89] S.M. Chowdhury, J. Fang, B. Sitharaman, Interaction of graphene nanoribbons with components of the blood vascular system, Future Sci. OA (2015) 1(3). [90] M.Wojtoniszak, X. Chen, R.J. Kalenczuk, A. Wajda, J. Lapczuk, M. Kurzewski, M. Drozdzik, P.K. Chu, E. Borowiak-Palen, Synthesis, dispersion, and cytocompatibility of graphene oxide and reduced graphene oxide, Colloids Surf. B: Biointerfaces 89 (2012) 79–85. [91] W. Hu, C. Peng, M. Lv, X. Li, Y. Zhang, N. Chen, C. Fan, Q. Huang, Protein corona-mediated mitigation of cytotoxicity of graphene oxide, ACS Nano 5 (5) (2011) 3693–3700. [92] Q. Mu, G. Su, L. Li, B.O. Gilbertson, L.H. Yu, Q. Zhang, Y.P. Sun, B. Yan, Size-dependent cell uptake of protein-coated graphene oxide nanosheets, ACS Appl. Mater. Interfaces 4 (4) (2012) 2259–2266. [93] D.A. Mbeh, O. Akhavan, T. Javanbakht, M. Mahmoudi, L.H. Yahia, Cytotoxicity of protein corona-graphene oxide nanoribbons on human epithelial cells, Appl. Surf. Sci. 320 (2014) 596–601. [94] S.K. Singh, M.K. Singh, P.P. Kulkarni, V.K. Sonkar, J.J. Grácio, D. Dash, Amine-modified graphene: thrombo-protective safer alternative to graphene oxide for biomedical applications, ACS Nano 6 (3) (2012) 2731–2740. [95] A. Sasidharan, S. Swaroop, C.K. Koduri, C.M. Girish, P. Chandran, L. Panchakarla, V.H. Somasundaram, G.S. Gowd, S. Nair, M. Koyakutty, Comparative in vivo toxicity, organ biodistribution and immune response of pristine, carboxylated and PEGylated fewlayer graphene sheets in Swiss albino mice: a three month study, Carbon 95 (2015) 511–524. [96] S. Zhang, K. Yang, L. Feng, Z. Liu, In vitro and in vivo behaviors of dextran functionalized graphene, Carbon 49 (12) (2011) 4040–4049. [97] X. Zhang, J. Yin, C. Peng, W. Hu, Z. Zhu, W. Li, C. Fan, Q. Huang, Distribution and biocompatibility studies of graphene oxide in mice after intravenous administration, Carbon 49 (3) (2011) 986–995. [98] K. Wang, J. Ruan, H. Song, J. Zhang, Y. Wo, S. Guo, D. Cui, Biocompatibility of graphene oxide, Nanoscale Res. Lett. 6 (8) (2011) 1–8. [99] J.-H. Liu, S.-T. Yang, H. Wang, Y. Chang, A. Cao, Y. Liu, Effect of size and dose on the biodistribution of graphene oxide in mice, Nanomedicine 7 (12) (2012) 1801–1812. [100] K. Yang, S. Zhang, G. Zhang, X. Sun, S.-T. Lee, Z. Liu, Graphene in mice: ultrahigh in vivo tumor uptake and efficient photothermal therapy, Nano Lett. 10 (9) (2010) 3318–3323. [101] K. Yang, J. Wan, S. Zhang, Y. Zhang, S.-T. Lee, Z. Liu, In vivo pharmacokinetics, long-term biodistribution, and toxicology of PEGylated graphene in mice, ACS Nano 5 (1) (2010) 516–522. [102] S. Kanakia, J. Toussaint, D.M. Hoang, S. Mullick Chowdhury, S. Lee, K.R. Shroyer, W. Moore, Y.Z. Wadghiri, B. Sitharaman, Towards an advanced graphene-based magnetic resonance imaging contrast agent: sub-acute toxicity and efficacy studies in small animals, Scie. Rep. 5 (2015) 17182. [103] S. Kanakia, J.D. Toussaint, S.M. Chowdhury, T. Tembulkar, S. Lee, Y.-P. Jiang, R.Z. Lin, K.R. Shroyer, W. Moore, B. Sitharaman, Dose ranging, expanded acute toxicity and safety pharmacology studies for intravenously administered functionalized graphene nanoparticle formulations, Biomaterials 35 (25) (2014) 7022–7031. [104] D.A. Jasim, C. Ménard-Moyon, D. Bégin, A. Bianco, K. Kostarelos, Tissue distribution and urinary excretion of intravenously administered chemically functionalized graphene oxide sheets, Chem. Sci. (2015). [105] K. Yang, H. Gong, X. Shi, J. Wan, Y. Zhang, Z. Liu, In vivo biodistribution and toxicology of functionalized nano-graphene oxide in mice after oral and intraperitoneal administration, Biomaterials 34 (11) (2013) 2787–2795. [106] H. Ali-Boucetta, D. Bitounis, R. Raveendran-Nair, A. Servant, J. Van den Bossche, K. Kostarelos, Purified graphene oxide dispersions lack in vitro cytotoxicity and in vivo pathogenicity, Adv. Healthcare Mater. 2 (3) (2013) 433–441. [107] A. Sahu, W.I. Choi, G. Tae, A stimuli-sensitive injectable graphene oxide composite hydrogel, Chem. Commun. 48 (47) (2012) 5820–5822.\n[108] B. Strojny, N. Kurantowicz, E. Sawosz, M. Grodzik, S. Jaworski, M. Kutwin, M. Wierzbicki, A. Hotowy, L. Lipińska, A. Chwalibog, Long term influence of carbon nanoparticles on health and liver status in rats, PLoS One 10 (12) (2015), e0144821. [109] C. Fu, T. Liu, L. Li, H. Liu, Q. Liang, X. Meng, Effects of graphene oxide on the development of offspring mice in lactation period, Biomaterials 40 (2015) 23–31. [110] D. Zhang, Z. Zhang, Y. Liu, M. Chu, C. Yang, W. Li, Y. Shao, Y. Yue, R. Xu, The short-and long-term effects of orally administered high-dose reduced graphene oxide nanosheets on mouse behaviors, Biomaterials 68 (2015) 100–113. [111] Q. Wu, L. Yin, X. Li, M. Tang, T. Zhang, D. Wang, Contributions of altered permeability of intestinal barrier and defecation behavior to toxicity formation from graphene oxide in nematode Caenorhabditis elegans, Nanoscale 5 (20) (2013) 9934–9943. [112] A. Schinwald, F.A. Murphy, A. Jones, W. MacNee, K. Donaldson, Graphene-based nanoplatelets: a new risk to the respiratory system as a consequence of their unusual aerodynamic properties, ACS Nano 6 (1) (2012) 736–746. [113] M.C. Duch, G.S. Budinger, Y.T. Liang, S. Soberanes, D. Urich, S.E. Chiarella, L.A. Campochiaro, A. Gonzalez, N.S. Chandel, M.C. Hersam, Minimizing oxidation and stable nanoscale dispersion improves the biocompatibility of graphene in the lung, Nano Lett. 11 (12) (2011) 5201–5207. [114] B. Li, J. Yang, Q. Huang, Y. Zhang, C. Peng, Y. Zhang, Y. He, J. Shi, W. Li, J. Hu, Biodistribution and pulmonary toxicity of intratracheally instilled graphene oxide in mice, NPG Asia Mater. 5 (4) (2013), e44. [115] L. Yan, Y. Wang, X. Xu, C. Zeng, J. Hou, M. Lin, J. Xu, F. Sun, X. Huang, L. Dai, Can graphene oxide cause damage to eyesight? Chem. Res. Toxicol. 25 (6) (2012) 1265–1270. [116] M. Sawangphruk, P. Srimuk, P. Chiochan, T. Sangsri, P. Siwayaprahm, Synthesis and antifungal activity of reduced graphene oxide nanosheets, Carbon 50 (14) (2012) 5156–5161. [117] O. Akhavan, E. Ghaderi, Toxicity of graphene and graphene oxide nanowalls against bacteria, ACS Nano 4 (10) (2010) 5731–5736. [118] X. Cai, M. Lin, S. Tan, W. Mai, Y. Zhang, Z. Liang, Z. Lin, X. Zhang, The use of polyethyleneimine-modified reduced graphene oxide as a substrate for silver nanoparticles to produce a material with lower cytotoxicity and long-term antibacterial activity, Carbon 50 (10) (2012) 3407–3415. [119] J. Chen, X. Wang, H. Han, A new function of graphene oxide emerges: inactivating phytopathogenic bacterium Xanthomonas oryzae pv. oryzae, J. Nanopart. Res. 15 (5) (2013) 1–14. [120] C.M. Santos, J. Mangadlao, F. Ahmed, A. Leon, R.C. Advincula, D.F. Rodrigues, Graphene nanocomposite for biomedical applications: fabrication, antimicrobial and cytotoxic investigations, Nanotechnology 23 (39) (2012) 395101. [121] I.E.M. Carpio, C.M. Santos, X. Wei, D.F. Rodrigues, Toxicity of a polymer–graphene oxide composite against bacterial planktonic cells, biofilms, and mammalian cells, Nanoscale 4 (15) (2012) 4746–4756. [122] W. Hu, C. Peng, W. Luo, M. Lv, X. Li, D. Li, Q. Huang, C. Fan, Graphene-based antibacterial paper, ACS Nano 4 (7) (2010) 4317–4323. [123] A. Áde Leon, On the antibacterial mechanism of graphene oxide (GO) Langmuir–Blodgett films, Chem. Commun. 51 (14) (2015) 2886–2889. [124] L. Hui, J.G. Piao, J. Auletta, K. Hu, Y. Zhu, T. Meyer, H. Liu, L. Yang, Availability of the basal planes of graphene oxide determines whether it is antibacterial, ACS Appl. Mater. Interfaces 6 (15) (2014) 13183–13190. [125] J. Li, G. Wang, H. Zhu, M. Zhang, X. Zheng, Z. Di, X. Liu, X. Wang, Antibacterial activity of large-area monolayer graphene film manipulated by charge transfer, Sci. Report. 4 (2014) 4359. [126] N. Kurantowicz, E. Sawosz, S. Jaworski, M. Kutwin, B. Strojny, M. Wierzbicki, J. Szeliga, A. Hotowy, L. Lipińska, R. Koziński, Interaction of graphene family materials with Listeria monocytogenes and Salmonella enterica, Nanoscale Res. Lett. 10 (1) (2015) 1–12. [127] S. Liu, T.H. Zeng, M. Hofmann, E. Burcombe, J. Wei, R. Jiang, J. Kong, Y. Chen, Antibacterial activity of graphite, graphite oxide, graphene oxide, and reduced graphene oxide: membrane and oxidative stress, ACS Nano 5 (9) (2011) 6971–6980. [128] S. Liu, M. Hu, T.H. Zeng, R. Wu, R. Jiang, J. Wei, L. Wang, J. Kong, Y. Chen, Lateral dimension-dependent antibacterial activity of graphene oxide sheets, Langmuir 28 (33) (2012) 12364–12372. [129] P. Begum, R. Ikhtiari, B. Fugetsu, Graphene phytotoxicity in the seedling stage of cabbage, tomato, red spinach, and lettuce, Carbon 49 (12) (2011) 3907–3919.\n[130] M.V. Khodakovskaya, K. de Silva, D.A. Nedosekin, E. Dervishi, A.S. Biris, E.V. Shashkov, E.I. Galanzha, V.P. Zharov, Complex genetic, photothermal, and photoacoustic analysis of nanoparticle–plant interactions, Proc. Natl. Acad. Sci. 108 (3) (2011) 1028–1033. [131] F. Ahmed, D.F. Rodrigues, Investigation of acute effects of graphene oxide on wastewater microbial community: a case study, J. Hazard. Mater. 256 (2013) 33–39. [132] W. Xing, G. Lalwani, I. Rusakova, B. Sitharaman, Degradation of graphene by hydrogen peroxide, Part. Part. Syst. Charact. 31 (7) (2014) 745–750. [133] G. Lalwani, W. Xing, B. Sitharaman, Enzymatic degradation of oxidized and reduced graphene nanoribbons by lignin peroxidase, J. Mater. Chem. B 2 (37) (2014) 6354–6362. [134] Y. Ma, H. Shen, X. Tu, Z. Zhang, Assessing in vivo toxicity of graphene materials: current methods and future outlook, Nanomedicine 9 (10) (2014) 1565–1580. [135] W. Zhang, C. Wang, Z. Li, Z. Lu, Y. Li, J.J. Yin, Y.T. Zhou, X. Gao, Y. Fang, G. Nie, Unraveling stress-induced toxicity properties of graphene oxide and the underlying mechanism, Adv. Mater. 24 (39) (2012) 5391–5397. [136] T. Wang, S. Zhu, X. Jiang, Toxicity mechanism of graphene oxide and nitrogen-doped graphene quantum dots in RBCs revealed by surface-enhanced infrared absorption spectroscopy, Toxicol. Res. (2015). [137] K. Liu, J.-J. Zhang, F.-F. Cheng, T.-T. Zheng, C. Wang, J.-J. Zhu, Green and facile synthesis of highly biocompatible graphene nanosheets and its application for cellular imaging and drug delivery, J. Mater. Chem. 21 (32) (2011) 12034–12040. [138] J. Huang, C. Zong, H. Shen, M. Liu, B. Chen, B. Ren, Z. Zhang, Mechanism of cellular uptake of graphene oxide studied by surface-enhanced raman spectroscopy, Small 8 (16) (2012) 2577–2584. [139] H. Ren, C. Wang, J. Zhang, X. Zhou, D. Xu, J. Zheng, S. Guo, J. Zhang, DNA cleavage system of nanosized graphene oxide sheets and copper ions, ACS Nano 4 (12) (2010) 7169–7174. [140] L. Zhang, Z. Wang, Z. Lu, H. Shen, J. Huang, Q. Zhao, M. Liu, N. He, Z. Zhang, PEGylated reduced graphene oxide as a superior ssRNA delivery system, J. Mater. Chem. B 1 (6) (2013) 749–755. [141] M. Wu, R. Kempaiah, P.-J.J. Huang, V. Maheshwari, J. Liu, Adsorption and desorption of DNA on graphene oxide studied by fluorescently labeled oligonucleotides, Langmuir 27 (6) (2011) 2731–2738. [142] Y. Li, H. Yuan, A. von dem Bussche, M. Creighton, R.H. Hurt, A.B. Kane, H. Gao, Graphene microsheets enter cells through spontaneous membrane penetration at edge asperities and corner sites, Proc. Natl. Acad. Sci. 110 (30) (2013) 12295–12300. [143] A.V. Titov, P. Král, R. Pearson, Sandwiched graphene–membrane superstructures, ACS Nano 4 (1) (2009) 229–234. [144] Y. Tu, M. Lv, P. Xiu, T. Huynh, M. Zhang, M. Castelli, Z. Liu, Q. Huang, C. Fan, H. Fang, Destructive extraction of phospholipids from Escherichia coli membranes by graphene nanosheets, Nat. Nanotechnol. 8 (8) (2013) 594–601. [145] M. Nurunnabi, Z. Khatun, K.M. Huh, S.Y. Park, D.Y. Lee, K.J. Cho, Y.-k. Lee, In vivo biodistribution and toxicology of carboxylated graphene quantum dots, ACS Nano 7 (8) (2013) 6858–6867. [146] G. Lalwani, Two- and three-dimensional all-carbon nanomaterial assemblies for tissue engineering and regenerative medicine, Ann. Biomed. Eng. (2016) 1–16, http://dx.doi. org/10.1007/s10439-016-1623-5 (Early View Online). [147] Lalwani, G., M. D'Agati, A. Gopalan, M. Rao, J. Schneller, and B. Sitharaman, Threedimensional macroporous graphene scaffolds for tissue engineering. J. Biomed. Mater. Res. Part A – (Accepted for publication), 2016. [148] B. Farshid, G. Lalwani, M. Shir Mohammadi, J. Simonsen, B. Sitharaman, Boron nitride nanotubes and nanoplatelets as reinforcing agents of polymeric matrices for bone tissue engineering, J. Biomed. Mater. Res. B Appl. Biomater. (2015), http://dx.doi.org/10.1002/ jbm.b.33565 (Early View Online). [149] J.T. Rashkow, Y. Talukdar, G. Lalwani, B. Sitharaman, Interactions of 1D-and 2D-layered inorganic nanoparticles with fibroblasts and human mesenchymal stem cells, Nanomedicine 10 (11) (2015) 1693–1706. [150] W.Z. Teo, E.L.K. Chng, Z. Sofer, M. Pumera, Cytotoxicity of exfoliated transition-metal dichalcogenides (MoS2, WS2, and WSe2) is lower than that of graphene and its analogues, Chem. Eur. J. 20 (31) (2014) 9627–9632. [151] E.L.K. Chng, Z. Sofer, M. Pumera, MoS2 exhibits stronger toxicity with increased exfoliation, Nanoscale 6 (23) (2014) 14412–14418."
    } ],
    "references" : [ {
      "title" : "Science of Fullerenes and Carbon Nanotubes: Their Properties and Applications",
      "author" : [ "M.S. Dresselhaus", "G. Dresselhaus", "P.C. Eklund" ],
      "venue" : "Academic press",
      "citeRegEx" : "1",
      "shortCiteRegEx" : null,
      "year" : 1996
    }, {
      "title" : "Graphene: status and prospects",
      "author" : [ "A.K. Geim" ],
      "venue" : "Science 324 (5934) ",
      "citeRegEx" : "2",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "Multifunctional fullerene-and metallofullerene-based nanobiomaterials",
      "author" : [ "G. Lalwani", "B. Sitharaman" ],
      "venue" : "Nano. LIFE 3 (3) ",
      "citeRegEx" : "3",
      "shortCiteRegEx" : null,
      "year" : 2003
    }, {
      "title" : "The rise of graphene",
      "author" : [ "A.K. Geim", "K.S. Novoselov" ],
      "venue" : "Nat. Mater. 6 (3) ",
      "citeRegEx" : "6",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "Band structure of graphite",
      "author" : [ "J. Slonczewski", "P. Weiss" ],
      "venue" : "Phys. Rev. 109 (2) ",
      "citeRegEx" : "7",
      "shortCiteRegEx" : null,
      "year" : 1958
    }, {
      "title" : "Quelques propriétés typiques des corps solides",
      "author" : [ "R. Peierls" ],
      "venue" : "Annales de l'institut Henri Poincaré",
      "citeRegEx" : "8",
      "shortCiteRegEx" : null,
      "year" : 1935
    }, {
      "title" : "Zur Theorie der phasenumwandlungen II",
      "author" : [ "L. Landau" ],
      "venue" : "Phys. Z. Sowjetunion 11 ",
      "citeRegEx" : "9",
      "shortCiteRegEx" : null,
      "year" : 1937
    }, {
      "title" : "Statistical physics",
      "author" : [ "L.D. Landau", "E. Lifshitz" ],
      "venue" : "part I, Course Theor. Phys. 5 ",
      "citeRegEx" : "10",
      "shortCiteRegEx" : null,
      "year" : 1980
    }, {
      "title" : "Crystalline order in two dimensions",
      "author" : [ "N.D. Mermin" ],
      "venue" : "Phys. Rev. 176 (1) ",
      "citeRegEx" : "11",
      "shortCiteRegEx" : null,
      "year" : 1968
    }, {
      "title" : "Electric field effect in atomically thin carbon films",
      "author" : [ "K.S. Novoselov", "A.K. Geim", "S. Morozov", "D. Jiang", "Y. Zhang", "S.A. Dubonos", "I. Grigorieva", "A. Firsov" ],
      "venue" : "Science 306 (5696) ",
      "citeRegEx" : "12",
      "shortCiteRegEx" : null,
      "year" : 2004
    }, {
      "title" : "Two-dimensional gas of massless Dirac fermions in graphene",
      "author" : [ "K. Novoselov", "A.K. Geim", "S. Morozov", "D. Jiang", "M. Katsnelson", "I. Grigorieva", "S. Dubonos", "A. Firsov" ],
      "venue" : "Nature 438 (7065) ",
      "citeRegEx" : "13",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "Twodimensional atomic crystals",
      "author" : [ "K. Novoselov", "D. Jiang", "F. Schedin", "T. Booth", "V. Khotkevich", "S. Morozov", "A. Geim" ],
      "venue" : "Proc. Natl. Acad. Sci. U. S. A. 102 (30) ",
      "citeRegEx" : "14",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "Europe invests €1 billion to become “graphene valley",
      "author" : [ "D. Johnson" ],
      "venue" : "IEEE Spectr. ",
      "citeRegEx" : "15",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "South Korea to spend US$40million on graphene development",
      "author" : [ "M. Spasenovic" ],
      "venue" : "Graphene Tracker",
      "citeRegEx" : "16",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Government announces £50m funding hub for UK graphene research,WIRED",
      "author" : [ "M. Brown" ],
      "venue" : null,
      "citeRegEx" : "17",
      "shortCiteRegEx" : "17",
      "year" : 2011
    }, {
      "title" : "Announces Partnership With the University of Manchester to Develop Graphene-based Technologies",
      "author" : [ "HUAWEI", "Huawei" ],
      "venue" : null,
      "citeRegEx" : "18",
      "shortCiteRegEx" : "18",
      "year" : 2015
    }, {
      "title" : "Ultrahigh electron mobility in suspended graphene",
      "author" : [ "K.I. Bolotin", "K. Sikes", "Z. Jiang", "M. Klima", "G. Fudenberg", "J. Hone", "P. Kim", "H. Stormer" ],
      "venue" : "Solid State Commun. 146 (9) ",
      "citeRegEx" : "19",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "Approaching ballistic transport in suspended graphene",
      "author" : [ "X. Du", "I. Skachko", "A. Barker", "E.Y. Andrei" ],
      "venue" : "Nat. Nanotechnol. 3 (8) ",
      "citeRegEx" : "20",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "Graphene-based ultracapacitors",
      "author" : [ "M.D. Stoller", "S. Park", "Y. Zhu", "J. An", "R.S. Ruoff" ],
      "venue" : "Nano Lett. 8 (10) ",
      "citeRegEx" : "21",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "Tunable metal–insulator transition in double-layer graphene heterostructures",
      "author" : [ "L. Ponomarenko", "A. Geim", "A. Zhukov", "R. Jalil", "S. Morozov", "K. Novoselov", "I. Grigorieva", "E. Hill", "V. Cheianov", "V. Fal'Ko" ],
      "venue" : "Nat. Phys. 7 (12) ",
      "citeRegEx" : "22",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Experimental observation of the quantum Hall effect and Berry's phase in graphene",
      "author" : [ "Y. Zhang", "Y.-W. Tan", "H.L. Stormer", "P. Kim" ],
      "venue" : "Nature 438 (7065) ",
      "citeRegEx" : "23",
      "shortCiteRegEx" : null,
      "year" : 2005
    }, {
      "title" : "Superior thermal conductivity of single-layer graphene",
      "author" : [ "A.A. Balandin", "S. Ghosh", "W. Bao", "I. Calizo", "D. Teweldebrhan", "F. Miao", "C.N. Lau" ],
      "venue" : "Nano Lett. 8 (3) ",
      "citeRegEx" : "24",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "Measurement of the elastic properties and intrinsic strength of monolayer graphene",
      "author" : [ "C. Lee", "X. Wei", "J.W. Kysar", "J. Hone" ],
      "venue" : "Science 321 (5887) ",
      "citeRegEx" : "25",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "Fine structure constant defines visual transparency of graphene",
      "author" : [ "R. Nair", "P. Blake", "A. Grigorenko", "K. Novoselov", "T. Booth", "T. Stauber", "N. Peres", "A. Geim" ],
      "venue" : "Science 320 (5881) ",
      "citeRegEx" : "26",
      "shortCiteRegEx" : null,
      "year" : 2008
    }, {
      "title" : "Graphene: synthesis and applications",
      "author" : [ "P. Avouris", "C. Dimitrakopoulos" ],
      "venue" : "Mater. Today 15 (3) ",
      "citeRegEx" : "27",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Simple method of preparing graphene flakes by an arc-discharge method",
      "author" : [ "K. Subrahmanyam", "L. Panchakarla", "A. Govindaraj", "C. Rao" ],
      "venue" : "J. Phys. Chem. C 113 (11) ",
      "citeRegEx" : "28",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "Large-scale pattern growth of graphene films for stretchable transparent electrodes",
      "author" : [ "K.S. Kim", "Y. Zhao", "H. Jang", "S.Y. Lee", "J.M. Kim", "K.S. Kim", "J.-H. Ahn", "P. Kim", "J.-Y. Choi", "B.H. Hong" ],
      "venue" : "Nature 457 (7230) ",
      "citeRegEx" : "29",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "Synthesis of graphene-based nanosheets via chemical reduction of exfoliated graphite oxide",
      "author" : [ "S. Stankovich", "D.A. Dikin", "R.D. Piner", "K.A. Kohlhaas", "A. Kleinhammes", "Y. Jia", "Y. Wu", "S.T. Nguyen", "R.S. Ruoff" ],
      "venue" : "Carbon 45 (7) ",
      "citeRegEx" : "30",
      "shortCiteRegEx" : null,
      "year" : 2007
    }, {
      "title" : "Longitudinal unzipping of carbon nanotubes to form graphene nanoribbons",
      "author" : [ "D.V. Kosynkin", "A.L. Higginbotham", "A. Sinitskii", "J.R. Lomeda", "A. Dimiev", "B.K. Price", "J.M. Tour" ],
      "venue" : "Nature 458 (7240) ",
      "citeRegEx" : "31",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "The reduction of graphene oxide",
      "author" : [ "S. Pei", "H.-M. Cheng" ],
      "venue" : "Carbon 50 (9) ",
      "citeRegEx" : "32",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Physicochemical characterization of a novel graphene-based magnetic resonance imaging contrast agent",
      "author" : [ "S. Kanakia", "J.D. Toussaint", "S.M. Chowdhury", "G. Lalwani", "T. Tembulkar", "T. Button", "K.R. Shroyer", "W. Moore", "B. Sitharaman" ],
      "venue" : "Int. J. Nanomedicine 8 ",
      "citeRegEx" : "33",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Graphene-based contrast agents for photoacoustic and thermoacoustic tomography",
      "author" : [ "G. Lalwani", "X. Cai", "L. Nie", "L.V. Wang", "B. Sitharaman" ],
      "venue" : "Photoacoustics 1 (3) ",
      "citeRegEx" : "34",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Synthesis",
      "author" : [ "G. Lalwani", "J.L. Sundararaj", "K. Schaefer", "T. Button", "B. Sitharaman" ],
      "venue" : "characterization, in vitro phantom imaging, and cytotoxicity of a novel graphene-based multimodal magnetic resonance imaging-X-ray computed tomography contrast agent, J. Mater. Chem. B 2 (22) ",
      "citeRegEx" : "35",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Cell specific cytotoxicity and uptake of graphene nanoribbons",
      "author" : [ "S. Mullick Chowdhury", "G. Lalwani", "K. Zhang", "J.Y. Yang", "K. Neville", "B. Sitharaman" ],
      "venue" : "Biomaterials 34 (1) ",
      "citeRegEx" : "36",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Graphene nanoribbons as a drug delivery agent for lucanthone mediated therapy of glioblastoma multiforme",
      "author" : [ "S.M. Chowdhury", "C. Surhland", "Z. Sanchez", "P. Chaudhary", "M.S. Kumar", "S. Lee", "L.A. Peña", "M. Waring", "B. Sitharaman", "M. Naidu" ],
      "venue" : "Nanomed.: Nanotechnol., Biol. Med. 11 (1) ",
      "citeRegEx" : "37",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Graphene based gene transfection",
      "author" : [ "L. Feng", "S. Zhang", "Z. Liu" ],
      "venue" : "Nanoscale 3 (3) ",
      "citeRegEx" : "38",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Photothermally enhanced photodynamic therapy delivered by nano-graphene oxide",
      "author" : [ "B. Tian", "C. Wang", "S. Zhang", "L. Feng", "Z. Liu" ],
      "venue" : "ACS Nano 5 (9) ",
      "citeRegEx" : "39",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Folic acidconjugated graphene oxide loaded with photosensitizers for targeting photodynamic therapy",
      "author" : [ "P. Huang", "C. Xu", "J. Lin", "C. Wang", "X. Wang", "C. Zhang", "X. Zhou", "S. Guo", "D. Cui" ],
      "venue" : "Theranostics 1 (2011) 240.  143  G. Lalwani et al. / Advanced Drug Delivery Reviews 105 ",
      "citeRegEx" : "40",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Two-dimensional nanostructure-reinforced biodegradable polymeric nanocomposites for bone tissue engineering",
      "author" : [ "G. Lalwani", "A.M. Henslee", "B. Farshid", "L. Lin", "F.K. Kasper", "Y.-X. Qin", "A.G. Mikos", "B. Sitharaman" ],
      "venue" : "Biomacromolecules 14 (3) ",
      "citeRegEx" : "41",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Fabrication and cytocompatibility of in situ crosslinked carbon nanomaterial films",
      "author" : [ "S.C. Patel", "G. Lalwani", "K. Grover", "Y.-X. Qin", "B. Sitharaman" ],
      "venue" : "Scie. Rep. 5 ",
      "citeRegEx" : "42",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "In vitro cytocompatibility of one-dimensional and two-dimensional nanostructure-reinforced biodegradable polymeric nanocomposites",
      "author" : [ "B. Farshid", "G. Lalwani", "B. Sitharaman" ],
      "venue" : "J. Biomed. Mater. Res. Part A 103 (7) ",
      "citeRegEx" : "43",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "The effects of graphene nanostructures on mesenchymal stem cells",
      "author" : [ "Y. Talukdar", "J.T. Rashkow", "G. Lalwani", "S. Kanakia", "B. Sitharaman" ],
      "venue" : "Biomaterials 35 (18) ",
      "citeRegEx" : "44",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Graphene for controlled and accelerated osteogenic differentiation of human mesenchymal stem cells",
      "author" : [ "T.R. Nayak", "H. Andersen", "V.S. Makam", "C. Khaw", "S. Bae", "X. Xu", "P.-L.R. Ee", "J.-H. Ahn", "B.H. Hong", "G. Pastorin" ],
      "venue" : "ACS Nano 5 (6) ",
      "citeRegEx" : "45",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Graphene based materials for biomedical applications",
      "author" : [ "Y. Yang", "A.M. Asiri", "Z. Tang", "D. Du", "Y. Lin" ],
      "venue" : "Mater. Today 16 (10) ",
      "citeRegEx" : "46",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Nano-graphene in biomedicine: theranostic applications",
      "author" : [ "K. Yang", "L. Feng", "X. Shi", "Z. Liu" ],
      "venue" : "Chem. Soc. Rev. 42 (2) ",
      "citeRegEx" : "47",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Health and ecosystem risks of graphene",
      "author" : [ "X. Hu", "Q. Zhou" ],
      "venue" : "Chem. Rev. 113 (5) ",
      "citeRegEx" : "48",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "R",
      "author" : [ "A.B. Seabra", "A.J. Paula" ],
      "venue" : "de Lima, O.L. Alves, N. Durán, Nanotoxicity of graphene and graphene oxide, Chem. Res. Toxicol. 27 (2) ",
      "citeRegEx" : "49",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Graphene in the aquatic environment: adsorption, dispersion, toxicity and transformation, Environ",
      "author" : [ "J. Zhao", "Z.Wang", "J.C. White", "B. Xing" ],
      "venue" : "Sci. Technol",
      "citeRegEx" : "50",
      "shortCiteRegEx" : "50",
      "year" : 2014
    }, {
      "title" : "Graphene-based nanomaterials: biological and medical applications and toxicity",
      "author" : [ "F.M. Tonelli", "V.A. Goulart", "K.N. Gomes", "M.S. Ladeira", "A.K. Santos", "E. Lorençon", "L.O. Ladeira", "R.R. Resende" ],
      "venue" : "Nanomedicine 10 (15) ",
      "citeRegEx" : "51",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Prospects and challenges of graphene in biomedical applications",
      "author" : [ "D. Bitounis", "H. Ali-Boucetta", "B.H. Hong", "D.H. Min", "K. Kostarelos" ],
      "venue" : "Adv. Mater. 25 (16) ",
      "citeRegEx" : "52",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Graphene: safe or toxic? The two faces of the medal",
      "author" : [ "A. Bianco" ],
      "venue" : "Angew. Chem. Int. Ed. 52 (19) ",
      "citeRegEx" : "53",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Behavior and toxicity of graphene and its functionalized derivatives in biological systems",
      "author" : [ "K. Yang", "Y. Li", "X. Tan", "R. Peng", "Z. Liu" ],
      "venue" : "Small 9 (9–10) ",
      "citeRegEx" : "54",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Biological interactions of graphenefamily nanomaterials: an interdisciplinary review",
      "author" : [ "V.C. Sanchez", "A. Jachak", "R.H. Hurt", "A.B. Kane" ],
      "venue" : "Chem. Res. Toxicol. 25 (1) ",
      "citeRegEx" : "55",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Recent advances in graphene family materials toxicity investigations",
      "author" : [ "A.M. Jastrzębska", "P. Kurtycz", "A.R. Olszyna" ],
      "venue" : "J. Nanopart. Res. 14 (12) ",
      "citeRegEx" : "56",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Biomedical applications of the graphene-based materials",
      "author" : [ "B. Zhang", "Y. Wang", "G. Zhai" ],
      "venue" : "Mater. Sci. Eng. C ",
      "citeRegEx" : "57",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Synthetic routes contaminate graphene materials with a whole spectrum of unanticipated metallic elements",
      "author" : [ "C.H.A. Wong", "Z. Sofer", "M. Kubešová", "J. Kučera", "S. Matějková", "M. Pumera" ],
      "venue" : "Proc. Natl. Acad. Sci. 111 (38) ",
      "citeRegEx" : "58",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Chemically reduced graphene contains inherent metallic impurities present in parent natural and synthetic graphite",
      "author" : [ "A. Ambrosi", "C.K. Chua", "B. Khezri", "Z. Sofer", "R.D. Webster", "M. Pumera" ],
      "venue" : "Proc. Natl. Acad. Sci. 109 (32) ",
      "citeRegEx" : "59",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Structural disruption increases toxicity of graphene nanoribbons",
      "author" : [ "S. Mullick Chowdhury", "S. Dasgupta", "A.E. McElroy", "B. Sitharaman" ],
      "venue" : "J. Appl. Toxicol. 34 (11) ",
      "citeRegEx" : "60",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Cytotoxicity effects of graphene and single-wall carbon nanotubes in neural phaeochromocytoma-derived PC12 cells",
      "author" : [ "Y. Zhang", "S.F. Ali", "E. Dervishi", "Y. Xu", "Z. Li", "D. Casciano", "A.S. Biris" ],
      "venue" : "ACS Nano 4 (6) ",
      "citeRegEx" : "61",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Toxicity of graphene in normal human lung cells (BEAS-2B)",
      "author" : [ "N.V. Vallabani", "S. Mittal", "R.K. Shukla", "A.K. Pandey", "S.R. Dhakate", "R. Pasricha", "A. Dhawan" ],
      "venue" : "J. Biomed. Nanotechnol. 7 (1) ",
      "citeRegEx" : "62",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Cytotoxicity evaluation of oxidized single-walled carbon nanotubes and graphene oxide on human hepatoma HepG2 cells: an iTRAQ-coupled 2D LC–MS/MS proteome analysis",
      "author" : [ "J. Yuan", "H. Gao", "J. Sui", "H. Duan", "W.N. Chen", "C.B. Ching" ],
      "venue" : "Toxicol. Sci. 126 (1) ",
      "citeRegEx" : "63",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Effect of graphene oxide on undifferentiated and retinoic acid-differentiated SH-SY5Y cells line",
      "author" : [ "M. Lv", "Y. Zhang", "L. Liang", "M. Wei", "W. Hu", "X. Li", "Q. Huang" ],
      "venue" : "Nanoscale 4 (13) ",
      "citeRegEx" : "64",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Graphene oxide nanoribbons exhibit significantly greater toxicity than graphene oxide nanoplatelets",
      "author" : [ "E.L.K. Chng", "C.K. Chua", "M. Pumera" ],
      "venue" : "Nanoscale 6 (18) ",
      "citeRegEx" : "65",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Genotoxicity of graphene nanoribbons in human mesenchymal stem cells",
      "author" : [ "O. Akhavan", "E. Ghaderi", "H. Emamy", "F. Akhavan" ],
      "venue" : "Carbon 54 ",
      "citeRegEx" : "66",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "In vitro evaluation of the effects of graphene platelets on glioblastoma multiforme cells",
      "author" : [ "S. Jaworski", "E. Sawosz", "M. Grodzik", "A. Winnicka", "M. Prasek", "M. Wierzbicki", "A. Chwalibog" ],
      "venue" : "Int. J. Nanomedicine 8 ",
      "citeRegEx" : "67",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Differential nano-bio interactions and toxicity effects of pristine versus functionalized graphene",
      "author" : [ "A. Sasidharan", "L.S. Panchakarla", "P. Chandran", "D. Menon", "S. Nair", "C.N. Rao", "M. Koyakutty" ],
      "venue" : "Nanoscale 3 (6) ",
      "citeRegEx" : "68",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "The effects of graphene oxide nanosheets localized on F-actin filaments on cell-cycle alterations",
      "author" : [ "M.C. Matesanz", "M. Vila", "M.J. Feito", "J. Linares", "G. Goncalves", "M. Vallet-Regi", "P.A. Marques", "M.T. Portoles" ],
      "venue" : "Biomaterials 34 (5) ",
      "citeRegEx" : "69",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Cellular distribution and cytotoxicity of graphene quantum dots with different functional groups",
      "author" : [ "X. Yuan", "Z. Liu", "Z. Guo", "Y. Ji", "M. Jin", "X. Wang" ],
      "venue" : "Nanoscale Res. Lett. 9 (1) ",
      "citeRegEx" : "70",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Evaluation of the toxicity of graphene derivatives on cells of the lung luminal surface",
      "author" : [ "L. Horváth", "A. Magrez", "M. Burghard", "K. Kern", "L. Forró", "B. Schwaller" ],
      "venue" : "Carbon 64 ",
      "citeRegEx" : "71",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Oxygenated functional group density on graphene oxide: its effect on cell toxicity",
      "author" : [ "S. Das", "S. Singh", "V. Singh", "D. Joung", "J.M. Dowding", "D. Reid", "J. Anderson", "L. Zhai", "S.I. Khondaker", "W.T. Self" ],
      "venue" : "Part. Part. Syst. Charact. 30 (2) ",
      "citeRegEx" : "72",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "The in vitro and in vivo toxicity of graphene quantum dots",
      "author" : [ "Y. Chong", "Y. Ma", "H. Shen", "X. Tu", "X. Zhou", "J. Xu", "J. Dai", "S. Fan", "Z. Zhang" ],
      "venue" : "Biomaterials 35 (19) ",
      "citeRegEx" : "73",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Cytotoxicity of halogenated graphenes",
      "author" : [ "W.Z. Teo", "E.L.K. Chng", "Z. Sofer", "M. Pumera" ],
      "venue" : "Nanoscale 6 (2) ",
      "citeRegEx" : "74",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Cytotoxicity of fluorographene",
      "author" : [ "W.Z. Teo", "Z. Sofer", "F. Šembera", "Z. Janoušek", "M. Pumera" ],
      "venue" : "RSC Adv. 5 (129) ",
      "citeRegEx" : "75",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Cytotoxicity profile of highly hydrogenated graphene",
      "author" : [ "E.L.K. Chng", "Z. Sofer", "M. Pumera" ],
      "venue" : "Chem. Eur. J. 20 (21) ",
      "citeRegEx" : "76",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Graphene functionalized with arginine decreases the development of glioblastoma multiforme tumor in a gene-dependent manner",
      "author" : [ "E. Sawosz", "S. Jaworski", "M. Kutwin", "K.P. Vadalasetty", "M. Grodzik", "M. Wierzbicki", "N. Kurantowicz", "B. Strojny", "A. Hotowy", "L. Lipińska" ],
      "venue" : "Int. J. Mol. Sci. 16 (10) ",
      "citeRegEx" : "77",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Size-dependent genotoxicity of graphene nanoplatelets in human stem cells",
      "author" : [ "O. Akhavan", "E. Ghaderi", "A. Akhavan" ],
      "venue" : "Biomaterials 33 (32) ",
      "citeRegEx" : "78",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "In vitro toxicity evaluation of graphene oxide on A549 cells",
      "author" : [ "Y. Chang", "S.T. Yang", "J.H. Liu", "E. Dong", "Y. Wang", "A. Cao", "Y. Liu", "H. Wang" ],
      "venue" : "Toxicol. Lett. 200 (3) ",
      "citeRegEx" : "79",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "The role of the lateral dimension of graphene oxide in the regulation of cellular responses, Biomaterials",
      "author" : [ "H. Yue", "W.Wei", "Z. Yue", "B. Wang", "N. Luo", "Y. Gao", "D. Ma", "G. Ma", "Z. Su" ],
      "venue" : null,
      "citeRegEx" : "80",
      "shortCiteRegEx" : "80",
      "year" : 2012
    }, {
      "title" : "The immunotoxicity of graphene oxides and the effect of PVP-coating",
      "author" : [ "X. Zhi", "H. Fang", "C. Bao", "G. Shen", "J. Zhang", "K. Wang", "S. Guo", "T. Wan", "D. Cui" ],
      "venue" : "Biomaterials 34 (21) ",
      "citeRegEx" : "81",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "The triggering of apoptosis in macrophages by pristine graphene through the MAPK and TGF-beta signaling pathways",
      "author" : [ "Y. Li", "Y. Liu", "Y. Fu", "T. Wei", "L. Le Guyader", "G. Gao", "R.S. Liu", "Y.Z. Chang", "C. Chen" ],
      "venue" : "Biomaterials 33 (2) ",
      "citeRegEx" : "82",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Graphene oxide",
      "author" : [ "A.V. Tkach", "N. Yanamala", "S. Stanley", "M.R. Shurin", "G.V. Shurin", "E.R. Kisin", "A.R. Murray", "S. Pareso", "T. Khaliullin", "G.P. Kotchey", "V. Castranova", "S. Mathur", "B. Fadeel", "A. Star", "V.E. Kagan", "A.A. Shvedova" ],
      "venue" : "but not fullerenes, targets immunoproteasomes and suppresses antigen presentation by dendritic cells, Small 9 (9–10) ",
      "citeRegEx" : "84",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Cytotoxicity of graphene oxide and graphene in human erythrocytes and skin fibroblasts",
      "author" : [ "K.H. Liao", "Y.S. Lin", "C.W. Macosko", "C.L. Haynes" ],
      "venue" : "ACS Appl. Mater. Interfaces 3 (7) ",
      "citeRegEx" : "85",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Thrombus inducing property of atomically thin graphene oxide sheets, ACS Nano",
      "author" : [ "S.K. Singh", "M.K. Singh", "M.K. Nayak", "S. Kumari", "S. Shrivastava", "J.J. Gracio", "D. Dash" ],
      "venue" : null,
      "citeRegEx" : "86",
      "shortCiteRegEx" : "86",
      "year" : 2011
    }, {
      "title" : "Amine-modified graphene: thrombo-protective safer alternative to graphene oxide for biomedical applications",
      "author" : [ "S.K. Singh", "M.K. Singh", "P.P. Kulkarni", "V.K. Sonkar", "J.J. Gracio", "D. Dash" ],
      "venue" : "ACS Nano 6 (3) ",
      "citeRegEx" : "87",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "In vitro hematological and in vivo vasoactivity assessment of dextran functionalized graphene",
      "author" : [ "S.M. Chowdhury", "S. Kanakia", "J.D. Toussaint", "M.D. Frame", "A.M. Dewar", "K.R. Shroyer", "W. Moore", "B. Sitharaman" ],
      "venue" : "Sci. Rep. 3 ",
      "citeRegEx" : "88",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Interaction of graphene nanoribbons with components of the blood vascular system",
      "author" : [ "S.M. Chowdhury", "J. Fang", "B. Sitharaman" ],
      "venue" : "Future Sci. OA ",
      "citeRegEx" : "89",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Protein corona-mediated mitigation of cytotoxicity of graphene oxide",
      "author" : [ "W. Hu", "C. Peng", "M. Lv", "X. Li", "Y. Zhang", "N. Chen", "C. Fan", "Q. Huang" ],
      "venue" : "ACS Nano 5 (5) ",
      "citeRegEx" : "91",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Size-dependent cell uptake of protein-coated graphene oxide nanosheets",
      "author" : [ "Q. Mu", "G. Su", "L. Li", "B.O. Gilbertson", "L.H. Yu", "Q. Zhang", "Y.P. Sun", "B. Yan" ],
      "venue" : "ACS Appl. Mater. Interfaces 4 (4) ",
      "citeRegEx" : "92",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Cytotoxicity of protein corona-graphene oxide nanoribbons on human epithelial cells",
      "author" : [ "D.A. Mbeh", "O. Akhavan", "T. Javanbakht", "M. Mahmoudi", "L.H. Yahia" ],
      "venue" : "Appl. Surf. Sci. 320 ",
      "citeRegEx" : "93",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Amine-modified graphene: thrombo-protective safer alternative to graphene oxide for biomedical applications",
      "author" : [ "S.K. Singh", "M.K. Singh", "P.P. Kulkarni", "V.K. Sonkar", "J.J. Grácio", "D. Dash" ],
      "venue" : "ACS Nano 6 (3) ",
      "citeRegEx" : "94",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Comparative in vivo toxicity",
      "author" : [ "A. Sasidharan", "S. Swaroop", "C.K. Koduri", "C.M. Girish", "P. Chandran", "L. Panchakarla", "V.H. Somasundaram", "G.S. Gowd", "S. Nair", "M. Koyakutty" ],
      "venue" : "organ biodistribution and immune response of pristine, carboxylated and PEGylated fewlayer graphene sheets in Swiss albino mice: a three month study, Carbon 95 ",
      "citeRegEx" : "95",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "In vitro and in vivo behaviors of dextran functionalized graphene",
      "author" : [ "S. Zhang", "K. Yang", "L. Feng", "Z. Liu" ],
      "venue" : "Carbon 49 (12) ",
      "citeRegEx" : "96",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Distribution and biocompatibility studies of graphene oxide in mice after intravenous administration",
      "author" : [ "X. Zhang", "J. Yin", "C. Peng", "W. Hu", "Z. Zhu", "W. Li", "C. Fan", "Q. Huang" ],
      "venue" : "Carbon 49 (3) ",
      "citeRegEx" : "97",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Biocompatibility of graphene oxide",
      "author" : [ "K. Wang", "J. Ruan", "H. Song", "J. Zhang", "Y. Wo", "S. Guo", "D. Cui" ],
      "venue" : "Nanoscale Res. Lett. 6 (8) ",
      "citeRegEx" : "98",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Effect of size and dose on the biodistribution of graphene oxide in mice",
      "author" : [ "J.-H. Liu", "S.-T. Yang", "H. Wang", "Y. Chang", "A. Cao", "Y. Liu" ],
      "venue" : "Nanomedicine 7 (12) ",
      "citeRegEx" : "99",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Graphene in mice: ultrahigh in vivo tumor uptake and efficient photothermal therapy",
      "author" : [ "K. Yang", "S. Zhang", "G. Zhang", "X. Sun", "S.-T. Lee", "Z. Liu" ],
      "venue" : "Nano Lett. 10 (9) ",
      "citeRegEx" : "100",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "In vivo pharmacokinetics",
      "author" : [ "K. Yang", "J. Wan", "S. Zhang", "Y. Zhang", "S.-T. Lee", "Z. Liu" ],
      "venue" : "long-term biodistribution, and toxicology of PEGylated graphene in mice, ACS Nano 5 (1) ",
      "citeRegEx" : "101",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "Towards an advanced graphene-based magnetic resonance imaging contrast agent: sub-acute toxicity and efficacy studies in small animals",
      "author" : [ "S. Kanakia", "J. Toussaint", "D.M. Hoang", "S. Mullick Chowdhury", "S. Lee", "K.R. Shroyer", "W. Moore", "Y.Z. Wadghiri", "B. Sitharaman" ],
      "venue" : "Scie. Rep. 5 ",
      "citeRegEx" : "102",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Dose ranging",
      "author" : [ "S. Kanakia", "J.D. Toussaint", "S.M. Chowdhury", "T. Tembulkar", "S. Lee", "Y.-P. Jiang", "R.Z. Lin", "K.R. Shroyer", "W. Moore", "B. Sitharaman" ],
      "venue" : "expanded acute toxicity and safety pharmacology studies for intravenously administered functionalized graphene nanoparticle formulations, Biomaterials 35 (25) ",
      "citeRegEx" : "103",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Tissue distribution and urinary excretion of intravenously administered chemically functionalized graphene oxide sheets",
      "author" : [ "D.A. Jasim", "C. Ménard-Moyon", "D. Bégin", "A. Bianco", "K. Kostarelos" ],
      "venue" : "Chem. Sci. ",
      "citeRegEx" : "104",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "In vivo biodistribution and toxicology of functionalized nano-graphene oxide in mice after oral and intraperitoneal administration",
      "author" : [ "K. Yang", "H. Gong", "X. Shi", "J. Wan", "Y. Zhang", "Z. Liu" ],
      "venue" : "Biomaterials 34 (11) ",
      "citeRegEx" : "105",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "J",
      "author" : [ "H. Ali-Boucetta", "D. Bitounis", "R. Raveendran-Nair", "A. Servant" ],
      "venue" : "Van den Bossche, K. Kostarelos, Purified graphene oxide dispersions lack in vitro cytotoxicity and in vivo pathogenicity, Adv. Healthcare Mater. 2 (3) ",
      "citeRegEx" : "106",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "A stimuli-sensitive injectable graphene oxide composite hydrogel",
      "author" : [ "A. Sahu", "W.I. Choi", "G. Tae" ],
      "venue" : "Chem. Commun. 48 (47) (2012) 5820–5822.  144  G. Lalwani et al. / Advanced Drug Delivery Reviews 105 ",
      "citeRegEx" : "107",
      "shortCiteRegEx" : null,
      "year" : 2016
    }, {
      "title" : "Long term influence of carbon nanoparticles on health and liver status in rats",
      "author" : [ "B. Strojny", "N. Kurantowicz", "E. Sawosz", "M. Grodzik", "S. Jaworski", "M. Kutwin", "M. Wierzbicki", "A. Hotowy", "L. Lipińska", "A. Chwalibog" ],
      "venue" : "PLoS One 10 (12) ",
      "citeRegEx" : "108",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Effects of graphene oxide on the development of offspring mice in lactation period",
      "author" : [ "C. Fu", "T. Liu", "L. Li", "H. Liu", "Q. Liang", "X. Meng" ],
      "venue" : "Biomaterials 40 ",
      "citeRegEx" : "109",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "The short-and long-term effects of orally administered high-dose reduced graphene oxide nanosheets on mouse behaviors",
      "author" : [ "D. Zhang", "Z. Zhang", "Y. Liu", "M. Chu", "C. Yang", "W. Li", "Y. Shao", "Y. Yue", "R. Xu" ],
      "venue" : "Biomaterials 68 ",
      "citeRegEx" : "110",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Contributions of altered permeability of intestinal barrier and defecation behavior to toxicity formation from graphene oxide in nematode Caenorhabditis elegans",
      "author" : [ "Q. Wu", "L. Yin", "X. Li", "M. Tang", "T. Zhang", "D. Wang" ],
      "venue" : "Nanoscale 5 (20) ",
      "citeRegEx" : "111",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Graphene-based nanoplatelets: a new risk to the respiratory system as a consequence of their unusual aerodynamic properties",
      "author" : [ "A. Schinwald", "F.A. Murphy", "A. Jones", "W. MacNee", "K. Donaldson" ],
      "venue" : "ACS Nano 6 (1) ",
      "citeRegEx" : "112",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Minimizing oxidation and stable nanoscale dispersion improves the biocompatibility of graphene in the lung",
      "author" : [ "M.C. Duch", "G.S. Budinger", "Y.T. Liang", "S. Soberanes", "D. Urich", "S.E. Chiarella", "L.A. Campochiaro", "A. Gonzalez", "N.S. Chandel", "M.C. Hersam" ],
      "venue" : "Nano Lett. 11 (12) ",
      "citeRegEx" : "113",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Biodistribution and pulmonary toxicity of intratracheally instilled graphene oxide in mice",
      "author" : [ "B. Li", "J. Yang", "Q. Huang", "Y. Zhang", "C. Peng", "Y. Zhang", "Y. He", "J. Shi", "W. Li", "J. Hu" ],
      "venue" : "NPG Asia Mater. 5 (4) ",
      "citeRegEx" : "114",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Can graphene oxide cause damage to eyesight? Chem",
      "author" : [ "L. Yan", "Y. Wang", "X. Xu", "C. Zeng", "J. Hou", "M. Lin", "J. Xu", "F. Sun", "X. Huang", "L. Dai" ],
      "venue" : "Res. Toxicol. 25 (6) ",
      "citeRegEx" : "115",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Synthesis and antifungal activity of reduced graphene oxide nanosheets",
      "author" : [ "M. Sawangphruk", "P. Srimuk", "P. Chiochan", "T. Sangsri", "P. Siwayaprahm" ],
      "venue" : "Carbon 50 (14) ",
      "citeRegEx" : "116",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Toxicity of graphene and graphene oxide nanowalls against bacteria",
      "author" : [ "O. Akhavan", "E. Ghaderi" ],
      "venue" : "ACS Nano 4 (10) ",
      "citeRegEx" : "117",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "The use of polyethyleneimine-modified reduced graphene oxide as a substrate for silver nanoparticles to produce a material with lower cytotoxicity and long-term antibacterial activity",
      "author" : [ "X. Cai", "M. Lin", "S. Tan", "W. Mai", "Y. Zhang", "Z. Liang", "Z. Lin", "X. Zhang" ],
      "venue" : "Carbon 50 (10) ",
      "citeRegEx" : "118",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "A new function of graphene oxide emerges: inactivating phytopathogenic bacterium Xanthomonas oryzae pv",
      "author" : [ "J. Chen", "X. Wang", "H. Han" ],
      "venue" : "oryzae, J. Nanopart. Res. 15 (5) ",
      "citeRegEx" : "119",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Graphene nanocomposite for biomedical applications: fabrication",
      "author" : [ "C.M. Santos", "J. Mangadlao", "F. Ahmed", "A. Leon", "R.C. Advincula", "D.F. Rodrigues" ],
      "venue" : "antimicrobial and cytotoxic investigations, Nanotechnology 23 (39) ",
      "citeRegEx" : "120",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Toxicity of a polymer–graphene oxide composite against bacterial planktonic cells",
      "author" : [ "I.E.M. Carpio", "C.M. Santos", "X. Wei", "D.F. Rodrigues" ],
      "venue" : "biofilms, and mammalian cells, Nanoscale 4 (15) ",
      "citeRegEx" : "121",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Graphene-based antibacterial paper",
      "author" : [ "W. Hu", "C. Peng", "W. Luo", "M. Lv", "X. Li", "D. Li", "Q. Huang", "C. Fan" ],
      "venue" : "ACS Nano 4 (7) ",
      "citeRegEx" : "122",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "On the antibacterial mechanism of graphene oxide (GO) Langmuir–Blodgett films",
      "author" : [ "A. Áde Leon" ],
      "venue" : "Chem. Commun. 51 (14) ",
      "citeRegEx" : "123",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Availability of the basal planes of graphene oxide determines whether it is antibacterial",
      "author" : [ "L. Hui", "J.G. Piao", "J. Auletta", "K. Hu", "Y. Zhu", "T. Meyer", "H. Liu", "L. Yang" ],
      "venue" : "ACS Appl. Mater. Interfaces 6 (15) ",
      "citeRegEx" : "124",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Antibacterial activity of large-area monolayer graphene film manipulated by charge transfer",
      "author" : [ "J. Li", "G. Wang", "H. Zhu", "M. Zhang", "X. Zheng", "Z. Di", "X. Liu", "X. Wang" ],
      "venue" : "Sci. Report. 4 ",
      "citeRegEx" : "125",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Interaction of graphene family materials with Listeria monocytogenes and Salmonella enterica",
      "author" : [ "N. Kurantowicz", "E. Sawosz", "S. Jaworski", "M. Kutwin", "B. Strojny", "M. Wierzbicki", "J. Szeliga", "A. Hotowy", "L. Lipińska", "R. Koziński" ],
      "venue" : "Nanoscale Res. Lett. 10 (1) ",
      "citeRegEx" : "126",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Antibacterial activity of graphite",
      "author" : [ "S. Liu", "T.H. Zeng", "M. Hofmann", "E. Burcombe", "J. Wei", "R. Jiang", "J. Kong", "Y. Chen" ],
      "venue" : "graphite oxide, graphene oxide, and reduced graphene oxide: membrane and oxidative stress, ACS Nano 5 (9) ",
      "citeRegEx" : "127",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Lateral dimension-dependent antibacterial activity of graphene oxide sheets",
      "author" : [ "S. Liu", "M. Hu", "T.H. Zeng", "R. Wu", "R. Jiang", "J. Wei", "L. Wang", "J. Kong", "Y. Chen" ],
      "venue" : "Langmuir 28 (33) ",
      "citeRegEx" : "128",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Graphene phytotoxicity in the seedling stage of cabbage",
      "author" : [ "P. Begum", "R. Ikhtiari", "B. Fugetsu" ],
      "venue" : "tomato, red spinach, and lettuce, Carbon 49 (12) ",
      "citeRegEx" : "129",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "K",
      "author" : [ "M.V. Khodakovskaya" ],
      "venue" : "de Silva, D.A. Nedosekin, E. Dervishi, A.S. Biris, E.V. Shashkov, E.I. Galanzha, V.P. Zharov, Complex genetic, photothermal, and photoacoustic analysis of nanoparticle–plant interactions, Proc. Natl. Acad. Sci. 108 (3) ",
      "citeRegEx" : "130",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Investigation of acute effects of graphene oxide on wastewater microbial community: a case study",
      "author" : [ "F. Ahmed", "D.F. Rodrigues" ],
      "venue" : "J. Hazard. Mater. 256 ",
      "citeRegEx" : "131",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Degradation of graphene by hydrogen peroxide",
      "author" : [ "W. Xing", "G. Lalwani", "I. Rusakova", "B. Sitharaman" ],
      "venue" : "Part. Part. Syst. Charact. 31 (7) ",
      "citeRegEx" : "132",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Enzymatic degradation of oxidized and reduced graphene nanoribbons by lignin peroxidase",
      "author" : [ "G. Lalwani", "W. Xing", "B. Sitharaman" ],
      "venue" : "J. Mater. Chem. B 2 (37) ",
      "citeRegEx" : "133",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Assessing in vivo toxicity of graphene materials: current methods and future outlook",
      "author" : [ "Y. Ma", "H. Shen", "X. Tu", "Z. Zhang" ],
      "venue" : "Nanomedicine 9 (10) ",
      "citeRegEx" : "134",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "Unraveling stress-induced toxicity properties of graphene oxide and the underlying mechanism",
      "author" : [ "W. Zhang", "C. Wang", "Z. Li", "Z. Lu", "Y. Li", "J.J. Yin", "Y.T. Zhou", "X. Gao", "Y. Fang", "G. Nie" ],
      "venue" : "Adv. Mater. 24 (39) ",
      "citeRegEx" : "135",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "Toxicity mechanism of graphene oxide and nitrogen-doped graphene quantum dots in RBCs revealed by surface-enhanced infrared absorption spectroscopy",
      "author" : [ "T. Wang", "S. Zhu", "X. Jiang" ],
      "venue" : "Toxicol. Res. ",
      "citeRegEx" : "136",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Green and facile synthesis of highly biocompatible graphene nanosheets and its application for cellular imaging and drug delivery",
      "author" : [ "K. Liu", "J.-J. Zhang", "F.-F. Cheng", "T.-T. Zheng", "C. Wang", "J.-J. Zhu" ],
      "venue" : "J. Mater. Chem. 21 (32) ",
      "citeRegEx" : "137",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "Mechanism of cellular uptake of graphene oxide studied by surface-enhanced raman spectroscopy",
      "author" : [ "J. Huang", "C. Zong", "H. Shen", "M. Liu", "B. Chen", "B. Ren", "Z. Zhang" ],
      "venue" : "Small 8 (16) ",
      "citeRegEx" : "138",
      "shortCiteRegEx" : null,
      "year" : 2012
    }, {
      "title" : "DNA cleavage system of nanosized graphene oxide sheets and copper ions",
      "author" : [ "H. Ren", "C. Wang", "J. Zhang", "X. Zhou", "D. Xu", "J. Zheng", "S. Guo", "J. Zhang" ],
      "venue" : "ACS Nano 4 (12) ",
      "citeRegEx" : "139",
      "shortCiteRegEx" : null,
      "year" : 2010
    }, {
      "title" : "PEGylated reduced graphene oxide as a superior ssRNA delivery system",
      "author" : [ "L. Zhang", "Z. Wang", "Z. Lu", "H. Shen", "J. Huang", "Q. Zhao", "M. Liu", "N. He", "Z. Zhang" ],
      "venue" : "J. Mater. Chem. B 1 (6) ",
      "citeRegEx" : "140",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Adsorption and desorption of DNA on graphene oxide studied by fluorescently labeled oligonucleotides",
      "author" : [ "M. Wu", "R. Kempaiah", "P.-J.J. Huang", "V. Maheshwari", "J. Liu" ],
      "venue" : "Langmuir 27 (6) ",
      "citeRegEx" : "141",
      "shortCiteRegEx" : null,
      "year" : 2011
    }, {
      "title" : "A",
      "author" : [ "Y. Li", "H. Yuan" ],
      "venue" : "von dem Bussche, M. Creighton, R.H. Hurt, A.B. Kane, H. Gao, Graphene microsheets enter cells through spontaneous membrane penetration at edge asperities and corner sites, Proc. Natl. Acad. Sci. 110 (30) ",
      "citeRegEx" : "142",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Sandwiched graphene–membrane superstructures",
      "author" : [ "A.V. Titov", "P. Král", "R. Pearson" ],
      "venue" : "ACS Nano 4 (1) ",
      "citeRegEx" : "143",
      "shortCiteRegEx" : null,
      "year" : 2009
    }, {
      "title" : "Destructive extraction of phospholipids from Escherichia coli membranes by graphene nanosheets",
      "author" : [ "Y. Tu", "M. Lv", "P. Xiu", "T. Huynh", "M. Zhang", "M. Castelli", "Z. Liu", "Q. Huang", "C. Fan", "H. Fang" ],
      "venue" : "Nat. Nanotechnol. 8 (8) ",
      "citeRegEx" : "144",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Z",
      "author" : [ "M. Nurunnabi" ],
      "venue" : "Khatun, K.M. Huh, S.Y. Park, D.Y. Lee, K.J. Cho, Y.-k. Lee, In vivo biodistribution and toxicology of carboxylated graphene quantum dots, ACS Nano 7 (8) ",
      "citeRegEx" : "145",
      "shortCiteRegEx" : null,
      "year" : 2013
    }, {
      "title" : "Two- and three-dimensional all-carbon nanomaterial assemblies for tissue engineering and regenerative medicine",
      "author" : [ "G. Lalwani" ],
      "venue" : "Ann. Biomed. Eng. ",
      "citeRegEx" : "146",
      "shortCiteRegEx" : null,
      "year" : 1623
    }, {
      "title" : "Boron nitride nanotubes and nanoplatelets as reinforcing agents of polymeric matrices for bone tissue engineering",
      "author" : [ "B. Farshid", "G. Lalwani", "M. Shir Mohammadi", "J. Simonsen", "B. Sitharaman" ],
      "venue" : "J. Biomed. Mater. Res. B Appl. Biomater. ",
      "citeRegEx" : "148",
      "shortCiteRegEx" : null,
      "year" : 1002
    }, {
      "title" : "Interactions of 1D-and 2D-layered inorganic nanoparticles with fibroblasts and human mesenchymal stem cells",
      "author" : [ "J.T. Rashkow", "Y. Talukdar", "G. Lalwani", "B. Sitharaman" ],
      "venue" : "Nanomedicine 10 (11) ",
      "citeRegEx" : "149",
      "shortCiteRegEx" : null,
      "year" : 2015
    }, {
      "title" : "Cytotoxicity of exfoliated transition-metal dichalcogenides (MoS2",
      "author" : [ "W.Z. Teo", "E.L.K. Chng", "Z. Sofer", "M. Pumera" ],
      "venue" : "WS2, and WSe2) is lower than that of graphene and its analogues, Chem. Eur. J. 20 (31) ",
      "citeRegEx" : "150",
      "shortCiteRegEx" : null,
      "year" : 2014
    }, {
      "title" : "MoS2 exhibits stronger toxicity with increased exfoliation",
      "author" : [ "E.L.K. Chng", "Z. Sofer", "M. Pumera" ],
      "venue" : "Nanoscale 6 (23) ",
      "citeRegEx" : "151",
      "shortCiteRegEx" : null,
      "year" : 2014
    } ],
    "referenceMentions" : [ {
      "referenceID" : 4,
      "context" : "The theoretical existence of graphene was discussed over 55 years ago by Slonczewski and Weiss [7].",
      "startOffset" : 95,
      "endOffset" : 98
    }, {
      "referenceID" : 9,
      "context" : "However, in 2004, Novoselov and Geim isolated single sheets of graphene by micromechanical cleavage of graphite or the “scotch-tapemethod” [12] and characterized their quantum electrodynamics [13,14].",
      "startOffset" : 139,
      "endOffset" : 143
    }, {
      "referenceID" : 10,
      "context" : "However, in 2004, Novoselov and Geim isolated single sheets of graphene by micromechanical cleavage of graphite or the “scotch-tapemethod” [12] and characterized their quantum electrodynamics [13,14].",
      "startOffset" : 192,
      "endOffset" : 199
    }, {
      "referenceID" : 11,
      "context" : "However, in 2004, Novoselov and Geim isolated single sheets of graphene by micromechanical cleavage of graphite or the “scotch-tapemethod” [12] and characterized their quantum electrodynamics [13,14].",
      "startOffset" : 192,
      "endOffset" : 199
    }, {
      "referenceID" : 12,
      "context" : "3 billion 10 year investment in graphene research and development to translate graphene-based technologies fromacademic labs to themarketplace [15].",
      "startOffset" : 143,
      "endOffset" : 147
    }, {
      "referenceID" : 3,
      "context" : "Schematic adapted from Reference [6] with permis $44 million 5 year investment for graphene research [16].",
      "startOffset" : 33,
      "endOffset" : 36
    }, {
      "referenceID" : 13,
      "context" : "Schematic adapted from Reference [6] with permis $44 million 5 year investment for graphene research [16].",
      "startOffset" : 101,
      "endOffset" : 105
    }, {
      "referenceID" : 14,
      "context" : "In 2011, United Kingdom committed £50 million investment for graphene research [17].",
      "startOffset" : 79,
      "endOffset" : 83
    }, {
      "referenceID" : 15,
      "context" : "Recently, in October 2015, Chinese company Huawei Technologies has announced a $1 billion 5 year investment towards the development of information and communication technologies focused on graphene [18].",
      "startOffset" : 198,
      "endOffset" : 202
    }, {
      "referenceID" : 16,
      "context" : "The sp(2) hybridization of 2D graphene plane results in delocalized out of plane π bonds that provide an exceptionally high carrier mobility (~200,000 cm(2) V s for suspended graphene [19,20] and ~500,000 cm(2) V s for graphene-based field effect transistors) [21,22].",
      "startOffset" : 184,
      "endOffset" : 191
    }, {
      "referenceID" : 17,
      "context" : "The sp(2) hybridization of 2D graphene plane results in delocalized out of plane π bonds that provide an exceptionally high carrier mobility (~200,000 cm(2) V s for suspended graphene [19,20] and ~500,000 cm(2) V s for graphene-based field effect transistors) [21,22].",
      "startOffset" : 184,
      "endOffset" : 191
    }, {
      "referenceID" : 18,
      "context" : "The sp(2) hybridization of 2D graphene plane results in delocalized out of plane π bonds that provide an exceptionally high carrier mobility (~200,000 cm(2) V s for suspended graphene [19,20] and ~500,000 cm(2) V s for graphene-based field effect transistors) [21,22].",
      "startOffset" : 260,
      "endOffset" : 267
    }, {
      "referenceID" : 19,
      "context" : "The sp(2) hybridization of 2D graphene plane results in delocalized out of plane π bonds that provide an exceptionally high carrier mobility (~200,000 cm(2) V s for suspended graphene [19,20] and ~500,000 cm(2) V s for graphene-based field effect transistors) [21,22].",
      "startOffset" : 260,
      "endOffset" : 267
    }, {
      "referenceID" : 10,
      "context" : "Graphene exhibits room temperature quantum hall effect for electrons and holes [13,23].",
      "startOffset" : 79,
      "endOffset" : 86
    }, {
      "referenceID" : 20,
      "context" : "Graphene exhibits room temperature quantum hall effect for electrons and holes [13,23].",
      "startOffset" : 79,
      "endOffset" : 86
    }, {
      "referenceID" : 18,
      "context" : "Graphene sheets also exhibit high surface area (2630 m(2) g) [21], thermal conductivity (~5000 Wm K) [24], mechanical property (Young's modulus of ~1 TPa) [25] and optical transparency (single layer graphene absorbs ~2.",
      "startOffset" : 61,
      "endOffset" : 65
    }, {
      "referenceID" : 21,
      "context" : "Graphene sheets also exhibit high surface area (2630 m(2) g) [21], thermal conductivity (~5000 Wm K) [24], mechanical property (Young's modulus of ~1 TPa) [25] and optical transparency (single layer graphene absorbs ~2.",
      "startOffset" : 101,
      "endOffset" : 105
    }, {
      "referenceID" : 22,
      "context" : "Graphene sheets also exhibit high surface area (2630 m(2) g) [21], thermal conductivity (~5000 Wm K) [24], mechanical property (Young's modulus of ~1 TPa) [25] and optical transparency (single layer graphene absorbs ~2.",
      "startOffset" : 155,
      "endOffset" : 159
    }, {
      "referenceID" : 24,
      "context" : "Graphene can be synthesized using various physical (such as mechanical cleavage (“scotch tape method”) [27] or arc discharge [28]) and chemical methods (chemical vapor deposition [29], Hummer's method (chemical oxidation of graphite followed by mechanical exfoliation) [30] or longitudinal unzipping of carbon nanotubes [31]).",
      "startOffset" : 103,
      "endOffset" : 107
    }, {
      "referenceID" : 25,
      "context" : "Graphene can be synthesized using various physical (such as mechanical cleavage (“scotch tape method”) [27] or arc discharge [28]) and chemical methods (chemical vapor deposition [29], Hummer's method (chemical oxidation of graphite followed by mechanical exfoliation) [30] or longitudinal unzipping of carbon nanotubes [31]).",
      "startOffset" : 125,
      "endOffset" : 129
    }, {
      "referenceID" : 26,
      "context" : "Graphene can be synthesized using various physical (such as mechanical cleavage (“scotch tape method”) [27] or arc discharge [28]) and chemical methods (chemical vapor deposition [29], Hummer's method (chemical oxidation of graphite followed by mechanical exfoliation) [30] or longitudinal unzipping of carbon nanotubes [31]).",
      "startOffset" : 179,
      "endOffset" : 183
    }, {
      "referenceID" : 27,
      "context" : "Graphene can be synthesized using various physical (such as mechanical cleavage (“scotch tape method”) [27] or arc discharge [28]) and chemical methods (chemical vapor deposition [29], Hummer's method (chemical oxidation of graphite followed by mechanical exfoliation) [30] or longitudinal unzipping of carbon nanotubes [31]).",
      "startOffset" : 269,
      "endOffset" : 273
    }, {
      "referenceID" : 28,
      "context" : "Graphene can be synthesized using various physical (such as mechanical cleavage (“scotch tape method”) [27] or arc discharge [28]) and chemical methods (chemical vapor deposition [29], Hummer's method (chemical oxidation of graphite followed by mechanical exfoliation) [30] or longitudinal unzipping of carbon nanotubes [31]).",
      "startOffset" : 320,
      "endOffset" : 324
    }, {
      "referenceID" : 29,
      "context" : "The pristine sp(2) characteristic of graphene can to a large extend (but not completely) be restored by treating oxidized graphene nanoparticles with reducing agents such as hydrazine and hydrogen iodide [32].",
      "startOffset" : 204,
      "endOffset" : 208
    }, {
      "referenceID" : 36,
      "context" : "Oxidized graphene nanoparticlebased formulations has been extensively explored for several biomedical applications such as bioimaging [33–35], drug and gene delivery [36–38], photothermal therapy [39,40], tissue engineering [41–43], and stem cell technology [44,45].",
      "startOffset" : 196,
      "endOffset" : 203
    }, {
      "referenceID" : 37,
      "context" : "Oxidized graphene nanoparticlebased formulations has been extensively explored for several biomedical applications such as bioimaging [33–35], drug and gene delivery [36–38], photothermal therapy [39,40], tissue engineering [41–43], and stem cell technology [44,45].",
      "startOffset" : 196,
      "endOffset" : 203
    }, {
      "referenceID" : 41,
      "context" : "Oxidized graphene nanoparticlebased formulations has been extensively explored for several biomedical applications such as bioimaging [33–35], drug and gene delivery [36–38], photothermal therapy [39,40], tissue engineering [41–43], and stem cell technology [44,45].",
      "startOffset" : 258,
      "endOffset" : 265
    }, {
      "referenceID" : 42,
      "context" : "Oxidized graphene nanoparticlebased formulations has been extensively explored for several biomedical applications such as bioimaging [33–35], drug and gene delivery [36–38], photothermal therapy [39,40], tissue engineering [41–43], and stem cell technology [44,45].",
      "startOffset" : 258,
      "endOffset" : 265
    }, {
      "referenceID" : 24,
      "context" : "Pristine or nearly pristine (oxidized graphene treatedwith reducing agents) graphene have also been investigated for several biomedical applications [27,35,46,47].",
      "startOffset" : 149,
      "endOffset" : 162
    }, {
      "referenceID" : 32,
      "context" : "Pristine or nearly pristine (oxidized graphene treatedwith reducing agents) graphene have also been investigated for several biomedical applications [27,35,46,47].",
      "startOffset" : 149,
      "endOffset" : 162
    }, {
      "referenceID" : 43,
      "context" : "Pristine or nearly pristine (oxidized graphene treatedwith reducing agents) graphene have also been investigated for several biomedical applications [27,35,46,47].",
      "startOffset" : 149,
      "endOffset" : 162
    }, {
      "referenceID" : 44,
      "context" : "Pristine or nearly pristine (oxidized graphene treatedwith reducing agents) graphene have also been investigated for several biomedical applications [27,35,46,47].",
      "startOffset" : 149,
      "endOffset" : 162
    }, {
      "referenceID" : 58,
      "context" : "investigated the interactions of graphene (diameter 100– 110 nm, thickness 3–5 nm) with rat pheochromocytoma PC12 cells using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and lactate dehydrogenase (LDH) assays and compared the results with single-walled carbon nanotubes (SWCNTs) [61].",
      "startOffset" : 302,
      "endOffset" : 306
    }, {
      "referenceID" : 59,
      "context" : "A significant dose- and time-dependent decrease in cell viability and an increase in the number of early and late apoptotic cells was observed using MTT assay [62].",
      "startOffset" : 159,
      "endOffset" : 163
    }, {
      "referenceID" : 60,
      "context" : "evaluated the cytotoxicity of graphene oxide on human hepatoma HepG2 cells using MTT assay, DFDA fluorescence analysis and 2D LC–MS proteome analysis [63].",
      "startOffset" : 150,
      "endOffset" : 154
    }, {
      "referenceID" : 38,
      "context" : "Image (A) adapted from Reference [41], (B–D) adapted from Reference [44], (E) adapted from Reference [95] and (F) adapted from Reference [145], with permissions.",
      "startOffset" : 33,
      "endOffset" : 37
    }, {
      "referenceID" : 41,
      "context" : "Image (A) adapted from Reference [41], (B–D) adapted from Reference [44], (E) adapted from Reference [95] and (F) adapted from Reference [145], with permissions.",
      "startOffset" : 68,
      "endOffset" : 72
    }, {
      "referenceID" : 90,
      "context" : "Image (A) adapted from Reference [41], (B–D) adapted from Reference [44], (E) adapted from Reference [95] and (F) adapted from Reference [145], with permissions.",
      "startOffset" : 101,
      "endOffset" : 105
    }, {
      "referenceID" : 140,
      "context" : "Image (A) adapted from Reference [41], (B–D) adapted from Reference [44], (E) adapted from Reference [95] and (F) adapted from Reference [145], with permissions.",
      "startOffset" : 137,
      "endOffset" : 142
    }, {
      "referenceID" : 61,
      "context" : "showed that GO does not elicit cytotoxic or apoptotic effects in human neuroblastoma SH-SY5Y cells at low concentrations (b80 μg/ml) [64].",
      "startOffset" : 133,
      "endOffset" : 137
    }, {
      "referenceID" : 41,
      "context" : "investigated the effects of graphene nanostructures of various morphologies (such as oxidized-nanoribbons (GONRs), oxidized-nanoplatelets (GONPs), andnanoonions (GNOs)) on the toxicity and stem cell differentiation potential of humanmesenchymal stem cells (hMSCs) [44].",
      "startOffset" : 264,
      "endOffset" : 268
    }, {
      "referenceID" : 62,
      "context" : "have reported a comparative study on the cytotoxicity of GONRs and GONPs [65].",
      "startOffset" : 73,
      "endOffset" : 77
    }, {
      "referenceID" : 63,
      "context" : "reported the cyto- and geno-toxicity of reducedGONRs and reduced graphene oxide sheets (rGOS) using human MSCs derived from umbilical cord blood [66].",
      "startOffset" : 145,
      "endOffset" : 149
    }, {
      "referenceID" : 58,
      "context" : "Adapted from Reference [61] with permission, copyright © American Chemical Society, 2010.",
      "startOffset" : 23,
      "endOffset" : 27
    }, {
      "referenceID" : 64,
      "context" : "reported the interactions of graphene platelets with human glioblastoma U87 and U118 cells [67].",
      "startOffset" : 91,
      "endOffset" : 95
    }, {
      "referenceID" : 41,
      "context" : "Adapted from Reference [44] with permission, copyright © Elsevier, 2014.",
      "startOffset" : 23,
      "endOffset" : 27
    }, {
      "referenceID" : 65,
      "context" : "investigated the cytotoxicity of pristine graphene and carboxylated GO (GO-COOH) using monkey renal cells at concentrations between 10 and 300 μg/ml to assess the differences between cellular interactions of hydrophobic and hydrophilic graphene derivatives [68].",
      "startOffset" : 257,
      "endOffset" : 261
    }, {
      "referenceID" : 67,
      "context" : "investigated the cytotoxicity and distribution of three kinds of GQD (NH2, COOH and CO-N(CH3)2 functionalized) in human neural glioma C6 and A549 lung carcinoma cells using MTT and Trypan blue assay [70].",
      "startOffset" : 199,
      "endOffset" : 203
    }, {
      "referenceID" : 68,
      "context" : "7 mouse peritoneal macrophages usingMTT assay, fluorometric DNAassay andfluorometricmicroculture cytotoxicity assay (FMCA) [71].",
      "startOffset" : 123,
      "endOffset" : 127
    }, {
      "referenceID" : 69,
      "context" : "reported higher cytotoxicity of GO sheets compared to reduced graphene oxide sheets of similar dimensions, an effect attributed to the presence of high density of oxidative functional groups on the surface of GO which lead to the generation of reactive oxygen species [72].",
      "startOffset" : 268,
      "endOffset" : 272
    }, {
      "referenceID" : 71,
      "context" : "investigated the cytotoxicity of halogenated graphene sheets [74].",
      "startOffset" : 61,
      "endOffset" : 65
    }, {
      "referenceID" : 70,
      "context" : "Adapted from Reference [73] with permission, copyright © Elsevier, 2014.",
      "startOffset" : 23,
      "endOffset" : 27
    }, {
      "referenceID" : 72,
      "context" : "reported the cytotoxicity of fluorinated graphene (FG) [75].",
      "startOffset" : 55,
      "endOffset" : 59
    }, {
      "referenceID" : 73,
      "context" : "synthesized highly hydrogenated graphene (HHG) and evaluated their in vitro cytotoxicity profile against A548 cells [76].",
      "startOffset" : 116,
      "endOffset" : 120
    }, {
      "referenceID" : 74,
      "context" : "have investigated the cytotoxicity of arginine (Arg) and proline (Pro) functionalized rGO using U87 glioblastoma multiforme (GBM) cells and tumors in vitro [77].",
      "startOffset" : 156,
      "endOffset" : 160
    }, {
      "referenceID" : 33,
      "context" : "reported the cytotoxicity screening of graphene oxide nanoribbons (GONRs) dispersed in DSPEPEG (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N[amino(polyethylene glycol)]) using six different assays and four representative cell lines: NIH-3T3 mouse fibroblast cells (NIH-3T3), Henrietta Lacks cells (HeLa) derived from cervical cancer tissue, Michigan cancer foundation-7 breast cancer cells (MCF7), and Sloan Kettering breast cancer cells (SKBR3) [36].",
      "startOffset" : 451,
      "endOffset" : 455
    }, {
      "referenceID" : 75,
      "context" : "4 μm) using human mesenchymal stem cells (hMSCs) [78].",
      "startOffset" : 49,
      "endOffset" : 53
    }, {
      "referenceID" : 76,
      "context" : "investigated the cytotoxicity of GO of various sizes (160 ± 90 nm, 430 ± 300 nm and 780 ± 410 nm) using A549 (human lung adenocarcinoma) cells [79].",
      "startOffset" : 143,
      "endOffset" : 147
    }, {
      "referenceID" : 57,
      "context" : "reported the size dependent cytotoxicity of graphene oxide nanoribbons (GONRs) after post processing sonication steps that result in a size reduction of nanoparticles [60].",
      "startOffset" : 167,
      "endOffset" : 171
    }, {
      "referenceID" : 77,
      "context" : "reported that cellular internalization and regulation of cellular responses are directly dependent on the lateral dimension of GO [80].",
      "startOffset" : 130,
      "endOffset" : 134
    }, {
      "referenceID" : 78,
      "context" : "reported the immunotoxicity of GO with and without functionalization by poly(vinyl pyrrolidone) (PVP) against human immune cells such as T lymphocytes, dendritic cells and macrophages [81].",
      "startOffset" : 184,
      "endOffset" : 188
    }, {
      "referenceID" : 79,
      "context" : "7 macrophage cells at concentrations between 5 and 100 μg/ml (dispersed in 1% pluronic F108 surfactant) [82].",
      "startOffset" : 104,
      "endOffset" : 108
    }, {
      "referenceID" : 80,
      "context" : "25 μg/ml results in an impaired stimulatory potential of DCs (activation of T-cells); treatment with similar concentrations of fullerenes (C60 and C60-tris) promotes the ability of DCs to activate T-cells [84].",
      "startOffset" : 205,
      "endOffset" : 209
    }, {
      "referenceID" : 33,
      "context" : "Adapted from Reference [36] with permission, copyright © Elsevier, 2013.",
      "startOffset" : 23,
      "endOffset" : 27
    }, {
      "referenceID" : 81,
      "context" : "investigated the cytotoxicity of graphene and GO using human erythrocytes (RBCs) [85].",
      "startOffset" : 81,
      "endOffset" : 85
    }, {
      "referenceID" : 82,
      "context" : "have reported the in vitro hemolytic toxicity of GO and rGO using human platelets [86].",
      "startOffset" : 82,
      "endOffset" : 86
    }, {
      "referenceID" : 75,
      "context" : "Adapted from Reference [78] with permission, copyright © Elsevier, 2012.",
      "startOffset" : 23,
      "endOffset" : 27
    }, {
      "referenceID" : 83,
      "context" : "showed that amine functionalized GO does not induce lysis of erythrocytes and has no stimulatory effects on platelets highlighting their nonthrombotoxic properties [87].",
      "startOffset" : 164,
      "endOffset" : 168
    }, {
      "referenceID" : 84,
      "context" : "showed that graphene oxide nanoplatelets (GONPs) functionalized with biocompatible polymer dextran (GNPDex) exhibit no hematological toxicity [88].",
      "startOffset" : 142,
      "endOffset" : 146
    }, {
      "referenceID" : 85,
      "context" : "(GONRs) with blood vascular system components [89].",
      "startOffset" : 46,
      "endOffset" : 50
    }, {
      "referenceID" : 86,
      "context" : "investigated the cytotoxic effects of fetal bovine serum (FBS) coated GO using A549 cells [91].",
      "startOffset" : 90,
      "endOffset" : 94
    }, {
      "referenceID" : 87,
      "context" : "investigated the cellular uptake of bovine serum albumin (BSA) coatedGO (flake size ~500nmor ~1 μm)bymousemesenchymal progenitor C2C12 cells [92].",
      "startOffset" : 141,
      "endOffset" : 145
    }, {
      "referenceID" : 88,
      "context" : "have reported the cytotoxicity of albumin functionalized GONRs against A549 cells evaluated using Trypan blue and apoptosis (hoechst and propidium iodide staining) [93].",
      "startOffset" : 164,
      "endOffset" : 168
    }, {
      "referenceID" : 82,
      "context" : "GO and rGO sheets were administered intravenously via tail vein injection to Swiss male mice (8–12 weeks old) at 250 μg/kg dose for 15min [86].",
      "startOffset" : 138,
      "endOffset" : 142
    }, {
      "referenceID" : 89,
      "context" : "investigated the in vivo thrombogenic properties of amine-modified GO (NH2-GO) [94].",
      "startOffset" : 79,
      "endOffset" : 83
    }, {
      "referenceID" : 90,
      "context" : "9A) administered intravenously to Swiss albino mice at 20 mg/kg for 1, 8, 30, and 90 days [95].",
      "startOffset" : 90,
      "endOffset" : 94
    }, {
      "referenceID" : 91,
      "context" : "have reported the toxicity of dextran functionalized graphene oxide (GO-Dex) intravenously administered via tail vein injection to female Balb/c mice at 20 mg/kg dose for 1, 3, and 7 days [96].",
      "startOffset" : 188,
      "endOffset" : 192
    }, {
      "referenceID" : 92,
      "context" : "have reported the distribution and biocompatibility of GO after intravenous administration to male Sprague Dawley rats at 1 and 10 mg/kg dose [97].",
      "startOffset" : 142,
      "endOffset" : 146
    } ],
    "year" : 2016,
    "abstractText" : "Article history: Received 22 January 2016 Received in revised form 28 March 2016 Accepted 26 April 2016 Available online 3 May 2016 Graphene basednanomaterials possess remarkable physiochemical properties suitable for diverse applications in electronics, telecommunications, energy and healthcare. The human and environmental exposure to graphenebased nanomaterials is increasing due to advancements in the synthesis, characterization and large-scale production of graphene and the subsequent development of graphene based biomedical and consumer products. A large number of in vitro and in vivo toxicological studies have evaluated the interactions of graphene-based nanomaterials with various living systems such as microbes, mammalian cells, and animal models. A significant number of studies have examined the shortand long-term in vivo toxicity and biodistribution of graphene synthesized by variety of methods and starting materials. A key focus of these examinations is to properly associate the biological responseswith chemical andmorphological properties of graphene. Several studies also report the environmental and genotoxicity response of pristine and functionalized graphene. This review summarizes these in vitro and in vivo studies and critically examines the methodologies used to perform these evaluations. Our overarching goal is to provide a comprehensive overview of the complex interplay of biological responses of graphene as a function of their physiochemical properties. © 2016 Elsevier B.V. All rights reserved.",
    "creator" : "Elsevier"
  }
}